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ABSTRACT
Human HepG2 hepatoma cells are used widely as a replicating cell system that 
expresses numerous liver-specific functions, including those associated with the 
biotransformation of foreign chemicals. In the work presented here the ability of this 
cell line to reproduce the in vivo modulation of CYP3A4, CYP3A5, CYP3A7, hGRa 
and hPXR gene expression by classical xenobiotic cytochrome P450 3A isoenzyme 
inducers was studied.
Transfection experiments using a plasmid construct containing 1 kb of the proximal 
region of CYP3A4 driving an alkaline phosphatase reporter cDNA did not reliably 
reproduce the in vivo activation of this promoter by dexamethasone or rifampicin even 
after co-transfection with hGRa or hPXR expression vectors.
RT-PCR experiments were performed as an alternative technique for direct 
investigation of CYP3A and hPXR mRNA induction. The results showed that HepG2 
cells constitutively express hGRa, hPXR, RXR, SRC-1, HNF-4, CYP3A5 and 
CYP3A7 but not CYP3A4 mRNAs. This is the first time that the expression of 
CYP3A5 mRNA has been identified in HepG2 cells. The results also demonstrated 
that the expression of hPXR, CYP3A5 and CYP3A7 was induced by dexamethasone 
or rifampicin in cells at passages 5 and 10 (after resuscitation from storage) but not at 
passages 15 and 20, unless the cells were dosed in serum-free medium. The results 
are in agreement with induction experiments performed by other authors and show 
that HepG2 cells can be used as a suitable in vitro system for the study of CYP3A 
gene induction by xenobiotics. However, the pattern of gene expression more closely 
resembles that in the human foetal liver and thus HepG2 cells could be of most use as 
an in vitro model of foetal drug metabolism and gene modulation.
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Chapter 1 INTRODUCTION
1.1. Drug metabolism
All organisms are exposed constantly and unavoidably to foreign chemicals 
(xenobiotics) which include both man-made and natural chemicals, e.g. drugs, 
industrial chemicals, pesticides, pollutants, chemical products in cooked food, 
alkaloids, secondary plant metabolites, and toxins produced by moulds, plants and 
animals. Unfortunately, the physical property that enables many xenobiotics to be 
absorbed through the skin, lung or gastrointestinal tract, namely their lipophilicity, is 
an obstacle to their elimination because lipophilic compounds can be readily 
reabsorbed. Consequently, the elimination of xenobiotics often depends on their 
conversion to water soluble chemicals by a process known as metabolism which is 
catalysed by enzymes in the liver and other tissues. An important consequence of 
metabolism is that the physical properties of a xenobiotic are generally changed from 
those favouring absorption (lipophilicity) to those favouring excretion in urine and 
faeces (hydrophilicity). An exception to this general rule is the elimination of volatile 
compounds by exhalation, in which case metabolism to non-volatile, water-soluble 
chemicals can retard their rate of elimination (Klaassen 1996).
A change in pharmacokinetic behaviour is not the only consequence of xenobiotic 
metabolism nor, in some cases, is it the most important outcome. In many instances, 
chemical modification of a xenobiotic by metabolism alters its biological effects. The 
importance of this principle to pharmacology is that some drugs must undergo 
metabolism to exert their pharmacological effect. The importance of this principle to 
toxicology is that many xenobiotics must undergo metabolism to exert their 
characteristic toxic or tumorigenic effect (i.e. the metabolite is more toxic than the 
parent compound). In most cases, however, metabolism terminates the 
pharmacological effects of a drug and lessens the toxicity of xenobiotics (Klaassen 
1996).
The reactions catalysed by xenobiotic-metabolising enzymes are generally divided 
into two groups (phase 1 and phase 2) as shown in Table 1.1. Phase 1 reactions
Table 1.1. General pathways of xenobiotic metabolism and their major 
subcellular location (Klaassen 1996)
Reaction Enzyme Localisation
Phase I
Hydrolysis Carboxylesterase 
Peptidase 
Epoxide hydrolase
Microsomes, cytosol 
Blood, lysosomes 
Microsomes, cytosol
Reduction Azo- and nitro- 
reduction 
Carbonyl reduction 
Disulfide reduction 
Sulfoxide reduxtion 
Quinone reduction 
Reductive dehalogenation
Microflora, 
microsomes, cytosol 
Cytosol 
Cytosol 
Cytosol
Cytosol, microsomes 
Microsomes
Oxidation Alcohol dehydrogenase 
Aldehyde dehydrogenase 
Aldehyde oxidase 
Xanthine oxidase 
Monoamine oxidase 
Diamine oxidase 
Prostaglandin H 
synthetase 
Flavin-mono-oxygenase 
Cytochrome P450
Cytosol
Mitochondria, cytosol
Cytosol
Cytosol
Mitochondria
Cytosol
Microsomes
Microsomes
Microsomes
Phase 2
Glucuronide conjugation 
Sulfate conjugation 
Glutathione conjugation 
Amino acid conjugation 
Acylation 
Méthylation
Microsomes
Cytosol
Cytosol, microsomes 
Mitochondria, microsomes 
Mitochondria, cytosol 
Cytosol
involve hydrolysis, reduction and oxidation. The reactions expose or introduce a 
functional group (-0H, -NH2, -SH or -COOH) and usually result in only a small 
increase in hydrophilicity. Phase 2 metabolic reactions include glucuronidation, 
sulfation, acétylation, méthylation, conjugation with glutathion (mercapturic acid 
synthesis) and conjugation with amino acids (such as glycine, taurine, and glutamic 
acid) (Table 1.1) (Klaassen 1996).
1.2. The cytochrome P450 enzyme superfamily
The liver plays an important role in the interaction between humans and the chemical 
environment. An important locus of this interaction is the supergene family of 
microsomal haemoproteins known collectively as the cytochrome P450s (CYPs) 
(Barwick et al 1996). The term cytochrome P450 is commonly used to refer to a 
group of heme proteins that are apparently unique in having a sulfur atom ligated to 
the iron and form carbon monoxide complexes that have a major absorption band at 
an unusually long wavelength (about 450 nm) (White & Coon 1980).
P450 enzymes in liver and extrahepatic tissues play a key role in detoxification of 
xenobiotics and important roles in the activation of xenobiotics to toxic and/or 
tumorigenic metabolites. Microsomal and mitochondrial P450 enzymes play key 
roles in the biosynthesis or catabolism of steroid hormones, bile acids, fat-soluble 
vitamins, fatty acids, and eicosanoids, which underscores the catalytic versatility of 
these enzymes (Klaassen 1996).
The cytochromes P450 comprise a superfamily of haem-thiolate enzymes, of which 
1200 or more individual members have been identified and sequenced (Lewis & 
Sheridan 2001). They exist in all species investigating so far, including bacteria, 
fungi, plants, fish, birds, reptiles, insects and mammalia, including man (Lewis et al 
1998).
The cytochrome P450 enzyme system consists of three essential components:
1) cytochrome P450 as the terminal oxidase component of the system that is 
classified as a haemoprotein with iron protoporphyrin IX as the prosthetic group 
(Gibson & Skett 1996). The active site of cytochrome P450 contains an iron
protoporphyrin IX moiety in a large, relatively open hydrophobic cleft or 
depression in the surface of the apoprotein. The heme is bound, apparently 
somewhat loosely, by a combination of hydrophobic forces, coulombic attractions, 
and one or two coordinate-covalent bonds to the central metal iron (White & Coon 
1980).
2) NADPH-cytochrome P450 reductase that is a flavoprotein responsible for 
transferring reducing equivalents from NADPH+H*" to cytochrome P450. It exists 
in close association with cytochrome P450 in the endoplasmic reticulum 
membrane.
3) phospholipids, mainly phosphatidyl choline that embeds the other two 
components and may be required for substrate binding, facilitation of electron 
transfer or providing a "template" for the interaction of cytochrome P450 and 
NADPH-cytochrome P450 reductase molecules (Gibson & Skett 1996).
The multicomponent membrane-bound chain (Figure 1.1) receives electrons from 
NADPH or NADH. The reducing equivalents are then passed, by way of a 
flavoprotein oxidoreductase, either via cytochrome b5 or directly to clusters of P450 
proteins. In combination with atmospheric oxygen and any one of innumerable 
substrates, the cytochrome P450 forms a trimolecular complex and the substrate is 
oxygenated (White & Coon 1980). Depending on the rate of formation of the reactive 
intermediate, the presence of nearby phase II enzymes, and the inherent chemical 
stability of the oxygenated intermediate, two possible pathways exist. First, there can 
be further metabolism (e.g. hydration or conjugation) and excretion of innocuous 
highly polar products from the cell. Second, covalent binding of the oxygenated 
intermediate to proteins (including the cytochrome P450 protein itself) and nucleic 
acid can occur. This pathway has been shown in many laboratories to be correlated 
with chemical carcinogenesis, mutagenesis, drug toxicity, and teratogenesis (Nebert & 
Gonzalez 1987).
There is a conserved structural fold among cytochrome P450s even though the amino 
acid sequence identity among proteins may be less than 20% and with only 3 
absolutely conserved amino acids across the superfamily (Hasemann et al 1995). 
Within the structural fold there appears to be a highly conserved core, as determined
REDUCTASE
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Figure 1.1. Three-dimentional concept of the monooxygenase system in the 
endoplasmic reticulum (Nebert & Gonzalez 1987).
from the comparison of the structures of the six crystalised, soluble cytochrome 
P450s. However, while the cytochrome P450 structural fold is the same for all 
determined structures, they have enough diversity in the primary, secondary, and 
tertiary sequences to accommodate specific substrates and redox partners and 
additionally to target the cellular location of the protein (e.g. whether soluble or 
membrane associated, mitochondrial or microsomal) (Graham & Peterson 1999).
All cytochrome P450s sequenced to date exhibit a so-called ‘P450 signature motif of 
10 amino acid residues, which includes the invariant cysteine residue that ligates the 
haem iron. This generally takes the form: FxxGxxxCxG where F is phenylalanine, G 
is glycine, C is cysteine and x is any amino acid. The occurrence of this signature 
sequence is indicative of heme-thiolate proteins of the cytochrome P450 superfamily 
and no other protein sequence have been found which display this motif, and it is 
probably essential for heme-binding proteins that possess cytochrome P450-like 
catalytic activity (Lewis et al 1998).
An evaluation of the mechanism for the metabolic clearance of 315 different drugs 
revealed that 56% of them were primarily cleared through the action of the 
cytochrome P450 enzymes. CYP3A4 was by far the most important isoenzyme 
(50%) followed by CYP2D6 (20%), CYP2C9 and CYP2C19 (15%), and the 
remaining metabolism carried out by CYP2E1, CYP2A6, CYP1A2 and other 
cytochrome P450s (Bertz & Granneman 1997). All of these enzymes are inducible 
except CYP2D6 (Ingelman-Sundberg et al 1999).
1.2.1. The mechanism of cytochrome P450 action
The central features of the cytochrome P450 catalytic cycle are the ability of the heme 
iron to undergo cyclic oxidation/reduction reactions in conjunction with substrate 
binding and oxygen activation as outlined in Figure 1.2 (Gibson & Skett 1996). Due 
to the fact that a single oxygen is inserted into the substrate, the cytochrome P450 
enzyme is often referred to as a mono-oxygenase, and the mono-oxygenated product 
(i.e. metabolite) of the reaction is usually a hydroxy compound (alcohol or phenol), 
epoxide, N-oxide (or S-oxide) or a hydroxylamine (Bernhardt 1995).
The precise molecular details of this catalytic cycle have not all been fully elucidated. 
There are 6 steps known in this cycle:
1. This is a relatively well characterised step and involves drug binding to the 
oxidised (Fe^ "^ ) form of cytochrome P450 to form a substrate-cytochrome P450 
complex.
2. This involves the first electron reduction of substrate-bound ferric cytochrome 
P450 to the ferrous form (Fe^^) of the haemoprotein. The reducing equivalent 
necessary for this reduction is originally derived from NADPH+H*' and is 
transferred by the flavoprotein, NADPH-cytochrome P450 reductase.
3. This step involves the binding of molecular oxygen to the binary ferrous 
cytochrome P450-substrate adduct.
4. Step 4, 5 and 6. These steps involve putative electron rearrangement, introduction 
of the second electron and subsequent oxygen insertion and product release. The 
precise oxidation states of iron and oxygen in these intermediates are not exactly 
known (Gibson & Skett 1996).
1.2.2. Substrates of the cytochrome P450s
Numerous cytochrome P450 enzymes found in liver microsomes have the potential to 
catalyse the various types of reactions including xenobiotic hydroxylation, 
epoxidation, dealkylation, oxygenation, dehydrogenation and so forth (Klaassen 
1996). This system has evolved to handle the constant onslaught of foreign chemicals 
that organisms ingest and absorb every day (Gonzalez 1989). It is also important in 
the metabolism of numerous endogenous compounds such as steroids, bile acids, fatty 
acids, prostaglandins, leukotriens, and biogenic amines. Many of these enzymes also 
metabolise a wide range of foreign chemicals including polyaromatic hydrocarbons 
e.g. benzo(a)pyrene, nitrosamines, alkenes, ketones, alcohols, nitro compounds, 
amids, barbiturates, heterocyclic compounds, halothanes, alkaloids, ethers, 
organophosphates, amines, carboxylic acid, organochlorine pesticides, azo 
compounds and p-blockers (Lewis & Sheridan 2001). The metabolism of foreign 
chemicals can frequently produce toxic metabolites, of which some have been 
implicated as agents that may be responsible for tumour initiation, promotion and 
progression (Nelson et al 1993). The activity of cytochrome P450 monooxygenase 
system can occasionally result in the activation of a compound into a carcinogenic
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species capable of covalently binding to DNA and forming adducts. The formation of 
DNA adducts is believed to be one of the primary steps in the initiation of chemically 
induced carcinogenesis. It is now apparent that the majority of xenobiotic 
carcinogens require metabolic activation in order to elicit their carcinogenic effects 
(Drahushuk et al 1998). It has been estimated that the total number of cytochrome 
P450 substrates may exceed 200,000 (Lewis et al 1998).
Not all P450s are associated with catabolic processes. Some of the most important 
enzymes in steroid biogenesis are cytochrome P450s located in the adrenal gland 
(Gonzalez 1989).
1.2.3. Subcellular localisation of cytochrome P450s
The cytochrome P450 enzyme system is found in the membranes of certain organelles 
in the cell. The most important and most abundant of them are embedded in the 
membrane of the endoplasmic reticulum (Gibson & Skett 1996). All the electron 
transport components of the liver microsomal P450 system are localised toward the 
cytoplasmic side of the endoplasmic reticulum (Ortiz de Montellano 1995).
This enzyme system also presents in mitochondria (Wang et al 2000). All 
steroidogenic organs and some non-steroidogenic organs including liver and kidney 
contain cytochrome P450 in mitochondria, and mitochondrial cytochrome P450s are 
distinct from their microsomal counterparts in the same cell. Mitochondrial 
cytochrome P450s are involved in the metabolism of steroids and related 
physiological substrates, e.g. vitamin Dg, and in contrast with many microsomal types 
of cytochrome P450, they do not have significant activities towards xenobiotic 
compounds. These enzymes are bound to the inner membrane and receive electrons 
from NADPH in the matrix (Schenkman & Greim 1993).
1.2.4. Cytochrome P450 categorisation and nomenclature
The system of classification is based on percentage amino acid sequence similarity 
between cytochrome P450s and, therefore, facilitates the construction of a 
phylogenetic tree for the enzyme superfamily which can be related to the development 
of biological species over time on the basis of the specific mutation rates for the
cytochrome P450 genes (Lewis & Sheridan 2001). This categorisation and 
nomenclature system results in their classification into gene families and gene 
subfamilies. A cytochrome P450 sequence from one gene family is defined as usually 
having less than 40% resemblance to that from any other family. In other words, 
members of different families exhibit 40% or less amino acid sequence similarity 
whilst members within families show more than 40% amino acid sequence similarity. 
Any two cytochrome P450 proteins belong to the same gene subfamily, if they have 
approximately 70% (or greater) similarity in their sequence (Gibson & Skett 1996).
Recommendations for naming a cytochrome P450 gene or cDNA include the 
italicised root symbol "CYP", indicating cytochrome P450, an Arabic number 
designating the P450 family, a letter indicating the subfamily, when two or more 
subfamilies are known to exist within that family, and an Arabic numeral representing 
the individual gene (Nelson et al 1996).
Currently, there are about 215 families and the number is growing in time. The large 
number of families is beginning to make the nomenclature cumbersome. One way to 
alleviate some of this is to recognise that the families naturally group into higher order 
clusters. Naming these clusters would automatically reduce the need to keep abreast 
of all the P450 families. Nelson began the process of naming consistent clusters of 
P450 in 1999 (http://dmelson.utmem.edu/famcount.html).
The term chosen for these clusters is a ‘clan’. A cytochrome P450 clan consists of 
families of cytochrome P450s that clearly belong together based on the many trees 
that have been constmcted (Nelson 1998). To try and place a quantitative measure on 
this, these clusters would be defined as having high ‘bootstrap values’. Perhaps a 
fixed bootstrap value would be analogous to the (approximately) 40% cutoff for 
membership in a given family. These clusters of cytochrome P450 families are not 
necessarily from organisms that share a single common ancestor, but they probably do 
present genes that diverged from a single common ancestor.
The plants have four main clans, the largest being the ‘group A’ plant cytochrome 
P450s (clan 71). Twenty-five of the 47 plant cytochrome P450 families are in this 
clan. The other three plant clans are the clan 72 with four families CYP72, 709, 714,
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and 715; clan 85 with nine families CYP85, 87, 88, 90, 702, 707, 708, 716, and 718; 
and clan 86 with four families CYP86, 94,96 and 704. There are some plant families 
(CYP51, 74, 97, 710, and 711) that fall outside these clans and it is not clear where 
they belong (Nelson 1999).
The fungi have four clans and a few nonaffiliated sequences. Clan 52 has three 
families, clan 53 has seven, clan 54 has five, and clan 64 has five. These sequences 
do not seem to have related functions. Some of them are involved in ergosterol 
biosynthesis (CYP51 and CYP61), others detoxify plant phytoalexins like CYP57, 
while others metabolise lipid carbon sources like CYP52, and still others are used to 
make mycotoxins as in CYP58, 59, 60, 62, 64, and 65. Again, there are a small 
number of families (CYP51, 56, 59,61, and 67) that do not seem to belong to any clan 
(Nelson 1999).
Animals currently are assigned 43 families. They cluster into several well-defined 
groups with a few floaters. The clans are named for a representative family as in the 
clans 2, 3, 4, and 7, a unique subcellular location e.g. the mitochondrial clan, or for a 
specific organism e.g. the C. elegans clan. The C. elegans clan is unique in that it 
contains no sequences from any other organism. It seems to have derived from a 
common ancestor with clan 2, so these two groups could be considered a superclan. 
More than half of the C. elegans cytochrome P450s are in this clan. Clan 3 has the 
mammalian families 3 and 5, the insect families 6 and 9, as well as the C. elegans 
families 13 and 25. Family 28 from insects, family 30 from the clam, and family 45 
from the lobster are also included. Clan 4 has been greatly expanded in insects so that 
it includes 24 subfamilies (Nelson 1999). This clan includes the CYP4, CYP29, 
CYP31, CYP32, and CYP37 families. Clan 7 includes the CYP7 and CYP8 families.
1.2.5. Evolution of the cytochromes P450
It is thought that the earliest forms of independent organisms were anaerobic bacteria, 
which appeared around 3800 million years ago, and the change from an originally 
reducing atmosphere to an oxidising one occurred about 2000 million years ago, as 
the evolution of photosynthetic systems gave rise to a steady increase in atmospheric 
oxygen and the emergence of animal species at 600 million years ago (Lewis et al 
1998). The ubiquitous distribution of cytochrome P450 enzymes throughout all
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aerobic organisms, and possibly many anaerobes indicates a prokaryotic origin, which 
has been retained by the evolving biota following the emergence of eukaryotes and 
the subsequent divergence of plants and animals, with continuing elaborations up to 
and including the mammalian radiation. In fact it is possible to compare the 
cytochrome P450 phylogenetic tree with the currently accepted time-scale for the 
evolution of terrestrial life forms over the last 1400 million years (Figure 1.3).
The cytochrome P450 system may thus have developed as early as 3500 million years 
ago during the diversification of archaebacteria. Although cytochrome P450 may 
have originated under reducing atmospheric conditions where its early role could have 
involved oxygen detoxification, the dramatic rise in atmospheric oxygen over the last 
2000 million years probably directed the functions of cytochrome P450 towards 
utilisation of dioxygen for the metabolism of, first, endogenous compounds and, 
subsequently xenobiotics (Lewis et al 1998). The animal-plant divergence had 
occurred by 1000 million years ego with the development of sexual reproduction. It 
is possible that branching of the eukaryote stem of the cytochrome P450 phylogenetic 
tree may have taken place during this period, where bifurcation into mitochondrial 
and microsomal cytochrome P450s would have coincided with the requirement for 
steroid hormone biosynthesis from cholesterol in order to regulate sexual 
characteristics. Elaboration of the animal phylogeny around 800 million years ego 
appears to correspond with a further branching of the cytochrome P450 tree where the 
CYP3 and CYP4 families split from the main microsomal cytochrome P450 limb. 
Radiation of the animal phyla at around 550 million years ago, during what is termed 
the Cambrian ‘explosion’, followed the divergence of animals about 650 million years 
ago; concordances with the cytochrome P450 tree development indicate that, initially, 
the remaining steroidogenic P450 families, CYP17 and CYP21, occurring in the 
Cambrian period. In this way, it would appear that the P450s primarily associated 
with exogenous metabolism (CYPl, CYP2 and CYP3) separated from those involved 
in endogenous compound metabolism (CYP4, C Y Pll, CYP17 and CYP21) over a 
period of 500 million years, from 1000 million years ago to about 500 million years 
ago, at a time where animal species underwent significant evolutionary development 
(Lewis & Sheridan 2001). The development of lungfish during the early Devonian 
appears to coincide with the elaboration of the CYP2 and CY Pll families, together 
with the separation of families CYP3 and CYP6. The rapid evolutionary
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Figure 1.3. An abbreviated version of the cytochrome P450 phylogenetic tree 
(Lewis & Sheridan 2001).
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developments from the Devonian period into the Cretaceous, where amphibia and 
reptilia diversify, together with the emergence of winged insects and the higher plants, 
appear to correspond with the separation of the CYP2D subfamily and its subsequent 
elaboration. The divergence of reptilia into bird- and mammal-like forms at the end 
of the Cretaceous period maps closely with the initial CYP2D subfamily branching 
point, whereas the remaining CYP2 family probably split around 250 million years 
ago. The emergence of placental mammals during the Cretaceous period concords 
with branching of the CYPIA subfamily into CYPlAl and CYP1A2. The 
manunalian radiation, which occurred around 100 million years ago, corresponds 
closely with several branching of the cytochrome P450 families and subfamilies in 
accordance with accepted dating of spéciation events (Lewis et al 1998).
1.2.6. Cytochrome P450 gene families
Over 1200 individual cytochrome P450s have had their protein sequences defined to 
date (Lewis & Sheridan 2001). Of 215 gene families so far described, 72 families 
belong to bacteria (CYP101-CYP171 + CYP51), 29 families belong to lower 
eukaryotes (CYP51-CYP69 + CYP51), 50 families belong to plants (CYP71-99 + 
CYP701-724 + CYP51 minus four discontinued family names CYP91, CYP95, 
CYP713, and CYP717), and 67 families belong to animals [(CYP1-CYP49 minus 
three discontinued/not used CYP16, CYP20, and CYP40) + CYP301-CYP320 -f- 
CYP51]. CYP51 is present in all four groups so it is counted four times. Full details 
have not been published but are available at the Nelson lab website 
(http ://dmelson .utmem. edu/famcount.html).
In mammals, CYPl, CYP2 and CYP3 appear to be primarily associated with the 
metabolism of exogenous compounds, although they are able to metabolise some 
endogenous chemicals such as steroids. In contrast, members of the other cytochrome 
P450 families, especially those in mammalia, have been shown to possess specific 
metabolic functions. For example, some enzymes of the CYP4 family are responsible 
for the end-chain hydroxylation of long-chain fatty acids, whereas some others are 
associated with the omega-hydroxylation of certain prostaglandins and leukotrienes. 
Cytochrome P450s belonging to gene families 5 and 8A are involved in thromboxane 
and prostacyclin synthesis (Lewis 1996). Cytochrome P450s from families 11,17,19, 
and 21 are required for steroid hormone biosynthesis. Cytochrome P450s from
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families 7, 8B, 24, 27, 46, and 51 catalyse reactions in the pathways leading to the 
biosynthesis of bile acid, vitamin D3 and cholesterol and CYP26 is involved in 
retinoid metabolism, a step that may be important during development. These 
cytochrome P450s usually have selective substrate specificities and they are subject to 
tight tissue-specific and hormone-dependent regulation (Honkakoski & Negishi
2000). The nomenclature of cytochrome P450 families involved in the biosynthesis 
of steroid hormones is derived from the various positions in the steroid nucleus where 
metabolism occurs (CYP7, C Y Pll, CYP17, CYP19 and CYP21) (Lewis 1996).
1.2.7. Species differences in xenobiotic metabolism
Although a substantial number of both endogenous and exogenous P450 substrates 
are metabolised in a similar fashion by mammalian species, there are also examples 
where differences occur which may be due to either the same chemical being 
metabolised by different isoforms or by orthologous cytochrome P450s within the 
same family/subfamily (Lewis et al 1998). For example phénobarbital treatment 
increases the toxicity of paracetamol in rat and mouse, but decreases the toxicity of 
this chemical in the hamster (Boobis et al 1990). Apparently, this is due to an 
increase in the detoxifying glucuronidation pathway in hamster as opposed to the 
cytochrome P450-mediated activation which is predominant in the mouse and rat. 
There is also a marked difference between the metabolism of coumarin in rat and 
mouse which results in activation in the rat {via 3-hydroxylation), but detoxification 
in the mouse involving the 7-hydroxylation pathway (Lewis & Lake 1995). It is 
likely that this is due to the variation between CYP2A orthologues in the rodent 
species.
There is, moreover, an interesting species difference between cytochrome P450 
complements in New and Old World primates, which may well be explained in terms 
of continental drift and changing habitat. Apparently, New World monkeys possess 
relatively high levels of CYP1A2 but virtually no CYP2A, whereas the opposite is 
found for Old World primates. Homo sapiens would appear to represent a 
combination of each type of primate species as both CYP1A2 and CYP2A6 are 
constitutively expressed in human liver (Lewis & Lake 1996).
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As far as the CYP2B subfamily is concerned, there are species differences in the 
steiio-selectivity of steroid metabolism (Oguri et al 1994). For example, both rat and 
dog CYP2B orthologues hydroxylate androgens in the 16a and 16P positions, 
whereas the guinea pig and monkey orthologues hydroxylate solely at the 16P 
position, and the rabbit form exhibits 16a-hydroxylation primarily. This is likely to 
be due to subtle differences in amino acid residues in the enzyme active sites, as it has 
been demonstrated that site-directed mutagenesis at two positions can alter the 
stereoselectivity of CYP2B1 (Aoyama et al 1989).
The CYP2C subfamily also shows marked variation in regio- and stereoselectivity of 
steroid metabolism between different species and also exhibits differences between 
CYP2C-mediated testosterone metabolism for male and female, which can be 
ascribed to gender-specific isoforms (reviewed in Lewis 1996). In the CYP2D 
subfamily there are also species variations in substrate metabolism. For example, 
unlike rat and human CYP2D enzymes, none of the mouse CYP2D orthologues are 
able to metabolise debrisoquine, but mouse CYP2D9 can carry out 16a-hydroxylation 
of testosterone, which is metabolized in the 6P position by both rat and human 
CYP2D isoforms (Funae & Imaoka 1993). Furthermore, there are species differences 
in metabolic pathways carried out by the CYP2E subfamily enzymes (Duescher & 
Elfarra 1994) which, as with other examples mentioned previously, suggest that 
considerable care must be exercised in using small rodents as surrogates for man in 
chemical safety evaluation.
Other differences between species reflect the alteration in cytochrome P450 
complements together with variability of expression and regulation of the cytochrome 
P450 genes which can be subject to alteration depending on not only species, sex and 
strain differences but also variations between organs and tissues. Thus, it is found 
that the anticancer agent tamoxifen is carcinogenic in both rat and mouse due to 
cytochrome P450-dependent pathways, but is readily detoxified via CYP3A4 in 
human (Wiseman & Lewis 1996). Consequently, the preferred experimental animal 
species for the screening of chemicals that are destined for human exposure will vary 
depending on the nature of the compound itself and the relevant pathways of 
metabolism.
16
1.2.8. Regulation of cytochrome P450 gene expression
DNA in the nucleus of a eukaryotic cell is found in the form of chromatin where both 
histone and non-histone proteins are bound to the genetic material. For a gene to be 
available for expression, it must be in the activated state so that transcription can take 
place. The transcribing molecule, RNA polymerase II, is then able to synthesise a 
pre-mRNA copy of the gene, including both the coding (exon) and non-coding 
(intron) regions. The introns of this pre-mRNA are removed by splicing and mature 
mRNA is produced. This is then transported to the cytoplasm where it is translated 
by ribosomes into the polypeptide apoprotein. The modification of this apoprotein 
yields active enzyme. Any of these stages (Figure 1.4) can be a site of regulatory 
control (Goldfarb 1989; Lewis 1996). The cytochrome P450 enzymes responsible for 
the metabolism of xenobiotics are generally present at low cellular levels, but are 
substantially induced in response to specific xenobiotics. This induction process 
makes biological sense because the xenobiotic inducers are generally substrates for 
the induced cytochrome P450. Induction of cytochrome P450 enzyme(s) then 
continues until the inducer is lowered to a threshold level (Dogra et al 1998). In 
addition to induction, the level of catalytic activity of cytochrome P450s can be 
lowered (or down-regulated) by a variety of other factors such as inhibition and post- 
translational loss of functionality (Lewis 1996). There is also some evidence that pre- 
transcriptional steps can affect the induction of some liver CYPs by phénobarbital e.g. 
extracellular matrix, disruption of the cytoskeleton and activation of cAMP- 
dependent protein kinase (Brown et al 1997).
I.2.8.I. Transcriptional regulation
Induction of cytochrome P450 enzymes occurs predominantly at the level of 
transcription (Dogra et al 1998). Regulation at the level of mRNA synthesis is 
dependent on two factors: the presence of cis-acting regulatory DNA sequences 
adjacent to or within the gene and the synthesis or activation of gene-specific DNA- 
binding proteins. The DNA-binding proteins dock specifically with their target 
regulatory DNA sequences and facilitate the entry of RNA polymerase molecules into 
the mRNA promoter site of the gene. These DNA-binding proteins, or trans-acting 
factors are present in both the nucleus and cytoplasm and can be activated by ligand 
binding (drugs or hormones), by phosphorylation (second messenger signalling
17
Haem pool
Cytochrome P450 gene
Transcription
(nucleus)
mRNA
Translation
(Endoplasmic
reticulum)
Apoprotein
Cytochrome P450 enzyme
Specific
inactivation
Cytochrome P420 (inactive)
Degradation and catabolism
Figure 1.4. Stages in cytochrome P450 gene expression (modified from Lewis
1996).
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systems) or in some instances, by metabolite-induced dimerization/dissociation 
(Goldfarb 1989).
Each ligand interacts with its cognate receptor to induce conformational changes in 
the tertiary protein structure, enabling productive interactions between the ligand- 
bound receptor and its target response element DNA sequences (Kumar & Thompson 
1999). Steroid hormones, some chemicals such as dioxin and related agents or the 
peroxisome proliferators bind steriospecifically to their cytoplasmic xenobiotic 
receptors in the process of stimulating expression of some cytochrome P450 genes 
(Brown et al 1997). Depending on the chemical nature of the ligand (xenobiotic), 
GYP isozymes belonging to a particular subfamily are predominantly induced (Figure 
1.5).
For example, the dioxin (TCDD) receptor mediates induction of cytochrome P450 
lA l expression via a protein kinase C-dependent phosphorylation mechanism. 
Inhibition of the receptor-mediated activation response is also achieved by treatment 
of the cells with a number of protein kinase inhibitors (Berghard et al 1993). 
Treatment of mouse hepatoma Hepa-1 cells with 2-aminopurine, an inhibitor of 
protein kinase activity, inhibits CYPlAl mRNA induction by TCDDs as well as the 
concomitant increase in CYPlAl enzyme activity. Formation of DNA-protein 
complexes between the Ah receptor and its XRE target is also inhibited by 2- 
aminopurine (Carrier et al 1992). Also, treatment of in vivo or in vitro ligand- 
activated dioxin receptor with potato acid phosphatase significantly reduced or 
abolished its specific binding activity. This effect was inhibited in the presence of 
sodium phosphate. These results suggest that phosphorylation may regulate the DNA 
binding activity of the ligand-occupied dioxin receptor (Pongratz et al 1991).
Several types of agents have been found to down-regulate CYPlAl transcription by 
inhibiting the binding of ligand-receptor complex to DNA. Transcriptional regulation 
of CYPlAl and CYP1A2 by TCDD requires protein kinase C-dependent 
phosphorylation, and inhibitors of Protein kinase activity, such as 2-aminopurine or 
phorbol esters, inhibit CYPlAl mRNA induction by TCDD as well as the 
concomitant increase in CYPlAl enzyme activity. Formation of DNA-protein 
complexes between the Ah receptor and its AhRE target is also inhibited by 2-
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response element; HRE, hormone responsive element; PXR, Pregnane X receptor; 
CAR, constitutively active receptor.
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aminopurine (Carrier et al 1992; Berghard et al 1993; Okino et al 1992).
1.2.8.2. Post-transcriptional regulation
Post-transcriptional regulation includes the mechanisms that may affect the splicing, 
transport, stability and translatability of mRNA. In the cytochrome P450s, post- 
transcriptional mechanisms have been reported to operate in the induction of CYP1A2 
(and possibly CYPlAl) by 3-methylcholanthrene or TCDD, the induction of 
CYP3A2 by troleandomycin or dexamethasone (Goldfarb 1989) and, the induction of 
CYP2E1 by triiodothyronine (Peng & Coon 1998). In all these instances, there 
appears to be a stabilisation of the mRNA by some unknown mechanism e.g. 
alternative mRNA splicing in the 3’ UTR as has been demonstrated in the case of 
CYP4A1 (Goldfarb 1989). Increased translational efficiency has been reported for 
CYP2E1 induction by pyridine (Kim et al 1993). Insulin may decrease CYP2E1 
mRNA stability (Peng & Coon 1998).
1.2.8.3. Post-translational regulation
Regulation of cytochrome P450 activity at the level of enzyme activity or stability has 
been shown to operate in a number of instances. The availability of heme is clearly 
an important factor and heme synthesis is readily induced following administration of 
TCDD or phénobarbital (Goldfarb 1989). Some organochloride insecticides have 
been reported to stabilise CYP3A1 protein (Yaun et al 1994) and ethanol has been 
shown to protect CYP2E1 from catalytic degeneration (Roberts et al 1995 and Hu et 
al 1995). DMSO increased CYP3A protein levels as a result of decreased protein 
degradation (Zangar & Novak 1998).
Inactivation or inhibition of cytochrome P450 can also occur by formation of a 
chemical complex between substrate or inhibitor and enzyme protein. Inactivation of 
cytochrome P450 by thiono-sulfur compounds occurs during their biotransformation 
and results in the binding of atomic sulphur to the cytochrome P450 apoprotein 
(Chang et al 1997).
The mechanism of cytochrome P450 inactivation is generally classified into two 
groups: one involves covalent binding of a reactive intermediate to the enzyme 
protein and/or heme, which leads to irreversible inhibition of catalytic function; the
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second involves a quasi-irreversible coordination of a reactive product to the 
cytochrome P450. The major classes of chemical entities that form cytochrome P450 
complexes include methylenedioxybenzene derivatives, alkylamines, macrolide 
antibiotics, and hydrazines. Compounds such as piperonyl butoxide, isosafrole and 
alkylamine functions undergo cytochrome P450-catalysed oxidation to form 
intermediates that coordinate tightly to the prosthetic heme iron (Chiba et al 1998). 
Also, grapefruit juice has been found to inhibit cytochrome P450 3A4 enzymatic 
activity and decrease the content of intestinal P450 3A4 (He et al 1998). The 
mechanism of the inactivation appears to involve modification of the CYP3A4 in the 
active site of the enzyme. Bergamottin, a constituent of grapefruit juice appears to be 
responsible for this inhibition.
1.3. Control of gene expression by nuclear receptors
1.3.1. Role of the ‘hormone’ receptors
The concept that small lipophilic hormones could regulate cellular function by 
interacting with specific cellular proteins called receptors, was first proposed more 
than 30 years ago from direct ligand-protein binding studies (Jensen et al 1966). Final 
proof of the ‘nuclear receptor’ hypothesis was provided by the molecular cloning and 
in vitro expression of functional steroid hormone receptors (reviewed in Sladek & 
Giguere 2000). The subsequent isolation and characterisation of receptors that were 
activated by nonsteroidal ligands such as vitamin A and thyroid hormone suggested 
that nuclear hormone receptors could potentially regulate gene expression in response 
to a wide variety of lipophilic ligands (Evans 1988). More than 70 such receptors 
have been identified so far. Nuclear receptors with no known ligands at the time of 
their discovery are referred to as ‘orphan’ nuclear receptors and considerable effort 
has been devoted to identifying ligands and physiological functions for these gene 
products (Sladek & Giguere 2000). The nuclear receptor gene family is structurally 
and functionally conserved across species and is represented within metazoan phylae 
from cnidarians to vertebrates (Esciiva et al 1997).
The discovery that certain orphan nuclear receptors are activated by nonclassical 
hormones such as vitamin A derivatives, prostanoids, sterols, and fatty acids, 
combined with the observation that nuclear receptor binding response elements (REs)
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are present in the 5' regulatory regions of genes encoding enzymes involved in 
cellular metabolism, suggest that many orphan nuclear receptors may be important 
regulators of as yet unidentified basic endogenous cellular functions in vivo (Sladek & 
Giguere 2000). This hypothesis has been corroborated by genetic linkage studies in 
patients with certain metabolic disorders (e.g. Nishigori et al 2001; Li et al 2000; 
Chang et al 2000; Naville et al 2000) as well as physiologie studies of mutant mice 
harbouring defective nuclear receptor genes (e.g. Shinoda et al 1995; Peet et al 1998). 
Members of the nuclear receptor family may thus perform key roles in balancing the 
metabolic demands of the whole organism, regulated by classical endocrine 
hormones, with those of individual organs and cells, encoded by lipophilic paracrine 
and intracrine signals (Sladek & Giguere 2000). Mutations in the structural genes of 
certain receptors may cause certain types of cancer and hormone-resistance 
syndromes (Honkakoski & Negishi 2000).
The majority of nuclear receptors bind specifically and with high affinity to their 
cognate hormone response elements (HREs) in DNA. Contacts between key amino 
acid residues in the receptor DNA-binding domain and nucleotide bases within the 
cognate HRE core motif are primarily responsible for recognition of the HRE. The 
HRE is usually composed of two half-sites related to the nucleotide hexamer 
AGGTCA. However the organisation of the HRE mirrors the nature of receptor 
binding:
(i) steroid-hormone receptors bind as homodimers to palindromes with a 3 bp 
spacing;
(ii) many other hormone and orphan receptors (e.g. PXR) form heterodimers with 
the retinoid X receptor (RXR) and bind to repeats with variable spacing;
(iii) some receptors bind as monomers (e.g. steroid receptor-related receptors) to a 
single AGGTCA-like site (Honkakoski & Negishi 2000).
Also, gene regulation by some nuclear receptors can occur independently of direct 
DNA binding and is mediated by protein-protein interactions involving other 
transcription factors or adapter proteins. This has been demonstrated most clearly for 
the glucocorticoid receptor (Sladek & Giguere 2000).
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1.3.2. Structure of the nuclear receptors
Members of the nuclear receptor family have a well-conserved protein domain 
structure that parallels the functions of the receptor protein. The DNA binding 
domain (DBD), displays the highest protein sequence conservation among family 
members and consists of cystein coordinated zinc-fingers involving between 66 and 
70 amino acids in the central region of the receptor. The ligand-binding domain 
(LBD), which is less well conserved among family members, occupies the C-terminal 
region of the receptor. This region also encodes a ligand-dependent RNA polymerase 
II transactivation function (AF-2), as well as protein surfaces that regulate 
dimérisation with other family members. The N-terminal region of the receptor, 
which displays the poorest sequence conservation among family members, contains a 
ligand-independent transactivation function (Berry et al 1990). For some family 
members, the N-terminal domain acts in concert with the central DNA-binding 
domain to modulate DNA-binding specificity and affinity (Giguere et al 1994; Wong 
& Privalsky 1995).
The DBD has the most conserved amino acid sequence among the members of the 
steroid-thyroid-retinoid receptor superfamily, and consists of two zinc finger motifs, 
each containing four highly conserved cysteine molecules coordinating binding a zinc 
atom (Figure 1.6). This results in the formation of a tertiary structure containing 
helices that interact specifically with DNA sequences that are organized appropriately 
in response elements (Freedman et al 1988(a); Freedman et al 1988(b); Luisi et al 
1991). The DBD may be considered as two interdependent subdomains, each 
consisting of a zinc ion, tetrahedrally coordinated to the sulfurus of four cysteine 
residues, and an amphipathic helix. They differ both structurally and functionally. 
The helix of the first subdomain is mainly involved in site-specific recognition based 
on its interaction with DNA response element hexamer (Luisi et al 1991; Lee et al 
1993). A loop formed in the second subdomain provides the DBD homodimerization 
interface and less specific DNA interactions.
The three dimentional structure of the recombinant LBDs of the retinoic acid receptor 
Y (RAR-y), thyroid receptor (TR) and oestrogen receptor (ER) have been solved by x- 
ray diffraction, as has that of the unliganded retinoid X receptor a  (RXR-a)
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Figure 1.6. Sequence of the amino acid residues of the human glucocorticoid 
receptor, showing two zinc finger motifs (after Kumar & Thompson 1999).
The three highlighted amino acids around the first zinc finger (P-box) are those 
essential for discrimination between GRE and ERE, whereas the highlighted amino 
acids around the second zinc finger, the D-box, are important for protein-protein 
interaction in the dimeric DBD:GRE complex.
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(Brzozoeski et al 1997; Bourguet et al 1995; Renaud et al 1995; Wagner et al 1995). 
Ail are composed of a series of 11-12 a-helices (HI-HI2) closely folded in a similar 
manner (Figure 1.7). The C-terminal part of the LBDs of these receptors has been 
shown to have a ligand-inducible trans-activation function, termed AF-2 (Green & 
Chambon 1988; Nagpal et al 1993). Both deletion and mutation studies have shown 
that the AF-2 activation helix is essential for ligand-induced transcriptional activation 
(Kumar and Thompson 1999). It appears that the activation of AF-2 upon ligand 
binding corresponds to major conformational changes, which create the surface 
required for efficient interaction with transcription factors, the putative mediators of 
AF2 function (Danielian et al 1992; Mclnemey et al 1996). The LBD not only serves 
to provide a class-specific ligand-binding site, but also as a homodimerization 
domain. It also interacts with other proteins in transactivating genes and still others in 
regulating receptor activation (Kumar and Thompson 1999). Thus a ligand interacts 
with its cognate receptor to induce conformational changes in the tertiary protein 
structure, enabling productive interactions between the hormone-bound receptor and 
its target response element DNA sequences (Heery et al 1997; Masuyama et al 1997).
1.3.3. Categories of nuclear receptors
The nuclear hormone receptor superfamily is divided into three well-known major 
categories based on functional studies, ligand specificity, and DNA- and ligand- 
binding regions:
i) steroid hormone receptors
ii) thyroid/retinoid/vitamin D and peroxisome proliferator activated receptors
iii) the largest category, receptors for which no ligand is known, or orphan 
receptors (Kumar & Thompson 1999).
Although these proteins are called the nuclear receptor family, some members such as 
glucocorticoid and mineralocorticoid receptors are transported to the nucleus only 
after ligand binding (Savory et al 1999; Lombes et al 1994).
The first decade of orphan nuclear receptor research has yielded a large number of 
new family members and many tantalizing clues as to their biological functions 
(Kliewer et al 1999). However, ligands have been identified for only a handful of the 
orphans. Given the large number of remaining orphan nuclear receptors and the
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Figure 1.7. Topology diagram of the RAR-y LBD and RXR-a LBD, showing the 
a-helical and P-sheet arrangements (Kumar & Thompson 1999).
H2 is found in RXR but not in RAR, and H 12 is found in RAR but not RXR. The 
LBDs of TR and ER have a similar overall topology.
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recent advances in combinatorial chemistry, high-throughput screening, and 
functional genomics, the next decade promises an explosion in our understanding of 
nuclear hormone signalling pathways.
1.3.4. Regulation of cytochrome P450 expression by nuclear receptors
The cytochrome P450 genes and the nuclear receptors and their ligands form a 
complex control network that may also involve feedback regulation (Figure 1.8 and 
Table 1.2). First, several cytochrome P450s degrade substrates that activate the 
receptor responsible for regulation of this specific cytochrome P450 form, thus 
creating a direct feedback loop. Clear examples of this can be recognised in 
cytochrome P450s metabolising vitamin D (CYP24 and VDR) and retinoids (CYP26, 
CYP2C7 and RAR). Peroxisome proliferator-activated receptor a  (PPARa), 
pregnane X receptor (PXR) and constitutively activated receptor (CAR) activated 
CYP4A, CYP3A and CYP2B genes also fall into this category: fatty acids and steroid 
hormone metabolites serve as ligands for PPARa and PXR which in turn increase 
ligand elimination by CYP4A-mediated (o-hydroxylation or CYPSA-catalysed 6|3- 
hydroxylation respectively (Roman et al 1993). Another example is methoxychlor 
which activates CAR and stimulates its own metabolism by CYP2B (Li et al 1995; 
Sueyoshi et al 1999). Other candidates for this class might include CYP2A isoforms, 
which are steroid-specific androgen 7a-hydroxylases (Honkakoski & Negishi 1997), 
present in testis and liver that are for androgen production and elimination 
respectively. Vitamin D (CYP2D25) and cholesterol-metabolising cytochrome P450s 
produce ligands for major classes of receptors, but the immediate cytochrome P450 
product is not a ligand. Instead, a more complex loop occurs, either involving the 
pituitary via action of trophic hormones (e.g. sex steroids and CYP17, CYP 19) or 
through suppression by ultimate products (e.g. bile acids and CYP7A) (Honkakoski & 
Negishi 2000). Some cytochrome P450s may ensure a steady elimination of a wide 
range of endobiotics or xenobiotics. This is made possible by prominent basal and 
liver-specific gene expression that is controlled by HNF-4 or related orphan receptors. 
Certain cytochrome P450s in gene families CYP2A (Yokomori et al 1997), CYP2C 
(Ibeanu & Goldstein 1995), CYP2D (Yoshioka et al 1990) and CYP3A (Ogino et al 
1999) belong to this class. For these, no activating ligand or feedback loop is evident.
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CYP-dependent metabolism 
of xenobiotics and endobiotics
CYP genesX ,E XO, EO
NRs
Other genes
Figure 1.8. Relationship between nuclear receptors, their ligands and 
cytochrome P450 enzymes (after Honkakoski & Negishi 2000).
NRs are ligand-activated transcription factors regulating the activity of cytochrome 
P450s and other genes to generate specific cellular responses to activating ligands. 
These ligands are formed and degraded via specific cytochrome P450 enzymes. The 
ligands may be xenobiotics (X), endobiotics (E) or their oxidation products (XO, EO).
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Table 1.2. Examples of interactions between genes and nuclear receptors 
(modified from Honkakoski & Negishi 2000)
CYP substrates/products that 
CYP gene can serve as NR ligands
NRs affected by the CYP 
substrate/product
NRs known to 
regulate CYP genes*
CYPIA Oestrogens, retinoids Ers, RARs, RXRs ER, GR, RAR
CYPIB Oestrogens Ers ER ,G R
CYP2A Androgens AR HNF-4
CYP2B Xenobiotics^ Many CAR (PXR)
Androgens^ oestrogens. AR, ER, PPAR, PXRs GR
retinoids
CYP2C Xenobiotics^, Many HNF-4, orphan
NSAIDs RAR
Androgens, retinoids. AR, ER, RARs, RXRs
fatty acids derivatives PPARs
CYP2D Xenobiotics^ Many ER
Androgens, oestrogens. A R ,E R VDR
vitamine D 3 HNF-4
CYP3A Xenobiotics^ Many PXR (CAR)
Methoxychlor HNF-4, orphan
Androgens, corticoids. AR, ER, GR GR
oestrogens, pregnanes^
CYP4A Fatty acid derivatives PPARs PPAR, (orphan)
CYP26 Retinoic acid RARs, RXRs RAR
CYP27B1 Vitamin D VDR
CYP24 Vitamin D VDR VDR (RXR, orphan)
Steroidogenic CYPs Androgens, oestrogens. AR, ER, GR, MR SF-1, orphan
corticoids, pregnanes^
CYP74 Precursors o f steroids CPF, LXR, FXR
Bile-acid-forming Oxysterols LX R ,FX R LXR?, FXR?
CYPs
CYP51 Sterols LXR
* Nuclear receptors in parentheses have a tentative role.
 ^Many compounds in this class are activators o f PXR, CAR or PPAR.
Abréviations: NSAIDS, nonsteroidal anti-inflammatory drugs; MR, mineralocorticoid receptor
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However, they may be indirectly suppressed by cytochrome P450 inducers or NR 
ligands (Emi & Omura 1988; Yeowell et al 1987). In addition to the above feedback 
regulation, cytochrome P450s may often produce metabolites that act as ligands for 
unrelated receptors (Honkakoski & Negishi 2000).
1.4. Co-activators and co-repressors of gene expression
1.4.1. Role of co-activators and co-repressors
The regulation of transcription by members of the nuclear receptor family occurs by a 
mixture of mechanisms, involving direct interaction of each receptor with specific 
DNA sequences and/or with a variety of proteins. These include other sequence- 
specific DNA-binding transcription factors, the basal transcription factors, various co­
activators, co-repressors, and ‘integrators’ of transcription (Kumar & Thompson 
1999).
The interplay between distinct nuclear receptor responsive transcription pathways has 
been recognised for some time (Bocquel et al 1989; Meyer et al 1989). The capacity 
for the activation of transcription by one nuclear receptor to compromise a 
transcriptional response which depends on a second receptor implies that shared 
components of transcriptional machinery were involved. An explanation for this 
transcriptional interference became apparent with the discovery of shared co-activator 
proteins that facilitated communication between nuclear receptors, the basal 
transcriptional machinery and the chromatin environment (reviewed by Torchia et al
1998).
1.4.2. Activation of co-activators and co-repressors
According to the current model of NR activation (Figure 1.9), ligand binding induces 
great structural changes in the folding of the LBD, with AF-2 repositioned so as to 
form a hydrophobic patch that is accessible to common co-activators and co­
integrators such as p300/CBP, SRC-1 and TIF2. Co-activators bind to ligand-bound 
nuclear receptors through their LXXLL (leucine zipper) repeats (Darimont et al 1998) 
and either possess intrinsic histone acetyltransferase activity or recruit additional 
histone acetyltransferases that relieve the suppressive effects of chromatin in order to 
activate transcription (Grant & Berger 1999). Some, but not all, ligand-free receptors
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interact with co-repressors such as N-CoR and SMRT (Xu et al 1999) to suppress 
gene transcription via recruitment of histone deacetylases (Johnson & Turner 1999). 
In addition, some receptors contain a separate activation domain (AF-1) that is ligand- 
independent but can interact with the AF-2 region (Shao et al 1998; Hammer et al 
1999). The effects of a nuclear receptor on target gene expression are therefore 
subject to regulation (and competition by other nuclear receptors) at DNA-binding- 
site selection, selective dimérisation, binding of distinct ligands and selective co­
activator assembly (Figure 1.9). In addition several other transcription factors may 
compete for the same co-activators (Glass et al 1997; Xu et al 1999). Receptor- 
mediated regulation may be complex in other ways as well. For example, multiple 
forms of nuclear receptors can be produced by the multiple promoters or alternative 
splicing in a cell-specific manner (Crofts et al 1998; Fasco 1998). Some nuclear 
receptors are predominantly cytoplasmic, being translocated to the nucleus only upon 
ligand binding (Savory et al 1999; Lombes et al 1994). Also, many receptors are 
phosphorylated either upon ligand binding or through cross-talk from other signaling 
systems (Weigel 1996).
1.4.3. Classes of co-activators and mode of action
Co-activators can be divided into two general classes: members of the switch/sucrose 
non-fermentable (SWl/SNF) family of proteins and members of the histone 
acetyltransferase family. Both classes of co-activators have the capacity to modify 
the chromatin environment facilitating transcription indirectly by alleviating the 
repressive effects of histone-DNA contacts. The two general classes of co-activators 
might act in concert to regulate transcription (Collingwood et al 1999). Acétylation of 
the core histones destabilises chromatin folding at all levels in chromatin fibre. A 
major consequence of this destabilisation is that histone acétylation facilitates 
transcription factor access to DNA and transcription itself (Lee et al 1993a; Tse et al 
1998; Ura et al 1997). An effect of acetylating the basic N-terminal tail domains of 
the core histones is to reduce the stability of electrostatic interactions between the tail 
domains and both the acidic phosphodiesterase backbone of DNA and the acidic 
domains of other proteins present in nucleosomes and other chromatin fibres (Hong et 
al 1993; Tse et al 1998). There may also be consequences for both histone secondary 
structure and interactions with non-histone proteins following acétylation (Hansen et 
al 1998). Both histone acétylation and the activity of SWl/SNF chromatin
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Ligand binding 
protein kinases 
Dimérisation 
Translocation
No ligand
Histone acetyl­
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Co-activato^^
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DNA DNA
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Figure 1.9. Model for gene activation and gene repression by nuclear receptors 
(after Honkakoski & Negishi 2000).
Ligand binding or other activating processes induce the binding of the nuclear 
receptor (NR) to the DNA element. The ligand-bound nuclear receptor then recruits a 
complex of common and/or NR-specific co-activators and co-integrators, and turns on 
acétylation of histones to activate transcription. In the absence of ligands or upon 
antagonist binding, some but not all, nuclear receptors bind co-repressors to trigger 
deacetylation of histones and maintenance of chromatin structure.
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remodeling complexes can facilitate the processivity of RNA polymerase through 
chromatin (Brown et al 1996; Ura et al 1997).
1.4.4. Mode of action of co-repressors
Just as co-activators facilitate the initiation of transcription by ligand-bound receptors, 
co-repressors can help repress RAR and TR-dependent transcription in the absence of 
ligand or ER-dependent transcription in the presence of antagonists (Collingwood et 
al 1999). Experiments have identified two potential classes of co-repressors. The 
nuclear hormone receptor co-repressor (NcoR) and silencing mediator of retinoid and 
thyroid receptors (SMRT) proteins are the major family (Chen & Evans 1995; Horlein 
et al 1995; Kurokawa et al 1995; Zamir et al 1997; Ordentlich et al 1999). The 
transcription intermediary factor 1 (TIFl) proteins are the other family (Le Douarin et 
al 1995; vom Baur et al 1996). Both classes of co-repressors will recruit histone 
deacetylase. The consequence of a localised increase in deacetylase concentration 
will be to stabilise chromatin structure and repress transcription (Collingwood et al
1999). The N-coR and SMRT co-repressors interact with the unliganded TR or RAR 
when these are associated with their RXR heterodimeric partner (Kurokawa et al 
1995; Lee et al 1995; Lavinsky et al 1998). Studies have defined a region, the CoR 
box, in the hinge between the receptor DBD and LBD that is critical for association 
with corepressors (Horlein et al 1995). ER can also bind the NcoR and SMRT 
corepressors in the presence of antagonists such as tamoxifen and RU486 (Laherty et 
al 1998; Lavinsky et al 1998).
1.5. The cytochrome P450 3A subfamily of isoenzymes
As noted previously, CYP3A is the only subfamily in the CYP3 family of cytochrome 
P450 isoenzymes and in man is the major hepatic cytochrome P450 subfamily 
involved in the metabolism of xenobiotics. The CYP3A isoenzymes also have an 
important metabolic role in other tissues. The CYP3A subfamily is characterised 
particularly by expression mainly in liver and intestine, catalysis of steroid hormone 
and bile acid 6|3-hydroxylation reactions, selective inhibition by the mechanism-based 
inactivator troleandomycin, and transcriptional induction by a broad range of steroids 
and antibiotics (Waxman 1999).
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1.5.1. Substrates of the CYP3A subfamily of cytochrome P450
The CYP3A subfamily of isoenzymes is the most important enzymes in cytochrome 
P450 superfamily in man and probably most animals. It constitutes about 30% of the 
cytochrome P450 content of human liver and is responsible for the biotransformation 
of more than half of all therapeutic drugs, including psychotherapeutic, 
anticonvulsant, cardiac, analgesic, hormonal, immunosuppressant, antineoplastic and 
antihistaminic agents (Chang et al 1997; von Moltke et al 1995; Ketter et al 1995).
The CYP3A gene subfamily is composed of several genes coding for active 
testosterone 6 beta-hydroxylases which are expressed in the liver and other tissues. 
They are involved in the metabolism of both endogenous and exogenous natural and 
synthetic compounds (Ourlin et al 2000). In addition to b^-hydroxylation as the 
common metabolic function among them they may also contribute to other metabolic 
pathways such as oxidation, dealkylation, dehydration, and reductive deamination 
(reviwed by Li et al 1995). In general, CYP3A isoenzymes mediate the detoxifying 
metabolism of exogenous substrates but a number of activating pathways have also 
been demonstrated, although other CYPs are also involved in activation of 
procarcinogens (Lewis et al 1996). CYP3A also involve in the activation of prodrugs 
such as cyclophosphamide and ifosfamide (Chang et al 1997).
There is considerable structural variation in the known substrates of CYP3A 
isoenzymes and it is difficult to categorise this diverse substrate specificity. However, 
CYP3A isoenzyme substrates are fairly lipophilic with log D 7 . 4  values ranging from 
0.4 (codeine) to 8 or more. Many (but not all) CYP3A substrates are of relatively low 
molecular weight (Lewis et al 1996). The substrates of human CYP3A isoenzymes 
will be discussed in more detail in section 1.5.3.
1.5.2. CYP3A isoenzymes in animals and man
Thirty-one known isoenzymes of this subfamily exist in different mammalian and 
non-mammalian species. CYPs 3A1, 3A2, 3A9, 3AI8 and 3A23 are all found in the 
rat. CYP3A2 and CYP3A9 gene expression is age and sex dependent, whereas 
CYP3A18 and CYP3A23 expression is not. Phénobarbital (PB) and dexamethasone 
(DEX) induce CYP3A genes in rat and PB appears to be more potent than DEX
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(Lewis 1996; Lacroix et al 1997). CYP3A4, CYP3A5, CYP3A7 (Li et al 1995) and 
CYP3A43 (Domanski et al 2001) are found in humans. The isoenzymes are found in 
different tissues, but the major xenobiotic metabolizing enzyme in human liver is 
CYP3A4. The highest level of CYP3A43 mRNA is observed in the prostate, an organ 
with extensive steroid metabolism. CYP3A43 is also expressed in several other 
tissues including liver, where it can be induced by rifampicin (RIF) (Gellner et al
2001). CYP3A6 is found in the rabbit and is inducible by rifampicin (Potenza et al 
1989) and dexamethasone (Barwick 1996). CYP3A11, CYP3A13 and CYP3A16 are 
found in mouse. CYP3A11 is probably the predominant CYP3A enzyme in mouse 
liver, compared to CYP3A13. Both these enzymes are inducible by DEX, 3- 
methylcholanthrene (3-MC), PB, polychlorinated biphenyls (PCBs), pregnenolone 16 
alpha-carbonitrile (PCN) and RIF, but the inducibility of CYP3A11 is more marked 
(Yanagimoto et al 1997; Itoh et al 1997). Recently, two other mouse hepatic CYP3A 
enzymes (CYP3A25 and CYP3A41) have been cloned (Dai et al 2001; Sakuma et al
2000). CYP3A25 has been shown to be expressed in both foetal and adult tissues. 
CYP3A41 is a female-specific enzyme. Its expression is not induced by classic 
CYP3A inducers like DEX or RIF and is suppressed by PCN. CYP3A14, CYP3A15, 
CYP3A17 and CYP3A20 are found in guinea pig and have about 94% amino acid 
sequence similarity with each other. The expression of these isozymes in this animal 
is regulated by ascorbic acid (Mori et al 1997; Mori et al 1998). CYP3A10 is a male 
specific enzyme in hamster and its expression is regulated by growth hormone 
(Subramania et al 1995). CYP3A31 is another CYP3A isoenzyme present in hamster 
liver. Its expression is increased by phénobarbital and decreased by dexamethasone 
(Alabouch et al 1998). CYP3A12 and CYP3A26 are expressed in dog liver and the 
former is inducible by RIF (Nishib et al 1998; Fraser et al 1997). CYP3A8 is found in 
monkey and is induced by PB (Bullock et al 1995). CYP3A21 is found in marmoset 
and shows 90% identity to human CYP3A4 (Igarashi et al 1997). CYP3A37 is a 
member of this subfamily found in embryonic and adult chicken and is induced by all 
the classic inducers of CYP3A, except RIF (Ourlin et al 2000). CYP3A30 is found in 
a teleost fish, Fundulus heteroclitus (Celander & Stegeman 1997). CYP3A38 and 
CYP3A40 are found in another fish, Oryzias latipes, and the latter is expressed in both 
foetal and adult animals (Kullman et al 2000; Kulman & Hinton 2001). Finally 
CYP3A27 is found in rainbow trout and is expressed in females considerably more 
than males (Lee et al 1998).
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All these CYP3A isozymes usually metabolise the same substrates but clearly show 
differences in their induction and inhibition profiles (Miranda et al 1998; Mori et al
1997).
1.5.3. CYP3A isoenzymes in different human tissues
CYP3A is the most abundantly expressed CYP subfamily in the human liver (Li et al 
1995) and small intestine (Schuetz et al 1996). It constitutes about 30% of the hepatic 
(Guengerich 1999; Westlind et al 1999) and 70% of the small intestinal cytochrome 
P450 content (Schuetz et al 1996). The activity of hepatic CYP3A shows great 
variation among individuals (Seree et al 1998). There is also marked inter-individual 
heterogeneity in intestinal expression of CYP3A4 and CYP3A5, which contributes to 
the heterogeneous pharmacokinetics of orally administered CYP3A substrates. Lown 
et al (1994) found a 6-fold variation in CYP3A catalytic activity (midazolam 
hydroxylation), an 11-fold variation in CYP3A4 protein content, and an 8-fold 
variation in CYP3A4 mRNA content in intestinal biopsies. Seree et al (1998) found 
an even larger variation (up to 80-fold) in CYP3A4 expression in 16 human liver 
samples. CYP3A4 and CYP3A5 are the main adult specific isoenzymes of 
cytochrome P450 3A in human livers, whereas CYP3A7 is expressed in the foetal 
liver. Although these isoenzymes are closely related structurally, they differ in their 
capacity to carry out monooxygenase reactions. After birth the activity of CYP3A7 
declines to a very low level in adult liver and that of CYP3A4 rises. It reaches 30- 
40% of the adult activity after one month (Lacroix et al 1997). The shift between 
CYP3A7 and CYP3A4 occurs immediately after birth, and this is transcriptionally 
controlled (Hakkola et al 1998).
CYP3A4 also seems to be present in nearly all parts of gastrointestinal lumen. Using 
a CYP3A4 specific hybridisation probe, which actually recognises all mRNAs of the 
CYP3A subfamily and RNA blotting analysis, CYP3A mRNA was detected in human 
oesophagus, duodenum, jejunum, ileum, colon, and rectum (McKinnon et al 1995). 
CYP3A activity, CYP3A content and CYP reductase activity was shown to rise 
slightly from duodenum to middle jejunum and then decline in the distal jejunum and 
ileum (McKinnon & McManust 1996; Paine et al 1997). These findings indicate that 
the upper small intestine (duodenum and proximal jejunum) may serve as the major 
site for intestinal first-pass metabolism of CYP3A substrates which exhibit poor or
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unpredictable bioavailability (Paine et al 1997). In all segments of the small intestine 
and colon, CYP3A mRNA was highest in mucosal cells within the non-proliferative 
compartment. The precise isoform of the CYP3A subfamily expressed varied along 
the gastrointestinal tract (McKinnon & McManust 1996).
In human liver, CYP3A4 is the most abundant of all P450s while CYP3A5 is 
expressed in approximately 25% of individuals (McKinnon & McManust 1996). 
However, there are other studies with conflicting results. Jounaidi et al (1996), using 
immunobloting and RT-PCR, could detect CYP3A5 protein in 74% of human liver 
samples and its mRNA in 100% of samples (19 samples). The basis for this variation 
in expression of the isoenzymes is not clear (Guengerich 1999). In two of the five 
individuals devoid of CYP3A5 protein, the allelic variation T398N (C to A 
transversion at 1280) was detected, which suggests that a basis of the polymorphism 
might be unstable proteins (Jounaidi et al 1996). Also, CYP3A5 is more commonly 
expressed in the liver of children and teens, as compared with adults, but is not 
present in all children (47%), nor it is gender-specific in this age group (Oesterheld 
1998). Interestingly, some researchers could also detect CYP3A5 expression in the 
distal small intestine (Paine et al 1997). However, the intestinal concentration of 
CYP3A5 protein, which seemed to vary greatly among patients, did not correlated 
with that of CYP3A4 protein. This suggests that in the intestine, as in the liver, the 
two isoenzymes are independently regulated, with CYP3A5 expression predominating 
in the stomach and colon (Paine et al 1997). RNA blot analysis of mRNA samples 
from 11 human colons revealed that multiple CYP3A genes were expressed in some 
samples and not in others (McKinnon et al 1996). CYP3A4 transcripts were 
demonstrated in 5 of the 11 samples, always at lower levels than seen in liver or small 
intestine and CYP3A5 expression was demonstrated in 6 of 11 samples. The 
expression of CYP3A was very low in rectal specimens.
CYP3A5 appears to be expressed polymorphically in the liver, with about 25% of 
individual adults showing appreciable hepatic expression. When it is expressed, the 
level is usually -25% of the level of P450 3A4, although the ratio varies. In spite of 
being in the minority in the liver and intestine, it has a dominant role in other 
extrahepatic tissues (Yanagimoto et al 1997). CYP3A5 is the more abundant enzyme 
in human lung (Anttila et al 1997), kidney (Haehner et al 1996) and the only CYP3A
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isoenzyme in blood (Jaranden et al 1996). It was shown that all kidneys in an 
experiment (25 samples) contained CYP3A5 protein and its mRNA. CYP3A4 was 
detected in 40% of the kidney samples and 70% of those that contained detectable 
CYP3A4 mRNA also expressed detectable levels of the corresponding protein 
(Haehner et al 1996). But renal enzyme levels are much lower than those in the liver 
(Ghosh et al 1995; Hammond et al 1997). In normal kidney the predominant cellular 
localization of CYP3A was to proximal tubular epithelial cells. Based on 
immunohistochemical studies of the human kidney, CYP3A seems to be located in 
the proximal tubule, thin limb of Henle, the cortical collecting ducts, and the cells 
lining the renal pelvis (Haehner et al 1996). In another study RT-PCR showed that 
both CYP3A5 mRNA and CYP3A7 mRNA were consistently present in both renal 
tumor and normal samples, while CYP3A4 mRNA was present in 65% of tumors and 
90% of normal samples (Murray et al 1999).
CYP3A5 is also present in the ciliated and mucous cells of the bronchial wall, 
bronchial glands, bronchial columnar and terminal cuboidal epithelium, type I and II 
alveolar epithelium, vascular and capillary endothelium, and alveolar macrophages. 
CYP3A4 is expressed in about 20% of individuals and is found in bronchial glands, 
bronchial columnar and terminal epithelium, type II alveolar epithelium, and alveolar 
macrophages (Anttila et al 1997).
It has now been shown that CYP3A5 activity is present in the pituitary gland and is 
localised to growth hormone-containing cells of the anterior pituitary (Murray et al 
1995). It may play a role in regulating growth hormone secretion in this gland, since 
the release of this hormone from rat pituitary somatotrophs in vitro is inhibited by 
broad-spectrum cytochrome P450 inhibitors and stimulated by some metabolites of 
arachidonic acid produced by P450. CYP3A5 and not CYP3A4 immunoreactive 
protein is also present in the cytoplasm of neutrophils (Jarandan et al 1996).
High levels of CYP3A7 exist in the liver during foetal life. In the 20 weeks old foetus 
it accounts for one third of the total foetal cytochrome P450 content (Oesterheld
1998). It is expressed at low levels in adult liver, and expression of the protein in 
adults is not induced in response to RIF (Harvey et al 2000). Using Northern blot and 
RT-PCR, Schuetz et al (1994) demonstrated the presence of CYP3A7 mRNA in the
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liver of 7 out of 13 of adults examined. Greuet et al (1996) also showed the presence 
of CYP3A7 in 8 out of 9 adult liver samples using RT-PCR. These findings confirm 
that CYP3A7 is not exclusively expressed in the foetus. However, the level of 
CYP3A7 mRNA in adult livers exhibited a wide inter-individual variability (one 
order of magnitude) and was approximately 2% of the level in foetal livers. CYP3A4 
mRNA was also detected in the foetal liver sample, albeit at a level which was 
approximately 10% of that found in adults (Greuet et al 1996). It is of note that no 
CYP3A isoform had until recently been reported in the foetal liver of experimental 
animals, such as rats, mice, and rabbits, except after induction or just before 
parturition (Yang et al 1994). However, it has now been shown that CYP3A25 is 
expressed constitutively in the mouse foetus (Dai et al 2001).
It has been reported that liver microsomes obtained from women have a higher 
specific activity of CYP3A enzymes than do liver microsomes obtained from men 
(Hunt et al 1992; Oesterheld 1998). Lown et al (1994) also observed that CYP3A4 
mRNA and protein are higher in women than in men. Gender differences in the 
expression of CYP3A has also been demonstrated in rats in both the liver and the 
intestine (Kolars et al 1992; Sakuma et al 2000).
Total hepatic CYP activity declines with age (Sotaniemi et al 1997) mainly due to the 
reduction in the CYP3A subfamily enzyme activity (Sotaniemi et al 1996) at a rate of 
5% in each decade (George et al 1995). This is reflected in the age-related decline in 
the clearance of known CYP3A substrates such as erythromycin, verapamil, 
quinidine, and midazolam (George et al 1995).
1.5.4. CYP3A gene structure in humans
The whole CYP3A locus in man has been isolated and sequenced (Gellner et al 2001). 
The 231 kb locus on chromosome 7 contains the three CYP3A genes described 
previously (CYP3A4, CYP3A5 and CYP3A7), three pseudogenes and a novel 
CYP3A gene termed CYP3A43 (Figure 1.10). The CYP3A4 gene is 27 kb long, with 
13 exons and 12 introns. The promoter region of this gene (Figure 1.11) contains a 
typical TATA box and the basic transcription element (BTE) which is reported to 
exist in the proximal region of several cytochrome P450 genes. In addition, the 
putative binding sites of transcriptional regulatory factors such as the oestrogen
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receptor (ER), the progesterone receptor/glucocorticoid receptor (PR/GR), hepatic 
nuclear factor-4 (HNF-4), hepatic nuclear factor-5 (HNF-5) and the tumour 
suppressor p53 exist upstream of the major transcription initiation site (Hashimoto et 
al 1993). No gene has been found for the cDNA sequence reported as CYP3A3 
which differs from CYP3A4 in 14 coding positions. It is now considered as being an 
artifact resulting from sequencing errors (Guengerich 1999).
The amino acid sequence deduced from CYP3A5 cDNA contained 502 residues, with 
a calculated protein molecular mass of 57,115 daltons and displayed 84% similarity 
with CYP3A4. The CYP3A5 promoter contains a CAT A box instead of the typical 
TATA box and a basic transcription element (BTE). The 5'-flanking region of 
CYP3A5, from nucleotide -1 to -1434, is 60% similar with the corresponding region 
of CYP3A4 and 59% with CYP3A7, respectively. However, the similarity increases 
to 74% when only nucleotides -1 to -700 were compared. The similarity between 
CYP3A4 and CYP3A7 in the same region is 92%. The 5'-flanking sequences of 
CYP3A4 and CYP3A7 appear therefore to be more closely related to each other than 
to CYP3A5. The similarity between the 5'-flanking sequences of CYP3A5 and that 
of the two other CYP3A genes drop abruptly to less than 42%, upstream from 
nucleotide -700, while the similarity between CYP3A4 and CYP3A7 remains greater 
than 89%, within the same region (Jounaidi et al 1994). The similarity between 
CYP3A4 and CYP3A7 is 95% at the nucleotide level and 87% at the amino acid 
level. The similarity of the 5'-flanking region sequences between CYP3A4 and 
CYP3A7 genes is 91% (Hashimoto et al 1993). The CYP3A7 apoprotein has been 
shown to have a slightly higher molecular weight than other members of the CYP3A 
subfamily (Oesterheld 1998).
When comparing the 5’-flanking region of CYP3A4, CYP3A5 and CYP3A7, several 
motifs or deletions appears to be characteristic of each gene. A ten nucleotide-long 
sequence is present in the 5’-flanking region of CYP3A4 (AGGGCAAGAG, termed 
the NFSE, from nucleotides -286 to -295) and CYP3A5 with two mismatches 
(AGGGCAgGtG, from -225 to -234) but is absent in CYP3A7. A nine nucleotide- 
long sequence is present in the 5’-flanking region of CYP3A7 (GATGGAGTG, 
termed the HFLaSE, from nucleotides -370 to -379) but absent in CYP3A4 and
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CTGCAGTGACCACTGCCCCATCATTGCTGGCTGAGGTGGTTGGGGTCCATCTGGCTATC
TGGGCAGCTGTTCTCTTCTCTCCTTTCTCTCCTGTTTCCAGACATGCAGTATTTCCAGAG
HNF-5 HNF-5
AGAAGGGGCCACTCTTTGGCAAAGAACCTGTCTAACTTGCTATCTATGGCAGGACCTT
TGAAGGGTTCACAGGAAGCAGCACAAATTGATACTATTCCACCAAGCCATCAGCTCCA
TCTCATCCATGCCCTGTCTCTCCTTTAGGGGTCCCCTTGCCAACAGAATCACAGAGGAC
CAGCCTGAAAGTGCAGAGACAGCAGCTGAGGCACAGCCAAGAGCTCTGGCTGTATTA
ATGACCTAAGAAGTCACCAGAAAGTCAGAAGGGATGACATGCAGAGGCCCAGCAATC
TCAGCTAAGTCAACTCCACCAGCCTTTCTAGTTGCCCACTGTGTGTACAGrArrrTGGT
HNF-4
AGGGACCAGAGCCATGACAGGGAATAAGACTAGACTATGCCCTTGAGGAGCTCACCT
CTGTTCAGGGAAACAGGCGTGGAAACACAATGGTGGTAAAGAGGAAAGAGGACAATA
GGATTGCATGAAGGGGATGGAAAGTGCCCAGGGGAGGAAATGGTTACATCTGTGTGA
ERE
GGAGTTTGGTGAGGAAAGACTCTAAGAGAAGGCTCTGTCTGTCTGGGTTTGGAAGGAT
AP-3
GTGTAGGAGTCTTCTAGGGGGCACAGGCACACTCCAGGCATAGGTAAAGATCTGTAGG
p53-bindmg motif
TGTGGCTTGTTGGGATGAATTTCAAGTATTTTGGAATGAGGACAGCCATAGAGACAAG
-289
GGCAAGAGAGAGGCGATTTAATAGATTTTATGCCAATGGCTCCACTTGAGTTTCTGAT
NFSE PRE/GRE CAAT box
AAGAACCCAGAACCCTTGGACTCCCCAGTAACATTGATTGAGTTGTTTATGATACCTC
ERE HNF-5
ATAGAATATGAACTCAAAGGAGGTCAGTGAGTGGTGTGTGTGTGATTCTTTGCCAACT
P X K - R E  o r  E K - 6  U c t a m e r  m o t i t
TCCAAGGTGGAGAAGCCTCTTCCAACTGCAGGCAGAGCACAGGTGGCCCTGCTACTGG
CTGCAGCTCCAGCCCTGCCTCCTTCTCTAGCATATAAACAATCCAACAGCCTCACTGAA
BTE TATA box
TCACTGCT
Figure 1.11 The cytochrome P450 3A4 promoter sequence [Amirimani et al (1998), 
genebank accession number API 81105]. TATA box (pre-initiation complex binding site), BTE 
(basic transcription element), Octamer motif and CAAT box (putative binding sites of general 
transcriptional regulatory factors), PXR-RE (pregnane-x-receptor response element), ER-6  
(everted repeat 6 ), HNF (hepatic nuclear factor), ERE (oestrogen response element), PRE 
(progesterone response element), GRE (glucocorticoid response element), NFSE (nifedipine- 
specific element), p53 (putative transcriptional factor and cancer preventing protein) and AP-3 
(activating protein 3). The designated motif and elements are taken from Hashimoto et al (1993) 
and PXR-RE or ER-6  is taken from Lehmann et al (1998).
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replaced by ACCATTAGTCTATTGCT in CYP3A5 (from nucleotides -695 to -711). 
A 12 nucleotide-long sequence GAGGGAATTGCA (from nucleotides -308 to -320) 
and an 8 nucleotide-long CT-rich sequence TTTCCTTT (from nucleotides -772 to -  
780) are present in CYP3A5 but absent in both CYP3A7 and CYP3A4. There is also 
a 50 bp deletion upstream of the BTE at -63 in CYP3A5. Whether or not these 
specific sequences play a part in the differential regulation of the CYP3A genes in 
man remains to be established (Jounaidi et al 1994).
1.5.5. The metabolic function of human CYP3A isoenzymes
CYP3A5 and CYP3A7 show similar metabolic function to CYP3A4. These enzymes 
metabolise some procarcinogens but a role in carcinogenesis has not been established 
for them (Anttila et al 1997; Oesterheld 1998). Renal cell cancer is considered to 
develop from proximal tubular epithelial cells and the presence of CYP3A in normal 
proximal tubular epithelium suggests that it may be involved in tumor development 
(Murray et al 1995).
It has been established that both human CYP3A4 (Waxman et al 1988) and CYP3A5 
(Wrighton et al 1990) catalyse the conversion of cortisol to its 6 P-hydroxy metabolite 
(6 P-GHC). Consequently, a pathophysiological role of renal CYP3A has been 
suggested to occur as a result of excessive intrarenal conversion of cortisol to 6 P- 
OHC. Increased levels of 6 P-OHC in the renal tubule may mediate enhanced sodium 
reabsorption via a unique nuclear receptor, which, in turn, could result in a clinical 
picture of salt-sensitive hypertension (Grogan et al 1990; Ghosh et al 1993). 
Cushing’s syndrome, oestrogen excess, and preeclampsia are human conditions that 
are associated with both hypertension and excessive urinary excretion of 6P-0HC. 
Also, in spontaneously hypertensive rats (SHR) increased levels of renal CYP3A have 
been linked with increased production of 6P-0HC (rat endogenous glucocorticoid) 
and systemic hypertension (Watlington et al 1992). The SHR exhibit a six-fold 
increase in renal cytochrome P450, systemic hypertension, and increased urinary 
excretion of 6P-0HC relative to normotensive rats. The nonspecific destruction of 
renal cytochrome P450 with stannous chloride and the more specific inhibition of 
CYP3A with TAG resulted in decreased 6 p-GHC excretion and significantly lower 
blood pressure in SHR.
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Protection of the foetus from maternal and foetal steroids is probably the main 
function of foetal CYP3A7. It has been shown in vitro (Kitada et al 1987; Kitada & 
Kamataki 1994) that CYP3A7 in foetal liver is responsible in part for the 6 -beta 
hydroxylation of testosterone and the 16-alpha hydroxylation of 
dehydroepiandrosterone 3-sulfate (DHEA-S), a step in the metabolic pathway to 
oestriol (Raucy & Carpenter 1993). The foetal adrenal also participates to some 
extent in the metabolism of DHEA-S, but is predominantly involved in the 
metabolism of progesterone (Rane et al 1992). CYP3A7’s ability to metabolise foetal 
and maternal steroids helps protect the foetus from the effects of maternal steroids and 
DHEA-S which are known to be toxic to the foetus in high concentrations (Schuetz et 
al 1993a). Also, DHEA-S hydroxylation is catalysed at a higher rate in foetal liver 
than in adult livers (Cresteil et al 1982). In the foetal liver, this reaction is almost 
exclusively catalysed by CYP3A7 (Kitada et al 1987), with a lower Km and higher 
Vmax than CYP3A4 or CYP3A5 (Lacroix et al 1997; Ohmori et al 1998). 16aOH- 
DHEAS is a precursor of placental oestriol synthesis, and 90% of it is produced by the 
foetus (Ryan 1980). In contrast, DHEAS, which is needed for placental oestrone and 
oestradiol synthesis, is of both maternal and foetal origin. Thus foetal liver CYP3A7 
may have a crucial role in placental oestriol synthesis (Hakkola et al 1998). However, 
CYP3A7 is known to also be present in placental and adult uterine tissue (Schuetz et 
al 1993). In these extra-hepatic sites, CYP3A7 may contribute to the alpha and beta 
hydroxylation of matemal/foetal steroids (Oesterheld 1998). CYP3A7 is also 
primarily responsible for the 4-hydroxylation of retinoic acid and thus might play an 
important role in protecting the human foetus against retinoic acid induced 
embryotoxicity (Chen et al 2000). Retinoic acid is essential for normal human 
development but both its excess and deficiency are now known to cause severe birth 
defects (Means & Gudas 1995).
1.5.6. CYP3A xenobiotic substrates in humans
CYP3A4 probably has the broadest catalytic activity of any cytochrome P450. The 
substrates vary in size from smaller molecules such as acetaminophen (Mr 151) to 
cyclosporine A (Mr 1201) (Guengerich 1999). An updated list of about 100 known 
human drug substrates is presented in Table 1.3. The list of substrates includes not 
only drugs but also synthetic steroids and carcinogens. Although an extensive list of
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other xenobiotic substrates such as pesticides (e.g. parathion, aldrin) has not been 
compiled, undoubtedly the number of substrates is larger. Studies are also in progress 
to determine whether the oxidation of certain peptides is catalysed by CYP3A4 
(Guengerich 1999).
CYP3A4 and CYP3A5 catalyse the 6 P-hydroxylation of the steroid hormones 
testosterone, progesterone, hydrocortison, and androstenedione, although CYP3A4 
exhibited several fold higher expressed activity than CYP3A5 (Aoyama et al 1989; 
Haehner et al 1996). CYP3A5 shows roughly the same substrate preference pattern 
but the turnover rates are lower. However exceptions appear to exist, since aflatoxin 
Bi and 1-nitropyrene are both activated by CYP3A4 but not by CYP3A5. However, 
both CYP3A4 and CYP3A5 are active in the metabolism of benzo(a)pyrene and some 
other procarcinogens (Anttila et al 1997). Several minor oxidation products of 
steroids (e.g. 15P-hydroxytestosterone) comprising up to - 2 0 % of the total 
metabolites, are formed by CYP3A4 but not CYP3A5 (Aoyama et al 1989). Clear 
differences were also detected in the catalytic activities toward the 
immunosuppressive drug cyclosporine, with two hydroxylated metabolites and one 
demethylated metabolite formed by CYP3A4 but only one hydroxylated metabolite 
formed by CYP3A5 (Aoyama et al 1989). Also, CYP3A4 N-demethylates 
erythromycin roughly 10-fold faster than does CYP3A5 (Lown et al 1994).
Of the large number of compounds identified as substrates of CYP3A sub-family 
members, CYP3A5 was found to rapidly metabolise nifedipine, testosterone, 
oestradiol, dehydroepiandrosterone 3-sulfate (DHEA), and cortisol, whereas it 
metabolised poorly or did not metabolise erythromycin, quinidine, 17a- 
ethinylestradiol, and aflatoxins (Wrighton et al 1990). Shimada et al (1989) 
demonstrated that CYP3A4 activates a number of procarcinogens in a transformation 
bioassay (mutation assay) with Salmonella typhimurium. Reconstituted CYP3A5 was 
found to have less than 15% of the activity of CYP3A4 in this assay with aflatoxin 
B l, sterigmatocystin, and (-)-benzo(a)pyrene-7,8-diol and no activity with (+)- 
benzo(a)pyrene-7,8-diol and 6 -aminochyrsene (Wrighton et al 1990). However, using 
purified CYP3A5 and heterologously expressed CYP3A4 in reconstitution systems, 
Wrighton et al (1990) found that CYP3A5 contributes relatively little to the
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Table 1.3. Drug substrates of CYP3A4 (modiffed from Guengerich 1999Y
Acetaminophen (quinoneimine formation) Lovastatin (6 'P, 6 '-exo-methylene,
Albendazole (S-oxide) 3",3',5'-dihydrodiol)
Alfentanil (noralfentanil formation) Meloxicam
Alprazolam Methadone (N-demethylation)
Amiodarone (N-deethylation) Midazolam
Amitryptyline (N-demethylation) Mifepristone (RU486) (N-demethylation)
Astemizole N-hydroxyarginine
Benzphetamine (N-demethylation) Nevaripine
Bupivacaine (N-dealkylation) Nicardipine (pyridine formation)
Carbamazepine (10, 11-epoxidation) Nifedipine (pyridine formation)
Citalopram (N-demethylation) Niludipine (pyridine formation)
Claritromycin Nimodipine (pyridine formation)
Clozapine Nisoldipine (pyridine formation)
Codeine (N-demethylation) Nitrendipine (pyridine formation)
Colchicine (2,3) Omeprazole (S, 5)
Cortisol (6 P) Oxodipine
Cyclophosphamide Paclitaxel (taxol) (3'-phenyl para-OH)
Cyclosporin A Progesterone (6 p, some 16a)
Cyclosporin G Propafenone
Dapsone (N) Proquanil (cyclisation)
Dehydroepiandroterone 3-sulfate (16a) Quinidine (3, N)
Delaviridine (6 ',N-dealkylation) Rapamycin (0-dealkylation)
Dextromethorphan (N-demethylation) Retinoic acid
Diazepam (3) Ritonavir
Digitoxin Sameterol (a)
Diltiazem Sequenavir
Disopyramide (N-dealkylation) Sertindole (N-dealkylation)
Emetine (O-demethylemetine) Sulfamethoxazole (N)
17p-Estradiol (2,4) Sulfentanil
Erythromycin (0-demethylation) Tacrolimus (FK 506) (several)
Ethylmorphine (N-demethylation) Tamoxifen (N-demethylation)
17P-Ethynylestradiol (2 ) Tasosartan
Etoposide Teniposide
Felodipine (pyridine formation) Terfenadine (/-butyl, N-dealkylation)
Finasteride (t-butyl) Terguride
Flutamide Testosterone (6 P, trace 15P, 2p)
Gestoden T etrahy drocannabinol
Granisterone (7,9') Theophylline
Haloperidol (alcohol oxidation) Toremifine (4, N-demethylation)
Ifosphamide Triazolam
Imipramine (N-demethylation) Trimethadone (N-demethylation)
Indinavir Trofosfamide (4-hydroxylation,
Ivermectin (several) N-dechloroethylation)
Lansoprazole (5) Verapamil
Lidocaine (N-deethylation) Warfarin (R-10, S-dehydro)
Lisuride (N-deethylation) Zatosetron (N)
^Parentheses, positions of oxidation, if identified.
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metabolism of the majority of the compounds known to be metabolised by the 
CYP3A subfamily. The lower number of substrates and catalytic rates of CYP3A5, 
relative to CYP3A4, suggest that the substrate binding sites of the two enzymes differ, 
although the amino acid differences between the two proteins appear to be evenly 
distributed (Wrighton et al 1990).
In in vitro systems, CYP3A7 metabolises substrates such as testosterone, 
erythromycin, TAO, nifedipine, aldrin, quinidine, benzo(a)pyrene, 7-ethoxycoumarin, 
ethylmorphine, N,N-dimethylaniline, aminopyrine, p-nitroanisole, cortisol, N- 
methylaniline, N,N-dimethylnitrosamine, indinavir and midazolam (Oesterheld 1998). 
Foetal hepatic CYPs have high mutagen-activating abilities. CYP3A7 can also 
activate promutagens such as aflatoxin B l. Benzo(a)pyrene is metabolised by foetal 
CYP3A7 and CYPlAl enzymes. These foetal reactions could be associated with 
foetal carcinogenesis and dysmorphogenesis (Oesterheld 1998).
1.6. Regulation of CYP3A isoenzyme expression
Regulation of CYP3A enzyme activity by either gene induction or enzyme inhibition 
can have a dramatic effect on the plasma levels of substrates and metabolites of these 
enzymes, which is of particular concern for those compounds of low therapeutic 
index. In one experiment (Backman et al 1998), a change from inhibition to induction 
of CYP3A isoenzymes caused a 400-fold change in the AUC of oral midazolam. It 
was also noted that some organ transplant patients had pronounced decreases in their 
blood levels of cyclosporin A, risking organ rejection, after they had begun treatment 
with RIF (Hebert et al 1992). Conversely, it has been reported that some transplant 
patients who received inhibitors of CYP3A4 (such as ketoconazole) had pronounced 
increases in their blood level of cyclosporin, resulting in potentially serious central 
nervous system and kidney toxicity (Inaba et al 1995).
It should be noted that induction of CYP3A expression can be organ-specific. DEX 
treatment of rats increased the CYP3A catalytic activity approximately 4 fold in the 
liver, but not in the kidney, suggesting that CYP3A is not inducible in the kidney 
(Zerillia et al 1998). There are two possible explanations for this. First, in some 
tissues the necessary transcription factors for regulation of the gene may be lacking.
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hPXR, the main transcriptional regulator of CYP3A4 expression is found in high 
amount in liver and intestine only but is very low in kidney. Secondly, there can be 
tissue-specific structural variation in CYP3A mRNAs. The human prostate CYP3A5 
mRNA has a unique 5'-untranslated sequence, suggesting that the prostate-specific 
regulation of CYP3A5 expression or mRNA processing is different from liver 
(Yamakoshi et al 1999).
1.6.1. Regulation of CYP3A4 gene expression
As described above, naturally occurring steroids and their synthetic analogues such as 
DEX modulate CYP3A gene expression at the transcriptional (Dogra et al 1998) and 
post-transcriptional (Eliasson et al 1994) levels. There are also several steroid 
hormone receptor response elements between about - 2 0 0  and about -500bp on the 
CYP3A4 gene (Figure 1.10). More recently, hormone response elements have also 
been found at around -8000 bp (Goodwin et al 2000).
Early studies in rats established that the induction mechanism of CYP3A by DEX 
apparently differed from that of the classical glucocorticoid receptor inducible genes, 
such as tyrosine aminotransferase (Schuetz & Guzelian 1984). For example, a higher 
concentration of DEX was required for CYP3A1 induction in rat hepatocytes, while 
the antiglucocorticoid PCN stimulated further induction of this mRNA but inhibited 
the induction of tyrosine aminotransferase mRNA. In vitro transient transfection 
studies (Quatrochi et al 1995) identified a DEX-responsive region in the proximal 
promoter of the rat CYP3A1 gene, but this region did not contain a classic 
glucocorticoid-response element (GRE) and did not bind recombinant glucocorticoid 
receptor protein. It has also been shown that glucocorticoid receptor does not 
associate with either the DEX RE-1 or RE-2 of CYP3A23, but instead, associates 
with a conserved region in the CYP3A1 and CYP3A2 gene promoters that contains a 
direct repeat (DR) of the nuclear receptor half-site sequence AGTTC A separated by a 
three nucleotide spacer, a so-called DR-3 motif (Huss et al 1996). There is other 
evidence to support the involvement of a receptor other than GR in CYP3A induction 
(Quattrochi et al 1998; Williams et al 1997; Quattrochi et al 1998). Using 
glucocorticoid receptor (+/+) and (-/-) mice, Schuetz et al (2000) demonstrated that 
CYP3A induction by glucocorticoids, anti glucocorticoids, and RIF proceeds via a
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mechanism that does not require the glucocorticoid receptor. Moreover, there 
appeared to be no influence of the glucocorticoid receptor on basal expression of the 
CYPSAs (Schuetz et al 2000). These unusual features suggest an alternate pathway 
through which glucocorticoids exerted their effects (Huss et al 1996). Induction of 
CYP3A by other agents such as metyrapone and possibly RIF was also not apparently 
related to GR (Dogra et al 1998).
A broad range of drugs, environmental chemicals, and steroids can serve as CYP3A 
inducers. However, important species differences in the induction response have been 
described (Wrighton et al 1985). Most notably, while the rat, rabbit, and human 
CYP3A genes were all inducible by DEX, the antiglucocorticoid PCN was an 
efficacious CYP3A inducer in the rat but not in humans or rabbits (Kocarek et al
1995). By contrast, the antibiotic RIF was an excellent CYP3A inducer in humans 
and rabbits, but not in the rat (Kocarek et al 1995). Transfection studies in rat and 
rabbit hepatocytes utilising CYP3A constructs containing DEX-responsive regulatory 
elements derived from rat CYP3A23, rabbit CYP3A6, and human CYP3A4 genes 
(Barwick et al 1996) demonstrated that the species-specific induction responses are 
not due to species differences in the individual CYP3A genes, but are rather a 
function of factor(s), most likely a receptor, provided by the host species liver cell. 
Moreover, the finding that the DEX response element is composed of two imperfect 
repeats of a consensus nuclear receptor half-site sequence AG(G/T)TCA (Quattrochi 
et al 1995; Huss et al 1996) strongly suggested a role for a nuclear receptor, albeit one 
that was distinct from GR.
Kliewer et al (1998) discovered that an orphan nuclear receptor, later named the 
pregnane X receptor (PXR), could bind as a heterodimer with RXR-a to the mouse 
CYP3A1 direct repeat separated by 3 bp, AGTTC A-N3-AGTTC A (DR-3) and caused 
transcriptional activation. Certain steroids like pregnenolone and its metabolites, as 
well as DEX and antisteroids (e.g. PCN) activated mPXR. However, additional 
proteins such as the steroid receptor co-activator protein-1 (SRC-1) were required for 
optimal transcriptional activation. In a short period of time the human (Bertilsson et 
al 1998; Lehmann et al 1998), rat (Zhang et al 1999) and rabbit (Savas et al 1999) 
analogues of PXR were also characterized and their role in CYP3A induction
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demonstrated. Human and rabbit PXRs also heterodimerized with RXR-a and 
efficiently activated an everted repeat separated by 6  bp (ER6 ), element TGAACT- 
Nô-AGGTCA) in the CYP3A4 and CYP3A6 genes respectively. Alignment of the 
PXR sequences revealed interesting differences between species. Although their 
DNA-binding domains (DBDs) are approximately 95% identical, the LBD of the 
rabbit, rodent and human PXR share only about 80% amino acid identity (Jones et al 
2000).
The human and rabbit PXR were both efficiently activated by RIF as well as by 
RU486, clotrimazole, /ran^-nonachlor, and phénobarbital (Jones et al 2000). 
However, rabbit PXR was much more sensitive than its human ortholog to activation 
by DEX, PCN, cyproterone acetate, and spironolactone. SRI2813 was a very potent 
and efficacious activator of both human and rabbit PXR, with EC50 values of 
approximately 200 nM and 700 nM respectively. This is the most potent PXR 
activator to be identified to date. By contrast, SR12813 was only a very weak 
activator of rat and mouse PXR. The profile of induction of CYP3A expression with 
RIF, PCN and SRI2813 in the different species tested was in agreement with the 
profile of PXR activation in the same species. These results demonstrate that the 
PXR activation profile is predictive of the effects of these agents on CYP3A induction 
(Jones et al 2000). Using transfection experiments with human PXR in primary rat 
liver cells and transgenic mice modified to express human PXR instead of mouse 
PXR, Xie et al (2000) showed that CYP3A induction in both cases mirrored the 
human pattern and thus PXR is the final determinant of CYP3A induction in any 
species. An important pharmaceutical implication of these findings is that PXR 
binding and activation assays can now be used to predict which compounds will 
induce CYP3A gene expression and thus affect the turnover of other drugs (Kliewer 
et al 1999). Thus while the observed inter-individual variation in the metabolism of 
different drugs has been suggested to be due to variation in the expression of 
CYP3A4, it could primarily be due to inter-individual differences in hPXR 
levels/activity and hence hPXR-mediated signal transduction, opening up new 
possibilities for investigating genetic differences in drug metabolism (Bertilsson et al
1998).
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Another nuclear receptor that is involved in CYP3A4 induction is CAR (Waxman 
1999; Xie et al 2000). Biochemical and genetic studies had previously established 
CAR as the main CYP2B regulator. Xie et al (2000) found that PXR could also 
regulate CYP2B in cultured cells and transgenic mice via ‘adaptive recognition’ of the 
phénobarbital response element (PBRE). In a type of functional symmetry, CAR was 
also found to activate CYP3A4 expression through previously defined PXR response 
elements (Xie et al 2000). These observations not only provide a rational explanation 
for the activation of multiple cytochrome P450 genes by xenobiotics, but also reveal 
the existence of a metabolic safety net that confers a second layer of protection for the 
harmful effects of toxic compounds. However, it also increases the propensity for 
drug-drug interactions.
Close inspection of reports regarding the role of hPXR and CAR in CYP3A gene 
induction suggests that these receptors may not totally account for drug and steroid 
induction of CYP3A, and therefore, the possibility requires that the glucocorticoid 
receptor (GR) is also required for the induction of this subfamily. First, DEX, which 
is an efficacious inducer of rat (Wrighton et al 1985), mouse (Yanagimoto et al 1997) 
and human (Watkins et al 1989) CYP3A expression, was only a weak ligand for 
mouse and human PXRs (Kliewer et al 1998; Bertilson et al 1998). Indeed, Bertilsson 
et al (1998) found no activation of human PXR by DEX, concluding that there must 
be additional mechanisms for DEX induction of CYP3A4. Second, none of the four 
reports on PXR activation have used the authentic CYP3A4 5'-flanking sequence 
which also contains putative GR binding elements (Ogg et al 1999). Instead, only 
reporter constructs with multiple copies of the PXR binding motif were used. Finally, 
RIF is a good inducer of mouse CYP3A (Wrighton et al 1985; Yanagimoto et al
1997), yet RIF is reported to be a weak activator of mouse PXR, suggesting there may 
also be an alternative mechanism for RIF induction of CYP3A in the mouse. Indeed, 
RIF was recently demonstrated to be a nonsteroidal ligand for the human GR. 
Therefore, it can be concluded that PXR and CAR are not the only transcription 
factors required for steroid and drug induction of CYP3A and the possibility exists 
that GR may also play a role in steroid and RIF induction of CYP3A (Zhang et al
1999). It has been suggested that cooperation of the upstream GRE and downstream 
elements (e.g. the PXR element) may be required for the maximal response of
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CYPS A to glucocorticoids (Schuetz et al 2000).
It has recently been shown that DEX increases the expression of hPXR mRNA. 
Pascussi et al (1999) used cultured primary human hepatocytes to study the induction 
of CYP3A4, especially the potentiation of RIF induction by low levels of DEX. 
Studies measuring hPXR mRNA levels demonstrated that levels of DEX in the range 
required to activate GR increased expression of both hPXR and RXR mRNAs, as well 
as tyrosine aminotransferase (TAT) mRNA with the same time and dose dependence. 
While induction of CYP3A4 expression by RIF was dependent upon de novo protein 
synthesis using cycloheximide as a protein synthesis inhibitor, there was no effect on 
induction of hPXR and TAT mRNA levels by DEX. Addition of RU486 blunted the 
hPXR and TAT mRNA increases and potentiated the effect of DEX on RIF induction 
of CYP3A4 mRNA levels. These data suggest that GR controls the expression of 
PXR and RXR genes in human hepatocytes. A similar effect has also been observed 
for CYP3A23 induction by DEX in the rat (Huss & Kasper 2000). According to these 
experiments, the response to glucocorticoids was divided into two steps: one mediated 
by submicromolar glucocorticoid concentrations and the other triggered at high 
concentrations of PXR ligands. At low DEX levels, activation of GR caused an 
increase in cellular PXR and RXRa levels. The second stage of the mechanism 
involved direct activation of PXR by high concentrations of PXR ligands such as 
DEX or PCN (Figure 1.12).
1.6.2. Modulation of CYP3A4 enzyme activity
The activity of CYP3A4 is further modulated by cooperativity between some but by 
no means all substrates (Guengerich 1999). Both homotropic and heterotropic 
cooperativity have been observed. Homotropic cooperativity (autoactivation) is a 
positive response, in which increasing concentrations of substrate stimulate enzyme 
activity, e.g. aflatoxin Bi 3a-hydroxylation and 8,9-epoxidation (Ueng et al 1997). 
Classically, this homotropic autoactivation response observed with some cytochrome 
P450s suggests that the binding of one substrate molecule facilitates the binding of the 
next, effectively increasing the affinity of the vacant binding site (Segel 1993). 
Amitryptyline, carbamazepine, nifedipine, and some other cytochrome P450 
substrates also demonstrate autoactivation kinetics in vitro. Autoactivation is
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Figure 1.12. Model summarizing the proposed roles of nuclear receptors in the 
transcriptional activation of CYP3A23 (Huss & Kasper 2000).
The pathway can be divided into two steps. First, submicromolar concentrations of 
glucocorticoids increase cellular PXR and RXRa levels via a GR-mediated 
mechanism. This leads to increased occupancy DexRE-2 by PXR/RXRa and a low 
level of transcriptional activation. Second, PXR is activated by PCN or 
dexamethasone at high concentrations resulting in further induction. The DexRE-1 
and HNF-4 sites are required for maximal dexamethasone activation. DexRE-1 does 
not strongly bind PXR and may contribute to the full induction response by binding 
accessory factors such as the proteins associated with complex B.
54
substrate-dependent and occurs with only certain cytochrome P450s and may not 
occur with all substrates (Ekins et al 1998).
Autoactivation may be the result of the effects of in vitro constituents on cytochrome 
P450 enzyme activity. Sodium chloride has been shown to increase rabbit CYP1A2 
enzyme activity and it was suggested that a conformational change of the protein to 
increase the a-helical content resulted in increased catalytic activity (Yun et al 1998). 
A similar effect has been observed in vitro with CYP3A4 (Maenpaa et al 1998). 
Another finding which is clinically relevant is the alteration in dietary salt intake in 
humans, which can affect CYP3A catalytic activity in vivo, suggesting that the in 
vitro salt effects may closely parallel this observation (Darber et al 1997). Further in 
vitro variables that increase P450 mediated activities include increasing ionic 
strength, different buffer systems and the addition of magnesium chloride and calcium 
chloride (Maenpaa et al 1998).
The second possible explanation for an increase in cytochrome P450 activity when 
using microsomes is cytochrome P450-cytochrome P450 and cytochrome P450-other 
protein interactions. This type of protein-protein interaction has been demonstrated in 
vitro between CYPlAl or CYP1A2 with GYP3A4. In these studies the presence of 
CYP1A2 along with CYP3A4 resulted in an increase in CYP3A4 activity (Yamazaki 
et al 1997). The effects of substrates on the binding kinetics of carbon monoxide in 
mammalian cytochrome P450s that have also been described for many cytochrome 
P450s suggesting that they consist of multiple conformers (Koley et al 1996). The 
activator ccNF can also change the conformation of CYP3A4 by decreasing a-helicity 
(Ueng et al 1997).
An alternative way of viewing the substrate dependent differences in cytochrome 
P450 autoactivation and activation may be the interaction with or displacement of 
water molecules from the enzyme active site. This will ultimately cause a decrease in 
hydrogen binding within the active site. It has been widely recognised for many 
enzymes that water molecules can permit conformational flexibility (Klibanov 1997), 
allow extremely fast conformational fluctuations between a-helix and p-structure 
(Barron et al 1997), and stabilize enzyme-substrate interactions (Poomima & Dean
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1995). The feasibility of one or more substrate molecules being able to displace more 
water molecules from the cytochrome P450 active site compared to another 
structurally different substrate would normally provide some explanation for the 
resultant activation by some substrates and not others (Ekins et al 1998). Finally, the 
activation of CYP activity may be independent of water but result from the second 
molecule binding in the active site, increasing the number of potential hydrogen 
bonds to alter enzyme conformation (Ekins et al 1998).
The fact that autoactivation occurs with mammalian cytochrome P450s suggest that 
this process has been preserved over the millennia during cytochrome P450 evolution 
(Ekins et al 1998). This would again imply a role for cytochrome P450s in the 
metabolism of endogenous regulatory compounds, which then act as a messenger 
system in a similar fashion to that suggested for regulatory enzymes (Newsholme & 
Start 1973) which display atypical Michaelis-Menten kinetics. The very nature of 
autoactivation or activation may allow cytochrome P450s to remain in a relatively 
inactive state in the presence of low levels of substrate, which prevents significant 
metabolism of a messenger molecule. However, when the messenger levels increase 
or exogenous compounds reach potentially toxic concentrations, the cytochrome P450 
reacts to the presence of substrate and significantly increases metabolism of this 
compound. This behavior has also been observed with other regulatory enzymes 
(Newsholme & Start 1973).
Heterotropic cooperativity is a stimulatory effect or the oxidation of one compound 
produced by another. This was first observed for the activation of aflatoxin Bi with 
a-naphtoflavone (ocNF) in human liver microsomes (Buening et al 1978). One 
explanation for this phenomenon is that the substrate-binding site is large and one 
substrate molecule can simply alter the juxtaposition of the other to modify patterns of 
oxidation (Harlow & Halpert 1997; Shou et al 1994). This proposal is consistent with 
the known large sizes of some P450 3A4 substrates and the observed 5,6-epoxidation 
of ocNF (Ueng et al 1997; Shou et al 1994). Another possibility is that the enzyme is 
truly allosteric, which in this case would mean that there is a binding site for substrate 
that can alter the protein conformation to modify its catalytic properties (Johnson et al
1998).
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1.6.3. Regulation of CYP3A5 gene expression
The PXR-RXR heterodimer cannot activate the imperfect ER6  element found in the 
CYP3A5 gene 5'-flanking region (Blumberg et al 1998). This is supported by the 
finding that PXR-activating compounds like RIF and clotrimazole do not induce 
CYP3A5 in human lung A549 adenocarcinoma cells (Hukkanen et al 1999). 
CYP3A5 is not inducible in human liver (Wrighton et al 1989; Schuetz et al 1993) 
and evidence suggests that CYP3A5 induction is regulated in a tissue-specific manner 
in extrahepatic organs such as the lung and colon where this enzyme is abundantly 
expressed (Hukkanen et al 1999). It is therefore possible that GR is the main 
endogenous regulator of CYP3A5 as postulated by Schuetz and co-workers (1996). 
In RT-PCR experiments in the A549 cell line, CYP3A5 was induced 8 -fold by DEX 
and 11-fold by PB while PCN, clotrimazole, RIF, and TCDD did not have any effect 
(Hukkanen et al 1999). In transfection experiments DEX also stimulated the CYP3A5 
enhancer 3-4-fold in HepG2 cells and 7- to 12-fold in immortalized primary human 
hepatocytes or primary rat hepatocyte cultures, respectively (Schuetz et al 1996). 
Two GR half-sites (TGTTCT) separated by 160 bp were found in the CYP3A5 
promoter and have been shown to be necessary for DEX induction. Transfection 
analysis in HepG2 cells demonstrated that neither GRE half-site could independently 
confer DEX responsiveness on the CYP3A5 promoter and mutations in either of the 
two GRE half-sites (TGTTCT) or point mutations at specific GR binding sites 
eliminated DEX inducibility, demonstrating that the half-sites need to interact 
(Schuetz et al 1996).
1.6.4. Regulation of CYP3A7 gene expression
In the case of the CYP3A7 gene, there is confusion regarding promoter functionality. 
Itoh et al (1992) identified a CYP3A7 ER6  (ER6 -Itoh) with three nucleotide 
differences compared to the CYP3A4 ER6  sequence, two of them disrupting both half 
sites of the element. Cotransfection experiments using plasmid constructs in which 
the reporter gene was under the control of the CYP3A7 ER6 -Itoh did not show any 
transactivation of the motif by hPXR. It seems that these mutations are responsible 
for the lack of inducibility of CYP3A7 in response to xenobiotics (Blumberg et al
1998). In subsequent experiments, Pascussi et al (1999) resequenced the promoter 
region of CYP3A7 and found that in fact there were only two mutations in the
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putative ER6  element compared to CYP3A4. Cotransfection experiments in two 
different cell lines (HepG2 and HuH7) showed that the element is able to bind the 
hPXR-RXR complex and transactivate the expression of a downstream promoter in 
response to REF, clotrimazole, and RU486. Competition binding experiments showed 
that the affinity of the hPXR-RXR heterodimer is greater for the CYP3A4 ER6  
compared with the ER6  in CYP3A7 (Pascussi et al 1999).
1.7. Polymorphic variation in phase I drug metabolism
In 1902 Garrod identified alkaptonuria as the first inborn error of metabolism, and 
attributed it to a recessive genetic trait (Garrod 1902). He considered that each person 
had a chemical individuality that would make that person more or less susceptible to 
disease. He subsequently speculated that individual variations in the liver enzymes 
might influence the response of patients to a particular drug.
Today we know that each human being is different from most other human beings at 
about one nucleotide in a thousand, or about 3 million sites in the genome. Only 3- 
5% of the genome is protein coding sequence and the frequency of polymorphism is 
about 1 in 1159 bases in the coding region of genes (Wang et al 1998), so about 
78,000 polymorphisms will occur in protein coding regions. Many will be silent, but 
theoretically 6 8 % of all possible mutations will result in an amino acid substitution. 
Therefore, we all harbor about 50,000 inherited amino acid differences in our 
proteome compared with our neighbor’s. With 30,000 to 40,000 genes in humans, 
about two-thirds of our proteins will have an amino acid difference between unrelated 
individuals. Since there are about 50 different cytochrome P450 genes in humans, we 
can expect about 30 of these will bear polymorphic sites that affect the protein 
sequence. Some of these are already known and have been associated with an altered 
ability to metabolize drugs (Yamano et al 1990; de Morals et al 1994; Haining et al
1996). Other polymorphic sites that lie outside the coding region may also influence 
gene expression (Rebbeck et al 1998). The need to name these inherited differences 
(polymorphisms) in a consistent manner has prompted the formation of a human 
cytochrome P450 allele nomenclature committee (Nelson 1999).
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In the discussion of natural variations in a population, it is important to distinguish 
between rare disease-causing mutations and polymorphisms that are present in greater 
than 1% of a population. Many mutations are known in the cytochrome P450s that 
are associated with specific diseases, e.g. CYP IB 1- congenital glaucoma (Martin et al 
2000), CYP 17 17-a-Hydroxylase deficiency (Fardella et al 1993), CYP19 pseudo- 
hermaphrodism (Conte et al 1994), CYP21- congenital adrenal hyperplasia (Delague 
et al 2000), and CYP27B1- pseudovitamin D deficiency rickets (Kitanaka et al 1999), 
but these clear-cut effects are different from polymorphisms that may affect drug 
metabolism or influence susceptibility to disease without causing disease directly.
Polymorphisms may be heterogeneous, having several alleles, as in nucleotide 
repeats, or they may be single nucleotide polymorphisms (SNPs) with only two 
different alleles and a heterozygosity near 50% (Nelson 1999). Automated searches 
of the human EST database for common sequence variations have already been 
performed and more than 3000 candidate coding region SNPs have been discovered 
(Buetow et al 1999). Some rare polymorphisms near the 1% frequency level may 
however be difficult to find unless hundreds of chromosomes are examined. But 
these small differences are important. Mutagenesis experiments on CYP2C2 (lauric 
acid hydroxylase) have shown that a single amino acid substitution, S473V, allows 
CYP2C2 to accept progesterone as a substrate (Ramarao & Kemper 1995). The 
change in substrate specificity from fatty acid to steroid is significant. This 
characterisation is being extended to all the P450 genes in humans. Such knowledge 
could characterise a person’s risk of adverse drug reactions and possible 
predisposition to disease (Nelson 1999). Owing to the rapid development of efficient 
and inexpensive methods for genotyping, plus the need to genotype a patient only 
once in a lifetime, it would be possible to include the genotype in the patient’s 
medical record. This would provide medical practitioners with valuable information 
in order to individualise the drug treatment (Ingelman-Sundberg et al 1999).
To assist genetic analysis the activity of a cytochrome P450 can be measured in vivo 
using a prototypic probe substrate (e.g. debrisoquine or dextrometorphan for 
CYP2D6). The amounts of unchanged drug and metabolite are measured in urine or 
plasma and expressed as a ratio. Those who have two null alleles and show no activity
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are termed poor metabolisers. The remainder of the population, who perform this 
reaction to varying degrees, are called extensive metabolisers (Sellers & Tyndale
2000). The relative activity of the enzyme expressed in this way is constant over time 
since it is genetically differed (Eichelbaum et al 1986; Vincent-Viry et al 1991). All 
polymorphic enzymes demonstrate large inter-racial differences in the frequency of 
allele variants (Kalow et al 1991). In addition to the null or deletion alleles described 
above, other variants resulting in lowered activity and gene duplications with 
increased activity have also been identified.
Approximately 40% of human P450-dependent drug metabolism is carried out by 
polymorphic enzymes, which can cause abolished, quantitatively/qualitatively altered, 
or enhanced drug metabolism. The main causes for the variation in drug metabolism 
are:
(1 ) genetic polymorphisms;
(2 ) induction or inhibition due to concomitant drug therapies or environmental 
factors;
(3) physiological status;
(4) disease states (Ingelman-Sundberg et al 1999).
Of these, the first two appear to be of most importance for the occurrence of adverse 
effects or lack of therapeutic efficacy in many cases.
1.7.1. Polymorphic variations in the cytochrome P450 genes
In general, alleles that cause defective, qualitatively altered, diminished or enhanced 
rates of drug metabolism have been identified for many of the P450 enzymes and the 
underlying molecular mechanisms elucidated (Figure 1.13). The genes encoding 
CYP2A6, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 are functionally polymorphic, 
thus at least 40% of P450-dependent drug metabolism is performed by polymorphic 
enzymes. The relative distribution of variant alleles for these P450s differs markedly 
between ethnic groups, making the extent and characteristics of genetically- 
determined differences in drug response quite specific for the global region in 
question (Ingelman-Sundberg et al 1999) (Table 1.4).
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Duplicated or 
multiduplicated genesDeleted gene Single gene
mRNA-AAAA
mRNA-AAAA mRNA-AAAA
mRNA-AAAA
Unstable
enzyme
No
enzyme
Normal
enzyme
Altered substrate 
specificity
Higher 
enzyme levels
No
metabolism
Reduced
metabolism
Normal Other metabolites 
metabolism possibly formed
CYP2D6*17 
CYP2C9*3
Increased
metabolismCYP2D6*10 CYP2D6*1 
CYP2C19*1 
CYP2C9*1 CYP2D6*2xN
Figure 1.13. Overview of the major molecular mechanisms that can result in 
altered human drug metabolism (Ingelman-Sundberg et al 1999).
The transcription-translation pathway resulting in normal enzyme and metabolism is 
shown by the thick arrows and the thin arrows represent genetically altered pathways. 
Polymorphisms resulting in amino acid substitutions can give rise to an unstable 
enzyme or an enzyme with an altered active site, causing a change in substrate 
specificity. Furthermore, duplication/multiplication of active genes can result in 
higher levels of mRNA and enzyme and therefore increased metabolic activity. 
Examples of common human cytochrome P450 variant alleles that have been found to 
cause the corresponding changes in drug metabolism are shown at the bottom of the 
diagram. AAA indicates the poly(A) tail.
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I.7.I.I. Cytochrome P450 alleles producing inactive enzymes
Completely inactive alleles have been found for CYP2D6, CYP2C19 and CYP2A6. 
Defective alleles can be the result of gene deletions, gene conversion with related 
pseudogenes and single base mutations causing frameshift, missense, nonsense or 
splice-site mutations. The homozygous presence of such alleles leads to a total 
absence of active enzyme and an impaired ability to metabolise probe drugs specific 
for the enzyme, hence the poor metaboliser (PM) phenotype (Ingelman-Sundberg et al
1999). The number of known defective alleles is growing and a total of at least 30 
different defective CYP2D6 alleles resulting in about 55 CYP2D6 variant genotypes 
have been identified (Marez et al 1997). It appears, however, that genotyping for only 
the six most common defective alleles will predict CYP2D6 phenotype with about 95- 
99% certainty (Sachse et al 1997; Griese et al 1998). Individuals that lack functional 
CYP2D6 genes have been shown to metabolise selective CYP2D6 substrates, 
particularly antidepressants (Carrillo et al 1996; Hamelin et al 1996; Spina et al 1997) 
and neuroleptics (Jerling et al 1996), at a substantially lower rate than normal. A lack 
of CYP2D6 enzyme would also be expected to result in reduced therapeutic 
effectiveness where prodrugs requiring CYP2D6 activation are used. For example, 
following administration of the prodrug codeine, no plasma morphine or any 
analgesic effect could be observed in CYP2D6 PMs (Poulsen et al 1996).
The polymorphism of CYP2C19, which causes impaired drug metabolism, affects as 
many as 20% of Asians but only 3% of Caucasians (Ingelman-Sundberg et al 1999), 
causing impaired metabolism of S-mephenytoin and certain other drugs (Goldstein et 
al 1994; de Moris et al 1994). Today, at least six different defective CYP2C19 alleles 
have been identified (Ibeanu et al 1998). Of these, CYP2C19*2 and CYP2C19*3 
contain mutations that create an aberrant splice site and a premature stop codon, 
respectively and are the most common defective alleles (Table 1.4). Three different 
defective CYP2A6 alleles have been described so far, of which CYP2A6*2 encodes 
an inactive enzyme resulting from a Leul60His substitution (Yamano et al 1990). 
CYP2A6*3 is proposed to have been generated through a gene conversion between 
CYP2A6 and CYP2A7 (Femandez-Salguero et al 1995). There are also alleles in 
which the CYP2A6 gene is deleted (Nunoya et al 1999; Oscarson et al 1999).
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I.7.I.2. Cytochrome P450 alleles producing diminished or altered 
metabolism
There are also variant alleles that cause diminished or altered drug metabolism. The 
most common CYP2D6 allele in the Chinese population is CYP2D6*10, which has a 
Pro34Ser substitution in the proline-rich region near the NHi-terminal. This results in 
an enzyme that exhibits impaired folding and the expression of functional enzyme is 
therefore severely diminished (Johansson et al 1994). CYP2D6*17 (Masimirembwa 
et al 1996), CYP2C9*2 (Crespi & Miller 1997) and CYP2C9*3 (Haining et al 1996) 
are other alleles that result in cytochrome P450 enzymes with diminished capacity for 
drug metabolism. Regarding the CYP2C9 polymorphism for example, reports have 
clarified the importance of the CYP2C9*2 and CYP2C9*3 alleles to CYP2C9- 
catalyzed 6 - and 7-hydroxylation of the anticoagulant S-warfarin. The enzyme 
variants, in particular CYP2C9*3, are much less effective at warfarin hydroxylation in 
vitro (Crespi & Miller 1997; Haining et al 1996) and the clearance of S-warfarin 
among subjects homozygous for the CYP2C9*3 allele has been shown to be reduced 
by 90% compared with subjects homozygous for the wild-type allele (Carrillo et al
1996).
17.1.3. Cytochrome P450 alleles producing ultra-rapid metabolism
Ultra-rapid metabolism as seen in some individuals for metabolism via CYP2D6 is 
caused by the presence of duplicated, multiduplicated, or tandem gene copies in the 
genome (Johansson et al 1993). At present, CYP2D6 alleles with two, three, four, 
five and 13 gene copies in tandem have been reported and the number of individuals 
carrying multiple CYP2D6 gene copies is highest in Ethiopia and Saudi Arabia, 
where up to the third of the population displays this genotype (Ingelman-Sundberg
1997). Interestingly, the number of defective CYP2D6 gene is very low in this 
region. Alleles with two-to-five gene copies in tandem have likely been formed by 
unequal recombination between two homologous but non-allelic sequences flanking 
the gene. The outcome is one locus that contains two genes in tandem and a deleted 
gene on the other locus. By contrast, the allele containing 13 copies of the gene has 
probably occurred by unequal segregation and extrachromosomal replication of 
acentric DNA (Lundquist et al 1999). Subjects with 13 CYP2D6 gene copies on one 
allele formed a substantially higher amount of metabolite(s) from substrates specific 
to this enzyme. For example, extensive formation of morphine occurs if these
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subjects take the prodrug codeine (Hedenmalm et al 1997) and severe abdominal pain, 
a typical adverse effect of morphine, was observed in an ultra-rapid metaboliser 
treated with codeine. Duplication of the genes encoding drug-metabolising enzymes 
is not restricted to CYP2D6 since duplicated glutathione-S-transferase, e.g. GSTMl 
genes have been identified in the GSTp locus, although this allele appears to be quite 
rare (McLellan et al 1997). Another type of ultra high metaboliser genotype is not 
related to gene amplification, but to mutation in the promoter region of the gene. 
Analysis of the 5'-flanking region of the CYP3A5 gene, has identified two linked 
polymorphisms, T-369G and A-45G, in transcriptional regulatory elements associated 
with increased expression of the gene (Paulussen, et al 2000). The polymorphisms 
fall within two separate regulatory elements, a basic transcription element (BTE or 
Spl site) at -45 and an activator protein-3 (AP-3) motif at -369. All genotypes were 
heterozygous for the linked polymorphisms and resulted in a substantial increase in 
midazolam metabolism.
1.7.2. Polymorphism in the CYP3A4 locus
The initial studies of in vivo nifedipine oxidation appeared to demonstrate 
polymorphism in a set of 53 healthy individuals (Kleinbloesem et al 1984) but 
subsequent pharmacokinetic studies with a larger group showed only a bimodal 
variation in metabolism (Schellens et al 1988). In other studies, several genetic 
polymorphisms in the CYP3A4 genes were found using restriction fragment length 
polymorphisms detected by Southern analysis, but none of these was associated with 
an altered level of nifedipine oxidase activity among various liver samples 
(Guengerich 1999). However, CYP3A4 expression does vary in some populations 
and racial differences in nifedipine oxidation has been reported. South Asians living 
in Great Britain were found to have substantially lower nifedipine oxidation 
parameters than did Caucasians (Ahsan et al 1991) and in vitro and in vivo differences 
between Caucasians and Japanese have been reported with regard to CYP3A4 activity 
(Shimada et al 1994). Rebbeck et al (1998) reported a transition mutation in a 
putative regulatory element of the P450 3A4 gene (-290 A-^ G) that might influence 
interactions with a transcription factor and alter expression, although direct evidence 
for altered gene expression was not provided. This polymorphism is reported to have 
an association with prostate cancer in Caucasian men and also a strong racial linkage.
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with a 50% frequency of the allele in African-Americans but only 4-7% in Caucasians 
or Asians (Guengerich 1999). However, Westlind et al (1999) showed subsequently 
that this mutation did not affect the expression of the enzyme despite there being a 
large (31 fold) inter-individual variation in CYP3A4 levels in the 46 human liver 
samples tested. Such inter-individual variation (up to 80-fold) has also been shown in 
another study (Seree et al 1998).
In our laboratory, other mutations have been found in the CYP3A4 promoter region 
(Hamzeiy H, personal communication). In addition to the polymorphism detected 
previously by Rebeck et al (1998), he has detected three novel mutations in the 5'- 
flanking region. The biological significance of these mutations in terms of CYP3A4 
mRNA expression has not yet been determined.
With regard to coding region mutations in the CYP3A4 gene, recent studies (Sata et al 
2000; Hsieh et al 2001, Eiselt et al, in press; Lamba et al, in press) have identified 
some 16 mutations by PCR screening of the CYP3A4 exons in genomic DNA 
samples. Also, a further 3 alleles are reported anecdotally on the CYP3A4 allele 
nomenclature website (http://www.imm.ki.se/cvpalleles/CYP3A4.htmV however, 
only one of these alleles, CYP3A4*2 (Sata et al 2000) has been shown so far to be 
associated with reduced nifedipine clearance. This allele is not however associated 
with a reduction in testosterone 6|3-hydroxylation.
1.7.3. Cytochrome P450 polymorphism and neoplastic disease
Many carcinogenic compounds require metabolic activation before being capable of 
reacting with cellular macromolecules. Thus individual features of carcinogen 
metabolism must play an essential role in the development of cancer (Raunio et al
1995). A complicating factor is the multistage etiology of carcinogenesis implying 
the involvement of many distinct events. However, it has become evident that the 
enzymes activating and inactivating exogenous carcinogens are involved in the 
ethiology of cancer (Hietanen 1999).
Many compounds are converted to reactive electrophilic metabolites by the oxidative 
(mainly cytochrome P450-related) enzymes (e.g. Bartsch et al 2000; Dehal & Kupfer
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1996). Secondary metabolism, mainly involving epoxide hydrolase (Miyata et al
1999), sulfotransferases (Seth et al 2000), and acetyltransferases (e.g. Ilett et al 1991) 
can also lead to the formation of the highly reactive metabolites that bind to genomic 
DNA. Thus the concerted action of these enzymes may be crucial in determining the 
final biological effect of a carcinogen. The activity of these enzymes is modulated by 
many host and environmental factors. Host factors include both life-style factors, 
diseases, and genetic factors while environmental factors include exposures to various 
chemicals as well as dietary habits (Hietanen 1999).
CYPlAl has been implicated in the conversion of numerous polycyclic aromatic 
hydrocarbons into electrophilic species capable of binding covalently to DNA and has 
therefore been postulated to be involved in the initiation of carcinogenesis (Geneste et 
al 1991; Petruzzelli et al 1998). In addition, a restriction fragment length 
polymorphism located in the 3’-noncoding region of this gene {MspI) identified in the 
Japanese population has been associated with an increase in CYPlAl activity and an 
elevated risk of lung cancer (Kawajiri et al 1990; Hayashi et al 1991). Another 
polymorphism of the CYPlAl gene, linked to the Mspl polymorphism, has been 
identified in exon 7 and results in a substitution of valine to isoleucin in the heme 
binding region (Hayashi et al 1991) and higher enzyme activity (1.5-fold) (Kawajiri et 
al 1993). It is associated with an elevated risk of developing lung and endometrial 
cancers (Esteller et al 1997; Spivack et al 1997), although opposing results have been 
shown as well (reviewed by Drahushuk et al 1998).
Numerous studies have demonstrated an association of certain CYP2D6 genotypes 
with lung cancer risk and poor metabolisers (defined by either genotyping or 
phenotyping) have a lower risk than other genotypes (Bouchardy et al 1996; Stucker 
et al 1995). The risk was dose-dependent with smoking and in persons with low or 
medium CYP2D6 activity no such an increase was found even at very high smoking 
levels. CYP2D6 gene mutations may also be involved in an increased risk of liver 
cancer since extensive metabolisers appear to have 6.4-fold greater risk of primary 
liver cancer in comparison with poor metabolisers (Agundez et al 1995).
CYP3A4 and CYP3A7 also mediate the metabolism of hepatocarcinogens, including 
mycotoxins, 2,4-dichlorophenol, and aflatoxin Bi, and overexpression of these
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cytochrome P450s in cultured human hepatoma cells is associated with an increase in 
aflatoxin-induced mutations, particularly in the P53 tumor suppressor gene (Kondoh 
et al 1999). Similarly, the presence of CYP3A5 in normal proximal tubular 
epithelium has been suggested as a causative factor in renal tumour development 
(Murray et al 1999).
1.8. Aims and objectives of the project
It is clear that inter-individual variation in the level or activity of the cytochrome P450 
enzymes may play an important role in the development of both adverse drug 
reactions and diseases such as cancer. Since CYP3A4 represents a significant 
proportion of the hepatic cytochrome P450 content, modulation of CYP3A4 gene 
expression by endogenous or exogenous factors may dramatically affect xenobiotic 
metabolising capacity. An understanding of the mechanisms controlling CYP3A 
isoenzyme gene expression and the role of nuclear transcription factors in this process 
will be of great value in elucidating the molecular basis of CYP3A modulation.
1.8.1. Overall aim
The human hepatocarcinoma cell line HepG2 will be investigated as a model system 
to examine CYP3A isoenzyme gene regulation and to determine if this in vitro cell 
culture system can be used to define the in vitro molecular mechanisms of CYP3A 
gene regulation by xenobiotics.
1.8.2. Specific objectives
1. To characterise the ability of HepG2 cells to modulate the expression of an 
exogenous DNA construct containing a reporter gene and the CYP3A4 proximal 
promoter region.
2. To examine the effect of co-transfection with cDNA for hGRa and hPXR on the 
expression of CYP3A4 reporter constructs in HepG2 cells.
3. To examine by RT-PCR the expression of endogenous CYP3A and nuclear 
receptor genes as mRNA in the presence and absence of classical CYP3A 
inducers.
4. To define the role of activated nuclear receptors in the modulation of their own 
and CYP3A gene expression.
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5. To relate the in vitro modulation of CYP3A gene expression in HepG2 cells to 
CYP3A regulation.
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Chapter 2. MATERIAL AND METHODS
2.1. Materials
2.1.1. Chemicals and reagents
Chemicals including dexamethasone, rifampicin, clotrimazol, RU486 and kenacid 
blue (brilliant blue) were purchased from Sigma-Aldrich Ltd (Dorset, England).
Minimum essential medium (MEM with Earle’s salts), L-glutamine and gentamicin 
solutions were supplied by Life Technologies Inc. (Paisley, Scotland).
HepG2 (human hepatoma) cells were supplied by the European Collection o f Animal 
Cell Cultures (ECACC) (Salisbury, Wiltshire UK) at passage 93.
PCR and RT-PCR kits as well as restriction enzymes were supplied by Promega UK 
(Southampton, UK) or BD Clontech UK (Basingstoke, Hampshire, UK). The mRNA 
extraction kits (PolyATtract system 1000) and genomic DNA purification kits were 
also purchased from Promega UK.
Chemiluminescence kits (Aurora™ AP assay system) for measuring alkaline 
phosphatase were purchased from ICN Pharmaceuticals (Basingstoke, Hampshire, 
UK).
P-Gal staining sets were purchased from Roche Diagnostics Ltd (East Sussex, UK).
Human liver mRNA was purchased from BD Clontech UK (Basingstoke, Hampshire, 
UK).
2.1.2. PCR and RT-PCR primers
Selecting the correct primers is one of the most important steps in designing a PCR 
experiment. The primer set should efficiently hybridize to the target sequence with as 
little hybridization as possible to other sequences that are also present in the sample. 
In general, oligonucleotides between 18 and 30 bases are extremely sequence- 
specific, provided that the anealing temperature is optimal and they have a G/C
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content of 45%-55%. The annealing temperature for the primer pair is generally 
calculated as 5°C lower than the estimated melting temperature (Tm). Differences of 
4°C - 6°C between forward and reverse primers do not seem to affect the yield of 
PCR, however, ideally the annealing temperature of each primer should match and be 
within the 55 °C to 72 °C range. The inclusion of a G or C residue at the 3' end of 
each primer helps to ensure correct binding at the 3’ end due to the stronger hydrogen 
binding of G/C residues (‘GC clamping’). 100% complimentarity between primer 
and template is not necessary for polymerase-catalyzed extension to occur. However, 
to ensure stable annealing, the primers should be as complimentary to the desired 
DNA sequence as possible.
The primers were purchased from Life Technologies Inc. (Paisley, Scotland) and 
MWG Biotech Ltd (Milton Keynes, UK). On arrival the primer tubes were 
centrifuged for a few seconds to collect the dry DNA at the bottom of the tube. An 
appropriate volume of TE buffer to make 50 pM stock solution was added to the tubes 
and, after rehydration for 2 minutes, the solution was vortexed for 15 seconds and 
stored at -20 °C.
The characteristics of the primers designed for the PCR and RT-PCR experiments are 
shown in Table 2.1.
2.1.3. Expression vectors
Human glucocorticoid receptor plasmid (pSG5-hGR)
This was a gift from Zeneca PLC (Dr. Jonathon Tagwood). It is a 2.7 kbp insert of 
hGRa cDNA in the pSG5 plasmid vector. The whole plasmid is 7.3 kbp in size 
(Figure 2.1).
Human pregnane X receptor plasmid (pSG5-hPXRAATG)
This was a gift from Dr. Steven Kliewer {GlaxoSmithkline Ltd). This expression 
vector was generated by PCR amplification and subcloning of 1.3 kb of the hPXR
cDNA, modified at the first amino acid (CTG ►ATG), into the pSG5 expression
vector (Lehman et al 1998) (Figure 2.2).
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Amp'’
SV40 Promoter
P-globin intron
pSG5-hGR 
7300 bp
hGRcDNA
PO L Y A
on
Figure 2.1. Map of pSG5-hGR, a plasmid encoding the human glucocorticoid 
receptor.
Amp"" : ampicillin resistance
hOR cDNA: human glucocorticoid receptor cDNA
ori: origin of replication
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San 2
SV4Ü
leta-globin intron
4843 539
T 7
EcoRI 1044
pSGS-hPXR
5383 bp
Ampr hPXR cDNA
2691
BamHI 2358ori Poly A
Xbal 2517Saiï 2511
Figure 2.2. Map of pSG5-hPXRAATG, a plasmid encoding the human pregnane 
X receptor.
Ampr: ampicillin resistance
HPXR cDNA: hPXRAATG, the human pregnane X receptor cDNA with a modified 
codon 1 (CTG — ^  ATG) 
ori: origin of replication
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Control alkaline phosphatase reporter vector plasmid (pCMV-cSPAP)
This vector was supplied by GlaxoSmithkline Ltd (Dr. S. Hood) (Figure 2.3).
CYP3A4 reporter construct plasmid (p3A4-CMV-cSPAP)
This plasmid was constructed in our laboratory (Ogg et al 1997). The promoter 
region of CYP3A4 (-1087 to -57) was isolated by PCR and subcloned into pCMV- 
cSPAP in front of the CMV promoter (Figure 2.4).
P-Galactosidase plasmid pCHllO
This plasmid was provided by Pharmacia Biotech (Buckinghamshire, UK) and 
contains the E. coli LacZ gene driven by a SV40 virus promoter (Figure 2.5).
2.1.4. Analytical instruments
The DNA engine model PTC-200 from Genetic Research Instrumentation (GRI) 
(Essex, UK) was used as the thermal cycler for PCR and RT-PCR reactions.
The Gen Quant II from Amersham Pharmacia Biotech (Buckinghamshire, UK) was 
used as a spectrophotometer for measuring RNA or DNA concentrations in samples. 
Gel electrophoresis apparatus GNA-100 and electrophoresis power supply EPS 
500/400 from Amersham Pharmacia Biotech was used to carry out electrophoresis. 
Image Master VDS from Amersham Pharmacia Biotech was used for taking photos of 
the agarose gels.
Lumicount™ from Packard (Berkshire, England) was used for measurement of the 
light emitted from the alkaline phosphatase substrate in 96-well plates.
The sequencing machine (model 373A version 1.2.1) from Applied Biosystems 
(Warrington, UK) was used for sequencing of DNA samples extracted from agarose 
gels.
The ‘LISCAP capture application’ is a software package from Amersham Pharmacia 
Biotech that was used for capturing gel images from the Image Master VDS used for
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Amp''
col (4379)
on
Spel (5964) 
Sail (5934)
pCMV-cSPAP 
5976 bp
CMV promoter
SPAP cDNA
SV40 t-intron & poly (A) sites
Figure 2.3. Map of pCMV-cSPAP, an alkaline phosphatase reporter plasmid.
This plasmid is referred to as ‘pCMV’ in this report.
Amp"^  : ampicillin resistance
SPAP cDNA: secretory placental alkaline phosphatase cDNA
ori: origin of replication
CMV: human cytomegalovirus strong promoter
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Amp''—
Sal I (6965)
Spe I (6995)
CYP3A4 (-1087 to -57)
5)36 1(1086)
p3A4-CMV-cSPAP 
7006 bp
SV40 t-intron & poly(A) sites
CMV promoter
SPAP oDNA
Xba I (3284)
Figure 2.4. Map of p3A4-CMV-cSPAP, an alkaline phosphatase expression 
vector containing the CYP3A4 5'-fIanking region (-1087 to -57) inserted into the 
Spe I site of in front of the CMV promoter.
Amp' : ampicillin resistance '
SPAP cDNA: secretory placental alkaline phosphatase cDNA
ori: origin of replication
CMV: human cytomegalovirus strong promoter
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SV40 on
oil
6317
1425
pCHllO
7125 bp
lacZ cDNA
Amp r' 4985
S a d  2225
EcoRI 4490
'EcoRI 3289BamHI 3739
Figure 2.5. Map of pCHllO, a plasmid used for estimation of transfection 
efficiency.
Amp r: ampicillin resistance 
ori: origin of replication
lac Z: the lac Z gene of E. coli, encoding for P-galactosidase activity 
SV40 ori: SV40 virus early promoter/origin of replication
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measuring the intensity of light emitted from the ethidium bromide stained 
electrophoretic bands by Image Master-2D-Elite {Amersham Pharmacia Biotech).
2.2. Molecular Biology procedures
2.2.1. Preparation of bacterial stock cultures
Bacterial cultures containing recombinant plasmids with DNA inserts of interest were 
stored in glycerol at -70°C. Overnight cultures of E. coli in LB medium containing 
100 pg/ml ampicillin (for plasmids coding for ampicillin resistance) were prepared. 
150 pi of sterile glycerol was added to 850 pi of bacterial culture in a sterile 1.5-ml 
centrifuge tube. The tube was vortexed briefly to ensure complete mixing of the 
contents before freezing the stocks at -80°C.
2.2.2. Growth of bacterial cultures
Most plasmids carry a marker gene for a specific antibiotic resistance. By 
supplementing the growth medium with the appropriate antibiotic, only cells 
containing the plasmid of interest will grow. Addition of antibiotic to the required 
concentration will help to maximize plasmid yields.
For growing plasmid-containing bacteria from a glycerol stock, a sterile inoculation 
loop was scraped across the surface of a frozen stock and then streaked on a LB agar 
plate containing lOOpg/ml ampicillin and incubated overnight at 37°C. An isolated 
colony from a freshly streaked plate (less than 5 days old) was then picked using a 
sterile loop and inoculated into 5ml LB medium containing 100 pg/ml ampicillin. 
This miniculture was incubated in a rotatory incubator at 225 rpm at 37°C for 8 hours. 
For subsequent maxi-culture, 500 pi of the miniculture was added to 250ml of LB 
medium containing 100 pg/ml ampicillin and incubated overnight (12-16 hours) in a 
rotatory incubator at 225 rpm at 37°C (recommendations of the manufacturer, Qiagen 
Endo Free Plasmid Maxi Kit).
2.2.3. Qiagen Endo-Free DNA Maxi Prep Protocol
Endotoxins are lipopolysaccharide (EPS) components of the lipid portion of the outer 
layer of the cell membranes of gram-negative bacteria such as E. coli (Rietschel and 
Brade 1992). Their presence in plasmid preparations decreases the transfection
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efficiency in sensitive cultured cells (Weber et al 1995). Plasmid DNA purified with 
the Endo Free Plasmid Maxi Kit contains only negligible amounts of EPS (less than 
0.1 endotoxin units/pg plasmid DNA) due to the use of a special ‘endotoxin removal’ 
buffer that prevents EPS molecules from binding to the resin in the purification tips 
(Qiagen kit protocol). DNA purified by this method can be used directly for 
transfection without the need for ethanol precipitation.
The bacterial suspension from the maxi-culture was centrifuged at 6,000 x g for 15 
minutes at 4°C and the resultant pellet was suspended in 10ml of buffer PI (see 
Appendix 1 for the kit components). 10ml of buffer P2 was added and mixed with the 
suspension by gentle inversion 4-6 times and then incubated for 5 minutes. Then 
10ml chilled buffer P3 was added to the lysate, and mixed immediately by inversion 
(4-6 times). The lysate was poured into a Qia Filter Maxi Cartridge and incubated at 
room temperature for 10 minutes after which it was gently filtered using the piston 
supplied and the filtrate was collected in a 50-ml tube. After adding 2.5ml of buffer 
ER and mixing by inversion (10 times), the solution was incubated on ice for 30 
minutes, during which a QlAGEN-tip 500 was equilibrated by applying 10 ml of 
buffer QBT. The cleared lysate was then applied to the tip, allowed to enter the resin 
by gravity flow, and was washed twice with 30 ml of QC buffer. The DNA was 
eluted with 15 ml of buffer QN. 10.5 ml of room temperature isopropanol was added 
to the eluted DNA, mixed and centrifuged immediately at 15,000xg for 30 minutes at 
4°C. After discarding the supernatant, the DNA pellet was washed with 2.5-5 ml of 
endotoxin-free, room temperature 70% ethanol and centrifuged at 15,000 x g for 10 
minutes. The supernatant was carefully discarded and the pellet was air-dried for 5 
minutes and suspended in suitable volume (200-500 |Lil) of endotoxin-free buffer TE.
2.2.4. mRNA extraction from HepG2 cells
RNA is found in the nucleus, cytoplasm and mitochondria of eukaryotic cells. Total 
cytoplasmic RNA consists of ribosomal RNA (rRNA), transfer RNA (tRNA), 
messenger RNA (mRNA) and other small species of RNA. Only 1-2% of the total 
RNA in eukaryotic cells is mRNA; the majority of total RNA consists of rRNA.
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The purity and integrity of isolated RNA is critical for its effective use in procedures 
such as RT-PCR, Northern blotting, oligo(dT) selection of poly(A)^ RNA, cDNA 
synthesis, and translation in vitro. This is especially true for the construction of 
cDNA libraries where efficient cDNA synthesis requires highly purified intact 
mRNA. While many applications for the analysis of RNA may be performed using 
total RNA, greater sensitivity is obtained using purified mRNA samples.
The successful isolation of intact RNA by any procedure requires that four important 
steps be performed:
1) effective disruption of cells or tissue
2) dénaturation of nucleoprotein complexes
3) inactivation of endogenous RNase activity and
4) purification of RNA away from contaminating DNA and protein.
The most important of these is the immediate inactivation of endogenous RNase 
activity which is released from membrane-bound organelles upon cell disruption.
GTC extraction buffer, biotinylated oligo(dT) probe, nuclease-free water, and SSC 0.5 
X solution, dilution buffer, p-mercaptoethanol and streptavidin paramagnetic particles 
(SA-PMP) were provided in the Promega Poly A  Tract kit (see Appendix I). The first 
three were removed from the refrigerator and warmed to room temperature before use. 
Dilution buffer was heated to 70 °C before starting the extraction process. Also, a 
mixture of 41 pi of P-mercaptoethanol per millilitre of extraction buffer was prepared 
(extraction/BME buffer).
1.5 ml of a fresh suspension of HepG2 cells containing roughly 10  ^ cells/ml was 
placed in a sterile 1.5-ml microcentrifuge tube after passage. This tube was 
centrifuged at 300 x g for 5 minutes to pellet the cells. After pouring off the media, 
the cell pellet was washed with 1ml of 1 x PBS and centrifuged again. The 
supernatant was poured off and the pre-warmed GTC extraction/MBE added to the 
cells. The cell pellet was vortexed until cell lysis was complete. The disruptive and 
protective properties of guanidine thiocyanate and P-mercaptoethanol inactivated the 
ribonucleases present in cell extracts.
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1ml of preheated dilution buffer mixed with 20.5 pi P-mercaptoethanol was added to 
the lysate and mixed thoroughly by inversion. Guanidine thiocyanate, in association 
with SDS, acts to disrupt nucleoprotein complexes, allowing RNA to be released into 
solution and isolated free of protein. 2 pi (100 pmol) of biotinylated oligo(dT) was 
added to this mixture and mixed well. This mixture was incubated at 70°C for 5 
minutes. The final GTC concentration allowed for hybridization between the poly(A) 
sequence of most mature eukaryotic mRNA species and the biotinylated oligo(dT), 
yet maintained complete inhibition of the cellular RNases. The lysate was transferred 
to a clean, sterile 1.5ml tube and centrifuged at 12,000 x g for 10 minutes at room 
temperature to clear the homogenate of cell debris and precipitated proteins. 
Hybridization continued during this centrifugation step.
While the extract was being centrifuged, SA-PMP particles were resuspended by 
gently rocking the tube. The SA-PMP particles went through a wash with 1 ml 0.5 x 
SSC solution and subsequent capture by the magnetic stand for three times and were 
resuspended again in 1 ml of 0.5 x SSC solution. After centrifugation of the mRNA- 
oligo dT mixture, the clear supernatant was added to the tube containing the washed 
SA-PMP particles in SSC solution. Biotinylated oligo(dT)-tagged mRNA bound to 
the SA-PMP particles. Using a magnetic stand, the particles carrying mRNA were 
captured at the bottom of the tube and the supernatant was poured off. The particles 
were washed with 1ml of 0.5 x SSC solution and captured for three more times as 
above. The mRNA was then eluted by adding 200 pi nuclease-free water to the 
particles, resuspending them and incubating at room temperature for 2 minutes to 
release the mRNA. After elution, the mRNA-free particles were captured by 
magnetic stand and the clear solution of mRNA was taken for determination of the 
yield.
2.2.5. Genomic DNA extraction from HepG2 cells
The isolation and purification of DNA is a key step for most protocols in molecular 
biology. Methods to purify DNA generally fall into two broad categories. The first 
category includes the isolation of recombinant DNA constructs such as plasmids or 
bacteriophage after propagation by the host organism. These techniques form the 
basis of molecular cloning experiments and constitute the most frequently used
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protocols in molecular biology laboratories. The second type of DNA purification 
involves the isolation of chromosomal or genomic DNA from prokaryotic or 
eukaryotic organisms. These purification techniques have greatly facilitated studies 
of complex genomes, particularly by enabling the construction of genomic DNA 
libraries representative of many different species.
Harvested HepG2 cells, were transferred to a 1.5-ml centrifuge tube and centrifuged 
at 13,000 X g for 10 second. The supernatant was removed, the cells were washed 
with PBS and centrifuged again using the same conditions. After removing the PBS, 
the cells were resuspended by vortexing vigorously. 600 pi of Nuclei Lysis Solution 
(Appendix I) were added to lyse the cells and pipetted until no visible cell clump 
remained. 3 pi of RNase solution were added to the nuclear lysate and mixed by 
inverting the tube 25 times. The mixture was incubated at 37 °C for 15-30 minutes 
and then allowed to cool to room temperature for 5 minutes before proceeding. To 
the room temperature sample, 200 pi of Protein Precipitation Solution (Appendix I) 
were added and vortexed vigorously at high speed for 20 seconds. The sample then 
chilled on ice for 5 minutes. The chilled sample was centrifuged for 4 minutes at
13.000 X g to pellet the protein. The precipitated protein formed a tight white pellet. 
The supernatant containing DNA was carefully removed and transferred to a clean 1.5 
ml microcentrifuge tube containing 600 pi of isopropanol at room temperature 
isopropanol. The solution was mixed gently by inversion until the white thread-like 
strands of DNA form a visible mass. The mixture was centrifuged for 1 minute at
13.000 X g. The DNA was now visible as a small white pellet and the supernatant was 
carefully decanted. To wash the DNA, 600 pi of room temperature 70% ethanol were 
added and gently inverted several times. The sample was centrifuged for 1 minute at
13.000 X g at room temperature and the ethanol carefully aspirated using a pipette tip. 
The tube was inverted on clean absorbent paper and the pellet then air-dried for 10-15 
minutes. DNA was rehydrated by adding 100 pi of DNA Rehydration Solution 
(Appendix I) to the pellet and incubated overnight at 4 °C. The DNA was stored at 4 
°C.
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2.2.6. PCR amplification of DNA sequences
Molecular biology relies on techniques that enable the detection or capture of minute 
quantities of nucleic acids. The use of radioisotopes and later non-radioisotope 
alternatives provides methods to detect and track nucleic acids. The cloning of 
nucleic acids into high copy number vectors allows amplification of DNA sequences 
in living cells, providing a nearly unlimited source of these DNA molecules for 
further manipulation. With the introduction of the polymerase chain reaction (PCR), 
more sensitive levels of detection and higher levels of amplification of specific 
sequences are achieved, and in less time compared to previously used methods.
PCR is a relatively simple technique by which a DNA or cDNA template is amplified 
many thousand or million-fold quickly and reliably. By amplifying just a small 
portion of a target nucleic acid, a researcher effectively isolates that portion from the 
rest of the nucleic acid in the sample, as with the traditional cloning methods. The 
PCR process generates sufficient material for subsequent experimental analysis. The 
entire amplification can now been performed in vitro as opposed to standard cloning 
procedures. While most biochemical analyses, including nucleic acid detection with 
radioisotopes, require the input of significant amounts of biological material, the PCR 
process requires very little. These features make the technique extremely useful, not 
only in basic research, but also in commercial uses including genetic identity testing, 
forensics, industrial quality control, and in vitro diagnosis. In order to analyze 
plasmid DNAs or gene promoter in genomic DNA, PCR reactions were performed 
using the appropriate primers.
The following components of the Promega PCR kit were combined in a sterile 0.5 ml 
microcentrifuge tube:
MgCb, 25 mM solution 3 pi
Thermophilic DNA polymerase lOX
Reaction buffer, MgCL-free 5 pi
PCR nucleotide mix, 10 mM each 1 pi
Upstream primer (50 pmol) 1 pi
Downstream primer (50 pmol) 1 pi
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Taq DNA polymerase (5 u/1) 0.25 \il
Template DNA 500 ng/1 1 pl
Nuclease-free water to a final volume of 50 pl
For the cloned 3 A4 promoter the following cycling conditions were used:
95°C for 2 minutes (initial dénaturation)
95°C for 1 minute (dénaturation)
55°C for 1 minute (annealing)
72°C for 1 minute (extension)
72°C for 5 minutes (final extension)
Steps 2 through 4 were repeated for 30 cycles.
For the cloned hPXR cDNA, the cycling conditions used were:
94°C for 2 minutes (initial dénaturation)
94°C for 30 seconds (dénaturation)
58°C for 30 seconds (annealing)
72°C for 1 minute (extension)
72°C for 5 minutes (final extension)
Steps 2 through 4 were repeated for 30 cycles.
For PCR amplification of the CYP3A4, CYP3A5 and CYP3A7 promoters in HepG2 
cell DNA, the Clontech PCR kit was used. The following components were 
combined in a reaction tube:
Enzyme 1 pi
Buffer 5 pi
dNTP mix 5 pi
Primer mix 4 pi
Template 1 pi (100-200 ng)
Water up to 50 pi
For the CYP3A4 the following cycling conditions were used:
94°C for 1 minute (initial dénaturation)
94°C for 30 seconds (dénaturation)
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65°C for 30 seconds (annealing)
72°C for 1 minute (extention)
72°C for 7 minutes (final extension)
Steps 2 through 4 were repeated for 30 cycles. For CYP3A5 and CYP3A7 PCR 
reactions the annealing temperature was 55°C.
10 pi of each reaction sample were run on agarose gel for assessment.
2.2.7. RT-PCR analysis of mRNA levels
The thermostable polymerases used in the basic PCR process require a DNA template 
and as such the technique is limited to the analysis of DNA samples. Yet numerous 
instances exist in which the amplification of RNA from an organism would be 
preferred. This is particularly true in analyses involving the differential expression of 
genes in tissues during development or the cloning of cDNAs from rare mRNAs. In 
order to apply PCR methodology to the study of RNA, the RNA sample must first be 
reverse-transcribed to cDNA to provide the necessary DNA template for the 
thermostable polymerase. This process is reverse transcription (RT), hence the name 
RT-PCR.
The following components of the Access RT-PCR system (Promega) were combined 
in a 0.5ml microcentrifuge tube:
AMV/Tfl 5X reaction buffer lOpl
dNTP mix (10 mM each) Ipl
Downstream primer (50 pmol) Ipl
Upstream primer (50 pmol) Ipl
MgS0 4  (25 mM) 2pl
AMV reverse transcriptase (5 u/pl) Ipl
Tfl DNA polymerase (5 u/|il) 1^1
RNA sample or control (lpg-1 fig/fil) Ipl
Nuclease-free water to a final volume of 50p,l
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The tube was then placed in a thermal cycler and for hPXR mRNA amplification the 
following cycling conditions were used:
48 °C for 45 minutes (reverse transcription)
94°C for 2 minutes (AMV RT inactivation and RNA/cDNA/primer 
dénaturation)
94°C for 30 seconds (dénaturation)
58°C for 1 minute (annealing)
68°C for 2 minutes (extension)
68°C for 7 minutes (final extension)
Steps 3 through 5 were repeated for 40-35 cycles.
The annealing temperature for amplification of hGRa, hSRC-1, hRXR, CYP3A and 
CYP3A4 mRNAs was the same as for PXR but for CYP3A5 and CYP3A7 mRNAs a 
temperature of 55°C was used. The annealing temperatures were determined 
experimentally with 10 fxl of the reaction sample electrophoresed on a gel for 
assessment.
2.2.8. Restriction enzyme digest of plasmid DNA
Restriction enzymes are endonucleases that cut double stranded DNA molecules at 
specific target sequences (usually 4-8 bp). The recognition sites are usually 
palindromic and the enzymes used often cut both strands of the DNA in a staggered 
fashion, to give fragments with overhanging or ‘sticky’ ends. All the enzymes used 
were purchased from Promega UK (Southampton, UK).
The reaction mixture consisting the following ingredients was incubated at 37°C for 
1-4 hours:
Restriction enzyme 10 x buffer 2pl
Bovine serum albumin, acetylated (Img/ml) 0.5pl 
DNA sample (0.2 pg/pl) Ipl
Restriction enzyme (10 unit/p-1) Ipl
Nuclease-free water 15.5til
Final volume 20pl
2.2.9. Agarose gel electrophoresis
Due to its negative charge, DNA will migrate toward the positive pole (anode) of an 
electric field. This property is used to separate and size fragments of DNA by 
electrophoresing them through an agarose gel in a running buffer. The smaller 
molecules travel more easily through the gel matrix, whilst the larger molecules are 
retarded, thus they separate according to size.
1% agarose in IxTAE (0.04M tris-acetate and O.OOIM EDTA) containing 0.2jLig/ml 
ethidium bromide was used to assess the quality of RNA, DNA or restriction 
digestions. After mixing with loading dye (bromophenol blue 0.25%, xylene cyanol 
FF 0.25%, glycerol 50% and water 50%), samples were electrophoresed at 5V/cm for 
about 1 hour, i.e. until the marker dye moved approximately two-thirds of the way 
down the gel. A control Ikbp DNA ladder {Promega) was run alongside the samples 
in order to estimate the size of the DNA molecules. The DNA was visualised using 
UV light (302nm).
2.2.10. DNA extraction from electrophoresis gels
Applications such as cloning, labeling and sequencing of DNA frequently require the 
purification of DNA fragments from agarose gels or amplification reactions. The gel 
extraction kit was provided by CamBio Ltd (Cambridge, UK) and includes ULTRA 
SALT (sodium iodide) solution, ULTRA BIND (uniform size silica matrix) 
suspension and ULTRA WASH (NaCl/Tris/EDTA) solution (see Appendix I).
After weighing the gel slice, 3 volumes of ULTRA SALT was added to it (e.g. 0.3 ml 
for 0.1 g gel) and mixed well. The mixture was incubated at 55 °C while mixed 
occasionally by inverting until the gel melted (approximately 5 minutes). The 
ULTRA BIND suspension was vortexed until homogeneous (about 30 seconds). 7 pi 
was added to the melted gel mixture and incubated at room temperature for 5 minutes. 
At this stage binding of DNA to silica occured. The mixture was mixed several times 
during this binding step by inversion. The mixture then was centrifuged for 5 seconds
and the supernatant removed (if the DNA does not bind, it can be recovered from this 
supernatant). The pellet was resuspended in 1 ml of ULTRA WASH and centrifuged 
for 5 seconds. The supernatant was discarded and the pellet was washed and 
centrifuged again for 5 seconds. All traces of ULTRA WASH were removed by 
aspirating with a narrow pipette tip. The pellet was resuspended in water or TE and 
mixed by pipetting until homogeneous. The suspension was incubated for 5 minutes 
at room temperature to ensure that elution was complete. After centrifuging for 1 
minute, the clear DNA containing supernatant was collected and stored at +4°C.
2.3. Cell Culture
Human HepG2 hepatoma cells {ECCAC No. 85011430) were grown in 75cm^ flasks 
in 5% CO2 in air at 37°C. Cells were cultured in minimum essential medium (MEM) 
with Earle's salts supplemented with 10% (v/v) fetal bovine serum (PCS), 2mM L- 
glutamine, 10% (w/v) gentamicin and 1% (v/v) non-essential amino acids. Cells were 
seeded at 2-3x 10"^  cells/cm^ and passaged using trypsin/EDTA.
2.3.1. Cell passage
Cells were split every 3-5 days (when 90% confluent) as follows. The medium was 
aspirated and the cells were washed with phosphate buffer saline pH 7.4 (PBS) or 
trypsin-EDTA (Appendix 1) to remove the dead cells and any remaining medium. 
The washing solution was removed by aspiration. 2 ml trypsin-EDTA solution were 
added and left for 2-3 minutes at 3TC  to detach the cells from the flask. The flask 
was shaken to detach the cells completely. 8 ml of medium were added to inactivate 
the trypsin. The required amount of cell suspension (usually 1/3 of the suspension) 
was added to a new flask containing 20 ml of prewarmed medium.
2.3.2. Storage of cells in liquid nitrogen
A flask of actively growing cells was trypsinised and resuspended in 20 ml medium. 
The cells were pelleted by centrifugation at 1,200 x g for 5 minutes and then 
resuspended at 10  ^cell/ml in 10% DMSO in medium. This suspension was dispensed 
into cryovials in 1 ml aliquots, packed in cotton wool and put into a polystyrene box. 
The cryovials were transferred to the -80°C freezer overnight to freeze slowly 
(UC/min). They were then transferred to liquid nitrogen for storage.
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2.3.3. Recovery of cells from liquid nitrogen
A cryovial of cells was incubated in the waterbath at 37°C for 2 minutes to thaw 
completely, wiped with 70% ethanol, and the contents transferred into a sterile 50ml 
centrifuge tube containing 20 ml prewarmed medium. The cells were pelleted by 
centrifugation at 5,000xg for 5 minutes after which the pellet was resuspended in 20 
ml prewarmed medium and transferred to a 75 cm^-cell culture flask.
2.3.4. Preparation of medium treated with dextran coated charcoal (DCC)
Activated charcoal is a strong general adsorber of numerous materials. It is a safe 
agent in clinical practice and can be used in relatively large doses (1 g/kg of body 
weight) in drug overdose situations. Fetal bovine serum (FBS) is a constituent of the 
prepared medium however it contains steroid hormones. These hormones may affect 
the results of the experiments on gene expression when they or their synthetic 
analogues are being used as test compounds. Charcoal treatment of FBS can remove 
these hormones and allow production of hormone-free medium (DCC-treated 
medium).
500 mg of activated charcoal and 50 mg dextran T70 were added to a bottle of 500 ml 
FBS and stirred for 30 minutes. Then the mixture was centrifuged in 50-ml aliquots 
to pellet the dextran and most of charcoal. The dark serum supernatant was filtered 
using a 500-ml sterile filter in the sterile hood and dispensed in aliquots of 50 ml for 
the preparation of DCC-treated MEM.
2.3.5. Transfection of HepG2 cells with plasmid DNA
The ability to introduce nucleic acids into cells has advanced our knowledge of gene 
regulation and protein function in eukaryotic cells, tissues and organisms. The 
process of introducing nucleic acids into cells by non-viral methods such as the 
DEAE-dextran and calcium phosphate techniques is defined as “transfection”. This 
process is distinct from “infection”, which is a virus based method of nucleic acid 
introduction into cells. Many transfection techniques have now been developed. 
Desirable features include high efficiency transfer of DNA into the nucleus, minimal 
intrusion or interference with normal cell physiology, low chemical toxicity, ease of 
use, reproducibility, successful generation of stable transfectants (if required).
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The calcium phosphate precipitation transfection technique is widely used because the 
components are easily available and reasonable in price, the protocol is easy to use 
and many different types of cultured cells can be transfected. The method is routinely 
used for both transient and stable transfection of a variety of cell types. The protocol 
involves mixing DNA with calcium chloride, adding this in a controlled manner to a 
buffered saline/phosphate solution and allowing the mixture to incubate for a period. 
This step generates a fine DNA precipitate that is dispersed onto the cultured cells. 
The precipitate is taken up by the cells via endocytosis. The calcium phosphate also 
appears to provide protection against intracellular nuclease digestion of the DNA. 
The transfection protocol is that used previously in our laboratory (Ogg et al 1999).
Day 1: Seeding of HepG2 cells. Following trypsinisation, cells were diluted to a 
concentration of 6 x 10  ^ cell/ml with medium for seeding into 96-well plates {Nunc 
International). 80 pi of prewarmed medium was dispensed per well, and then 40 pi 
of cell suspension was added. The plates were placed in a humidified container in the 
cell culture incubator at 37°C for 24 hours.
Day 2: Transfection. One hour prior to transfection, the growth medium was 
removed and replaced with 80pl fresh medium and the plates returned to the 
incubator. The transfection mix was then prepared on ice for optimum precipitate 
formation. In a sterile tube 100 pi of 2 M CaCli was added to 25 pg plasmid DNA 
and the required volume of 0.1 x TE (1 mM Tris.Cl pH 8.0, 0.1 mM EDTA pH 8.0) 
was added to a final volume of 1 ml. Then 1 ml of 2 x HBS (280 mM NaCl, 10 mM 
KCl, 1.5 mM Na2HP0 4 .2 H2 0 , 12mM dextrose and 50mM HEPES) was added and 
incubated on ice for 1 minute after which 4.6 ml medium was added to terminate the 
precipitation reaction. After removal of the medium, 80 pi of transfection mix were 
added per well of the 96-well plate followed by 40 pi of medium to a final volume of 
120 pl/well. The plates were replaced in the humidified container and transferred to 
the cell culture incubator.
Day 3: Dosing. A sample of growth medium was removed for alkaline phosphatase 
assay and then drug solutions or control solvent were added to the cell cultures. The
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maximum final solvent concentration was 0.1%. All solutions were freshly prepared 
on the day of dosing. Incubation was then continued for a further 48 hours.
Day 5: Reporter assay. A further sample of the growth medium was removed for 
chemiluminescent assay of alkaline phosphatase activity.
2.3.6. Chemiluminescent assay of alkaline phosphatase activity
Secreted Placental Alkaline Phosphatase (SPAP or SEAP) can be assayed using a 
chemiluminescent alkaline phosphatase substrate. Alkaline phosphatase-catalysed 
dephosphorylation of the chemiluminescent substrate produces a destabilised 
dioxetane anion. This decomposes rapidly with the concomitant production of light. 
Unique chemiluminescence-enhancing reagents consisting of a water-soluble 
macromolecule, e.g. poly (benzylmethylvinylbenzyl) amonium chloride, and a 
fluorescent dye are key to the rapid production of an intense stable signal from the 
excited state generated in these alkaline phosphatase-catalysed reactions. The 
polymer sequesters the dephosphorylated dioxetane anion into hydrophobic domains 
of the polymer chain, thereby eliminating the aqueous quenching reactions, which 
profoundly lower the intensity of the chemiluminescent signal. In the presence of this 
type of enhancer approximately 2.5-3 orders of magnitude signal enhancement is 
achieved (Bronstein et al 1994).
Dilution buffer, assay buffer (a mixture of cellular alkaline phosphatase inhibitors) 
and reaction buffer (contains luminescence enhancer) were allowed to equilibrate to 
room temperature (Appendix 1). 25 pi samples from each well were placed in the 
wells of a fresh 96-well Optiplate (polystyrene microplates from Packard UK). 50 pi 
of 1 X dilution buffer was added to each well and the plates were incubated at 65 °C 
for 1 hour. The plates were removed, incubated on ice for 2 minutes and then left to 
reach room temperature (about 15 minutes). 60 pi of assay buffer was then added and 
the samples were incubated for 5 minutes at room temperature. 60 pi of the reaction 
buffer was added and left for 10 minutes after which time the plates were analysed for 
chemiluminescence using the Lumicount™ {Packard) plate reader.
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2.3.7. Assay of cell number by protein assay
The number of cells in a series of wells can be compared by protein assay. This has 
been shown to be directly proportional to the number of cells in the wells (Knox et al, 
1986).
Adherent cells were washed three times with PBS and then fixed with 3% 
glutaraldehyde in PBS for 10-20 minutes. After removal of the fixative, the cells 
were stained with 100 pl/well of the kenacid blue (Brilliant blue) stain solution. The 
stain solution was prepared immediately before filtration and use by addition of 12 ml 
glacial acetic acid to 88 ml of a stock solution made by dissolving 0.4 g brilliant blue 
R in 250 ml ethanol and 630 ml water. After staining for 30 minutes with gentle 
agitation, unbound stain was removed with several changes of ethanol-glacial acetic 
acid-water (10:5:85, by volume). The multi-well plates were agitated during this step 
and the process was continued until there was no visible blue colour in the washing 
solution (normally 2-3 washings). After removal of the final washing solution, 100 pi 
of a desorb solution consisting of IM potassium acetate in 70% ethanol was added to 
each well. After gentle agitation for 15 minutes, the dye concentration in the ‘desorb’ 
solution was measured spectrophotometrically at 570nm using a multi-well plate 
reader. After removal of the desorb solution and rinsing, the multi-well plates could 
be dried and kept in case the assay needed to be repeated (Knox et al, 1986).
2.3.8. P-galactosidase staining procedure
The LacZ gene of E. coli, encoding P-galactosidase activity, is a preferred reporter 
gene for normalisation of co-transfection experiments due to the ease of the P- 
galactosidase assay. The pCHllO plasmid carries the P-galactosidase cDNA driven 
by the early promoter/enhancer of the SV40 virus (Figure 2.5). Another advantage of 
the pCHllO system is the availability of a precipitating P-galactosidase substrate, X- 
gal, classically used in prokaryotic clone selection procedures. Thus X-gal offers an 
easy-to-use histochemical stain procedure, enabling detection of individual cells 
expressing a transfected bacterial LacZ gene by light microscopy. Although this 
technique is less accurate than colorimetric assay using the substrate ONPG, it 
provides an easy estimation of transfection efficiency.
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Transfected cells were washed with PBS and fixed for 15 minutes at 37°C in 100 
pl/well of fixing solution (2% formaldehyde and 0.2% glutaraldehyde in PBS). The 
fixing solution was removed and the cells were washed three times with PBS. 100 pi 
of staining solution (5 pi X-gal solution in 95 pi dilution buffer) were added 
(Appendix 1) and cells were incubated at 37°C for 1-2 hours until a blue colour 
developed. The number of blue cells present were counted manually under the 
microscope as an indicator of the proportion of cells successfully transfected with the 
pCHllO control plasmid.
2.3.9. Calculation of fold induction in reporter transfection experiments
An ideal method of calculation of fold induction of gene promoters by xenobiotics 
should fulfil these criteria:
(i) It must account for variation in transfection efficiency and cell number.
(ii) It must not be susceptible to the proliferative or cytotoxic effects of drugs,
otherwise false positive and false negative results may be produced.
(iii) In receptor addition studies, it must allow for determination of the fold effects 
of the receptor, as well as the drug.
The average readings from the Lumicount™ for control and test transfections at days 
3 (baseline) and 5 (dosed) were calculated. Using the plots in Figure 2.6 as the 
theoretical outcome of a model experiment, the calculation of fold induction is as 
follows (Plant et al 2000):
(a) Normalised value for each transfection = day 5 reading/day 3 reading
(ratio 4:3)(b) Fold induction due to drug =
(ratio 2:1)
(ratio D:C)
(c) Fold induction due to drug + GR =
(ratio B:A)
(d) Fold change due to GR = ratio (c) : (b)
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Figure 2.6. Alkaline phosphatase (AP) production in a model experiment.
CMV is the control SPAP plasmid, 3A4 is the reporter construct plasmid and GR is 
the co-transfected receptor cDNA. DMSO is the drug solvent.
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Chapter 3: ANALYSIS OF CYP3A4 GENE
REGULATION IN HepG2 CELLS USING A 
TRANSFECTION APPROACH
3.1. Introduction
Transfection, or the introduction of DNA into cells by non-viral methods such as the 
DEAE-dextran and calcium phosphate techniques, is one of the commonly used 
methods in molecular biology to investigate the effects of different factors on gene 
regulation. It has been used previously in our laboratory for the study of regulation of 
CYP3A enzymes in cell cultures such as HepG2 cells (e.g. Ogg et al 1999; El- 
Sankary et al 2000). The system also allows for the separate and combined 
transfection of expression plasmids encoding transcription factors such as the human 
glucocorticoid receptor (hGR) or the human pregnane X receptor (hPXR), and, 
therefore, the opportunity to assess the role of these receptors in CYP3A4 induction. 
The reporter gene in this system is secreted placental alkaline phosphatase 
(SPAP/SEAP) an isoenzyme not produced in liver cells. It is more resistant to heat 
than human liver alkaline phosphatase and can thus be distinguished from it.
3.2. Analysis of HepG2 cell distribution and growth in 96-well tissue 
culture plates
In primary transfection experiments. Large inter-well variation in alkaline 
phosphatase (AP) activity was found even in a row of identical wells. An analysis of 
cell distribution between wells was performed using the protein assay procedure. As 
shown in Figure 3.1 following a typical seeding, the number of cells gradually 
declined across the rows. As the trypsinized cells were in suspension, settling with 
time in the seeding ‘boat’ must have caused this uneven distribution of cells. To 
prevent this problem, cell suspensions were shaken before taking each multi-channel 
pipette sample for seeding. Using this procedure, the difference in cell number 
between rows was substantially reduced (Figure 3.2).
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However, inter-row and inter-well variation in alkaline phosphatase production 
following transfection was still found (results not shown) indicating that inter-well 
variation in activity was not simply a result of differences in cell number. The main 
factor that appeared to be involved was differences in the volume of the medium in 
wells at the edge of the 96-well plate. By close examination of the wells during a 5- 
day incubation, it was found that the volume of the medium declined in outer wells 
compared to the central ones. By incubating the 96-well plates in a closed box 
containing a small beaker of water (humidifying chamber) this problem decreased but 
was not overcome completely. Generally, outer wells were not used if at all possible. 
This series of experiments demonstrated the ease with which variability can be 
introduced into the transfection procedure, producing erroneous data.
3.3. DNA transfer and transfection efficiency
Transfection efficiency can be measured by two different methods.
1) transfection of the lac Z PCHl 10 plasmid and subsequent assay of P- 
galactosidase activity
2) consideration of the gain level of the Lumicount™ instrument used to measure 
the activity of alkaline phosphatase.
3.3.1. Measurment of P-galactosidase activity
The plasmid PCHllO contains a functional LacZ gene which can be expressed in a 
wide variety of cells following transfection. The LacZ gene encodes p-galactosidase 
(p-Gal) and produces a coloured metabolite with the appropriate substrate. Using the 
P-Gal staining kit, the efficiency of the calcium phosphate transfection procedure was 
measured after transfecting cells with PCHllO plasmid DNA (data not shown). The 
efficiency was between 3% and 6% in different parts of the cell sheet. It was higher in 
less dense areas and lower in denser ones. In dense areas, cell exposure to DNA 
appeared to be less efficient possibly because cell-cell overlap leads to less exposure 
to the DNA precipitate.
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Figure 3.1. Protein assay of 12 rows of a 96-weIl plate containing seeded HepG2 
cells.
HepG2 cells were seeded without shaking of the cell suspension and incubated at 
37°C for 24 hours. They were then fixed and the number of cells measured indirectly 
using the Brilliant blue protein assay. Data are shown as mean ± SEM (n =8).
* P<0.05 compared to row 1.
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Figure 3.2. Protein assay of 12 rows of a 96-weII plate containing seeded HepG2 
cells.
HepG2 cells were seeded with frequent shaking of the cell suspension and incubated 
at 37°C for 24 hours. They were fixed and the number of cells measured indirectly 
using Brilliant blue protein assay. Data are shown as mean ± SEM (n =8). * p<0.05 
compared to row 1.
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3.3.2. Lumicount™ gain level
The relative amount of alkaline phosphatase was determined by measuring the amount 
of light emitted from a luminescent substrate. This measurement is based on the 
average amount of the light emitted from the substrate. This average is expressed as 
the gain level for a specific sample. The higher the amount of the emitted light the 
less gain required and vice versa (Lumicount™ manual). The gain level in 
chemiluninescence assays for alkaline phosphatase in these experiments were 
normally between 1 and 5, indicating that a high amount of alkaline phosphatase 
expression (Ogg et al 1999) and thus reasonable efficient transfection levels were 
obtained.
The results of both these procedures showed that transfection of HepG2 cells by the 
calcium phosphate procedure was successful, producing significant levels of DNA 
uptake and expression.
3.4. Xenobiotic modulation of reporter gene expression following 
transfection in HepG2 cells
DNA from plasmids p3A4-cSPAP, pCMV-cSPAP, pSG5-hGR, pSG5-hPXRAATG 
and pCHl 10 were used to replicate the experiments carried out previously (Ogg et al 
1999). Plasmid DNAs were checked for purity and the results demonstrate good 
quality and yield (Figure 3.3). HepG2 cells were seeded in 96-well plates and 
incubated for 24 hours at 37°C. The plasmid DNAs were transfected and incubation 
was continued in DCC-treated MEM for a further 24 hours. A 15 |il sample of the 
medium was taken from each well for baseline chemiluminescence alkaline 
phosphatase assay in day 3. The cells were dosed with DEX or RIF and incubated in 
DCC-treated MEM for a further 48 hours. Another 15 p-l of the medium was taken 
for chemiluminescence alkaline phosphatase assay in day 5. In some experiments 
there was a significant induction by 50 fiM DEX (Figure 3.4). These results are in 
agreement with previous results (Ogg et al 1999; El-Sankary et al 2000) and show that 
DEX and RIF can modulate the activity of CYP3A4 promoter in HepG2 cells. In 
some experiments (Figure 3.5), although there appear to be no induction on first 
inspection of the data, the calculated fold induction increased due to a reduction in the
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control levels of alkaline phosphatase expression. However, in the majority of 
experiments there was no significant induction by DEX or RIF (Figure 3.6), even 
using different concentrations (10, 20 and 50 piM).
The reason for this variability in alkaline phosphatase expression and induction in the 
system was not clear. The use of different passages of HepG2 cells and DNA 
prepared by different procedures had no effect. It was decided to consider a number 
of other possibilities:
1. The reporter plasmid was incorrect or had undergone some change during 
bacterial culture and DNA preparation.
2. The level of nuclear receptors such as GR and PXR in the HepG2 cells were 
too low to give reproducible results.
3. The response relates to the passage number of the HepG2 cells. During 
culture morphological changes were noticeable after passage 20 from 
resuscitation of frozen stocks. This might relate to loss of liver phenotype.
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Figure 3.3. Gel electrophoresis of plasmid DNAs used in transfection 
experiments.
Lane A: DNA marker ladder 
Lane B: pCMV-cSPAP plasmid 
Lane C: p3A4-CMV-cSPAP plasmid 
Lane D: pSG5-hGR plasmid 
Lane E: pSG5-hPXR plasmid 
Lane F; pCHl 10 plasmid
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Figure 3.4. Alkaline phosphatase expression in dexamethasone treated HepG2 
cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 50 pM
dexamethasone in DCC-treated medium. Samples of medium were taken for alkaline 
phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment and the 
fold induction for Dex is 6.4.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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Figure 3.5. Alkaline phosphatase expression in rifampicin treated HepG2 cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 50 pM rifampicin in
DCC-treated medium. Samples of medium were taken for alkaline phosphatase assay 
48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment and the 
fold induction for Rif is 1.69.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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Figure 3.6. Alkaline phosphatase expression in dexamethasone or rifampicin 
treated HepG2 cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 50 pM rifampicin or
dexamethasone in DCC-treated medium. Samples of medium were taken for alkaline 
phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Dex is 1.06 and for Rif is 1.02.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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3.5. Analysis of the p3A4-cSPAP reporter construct
Transfection experiments in HepG2 cells failed to reliably reproduce the induction of 
CYP3A4 promoter constructed in p3A4-cSPAP by the standard inducers of CYP3A4 
gene, dexamethasone and rifampicin. As one of the possible reasons for this problem 
might be structural abnormalities produced in the p3A4-cSPAP reporter DNA during 
bacterial growth or plasmid DNA isolation, a number of experiments were performed 
to examine the p3A4-cSPAP reporter plasmid DNA.
3.5.1. PCR analysis of CYP3A4 promoter region
In order to examine the authenticity of CYP3A4 promoter region engineered into 
p3A4-cSPAP reporter plasmid, a PCR reaction was performed with a pair of primers 
that could amplify a significant portion of the CYP3A4 promoter (617 base pairs from 
-951 to -33) in this reporter. As Figure 3.7 shows, the reaction produced a band with 
the expected size. This confirms that this part of the reporter construct is intact and 
the transfection problem might relate to a problem in the rest of the reporter plasmid.
3.5.2. Further analysis of the CYP3A4-SPAP reporter plasmid
Restriction digestion of the p3A4-cSPAP reporter plasmid was performed with 
specific enzymes (Figure 2.4). Xba I cuts the plasmid at 3284 bp and Sal I cuts it at 
6965 bp. Using both enzymes in the same digest, two DNA fragments of 3324 bp and 
3682 bp are expected. As shown in Figure 3.8, restriction digest of the plasmid 
simultaneously with these two enzymes resulted in two fragments of the expected 
sizes (approximately 3300 and 3700 bp). This is a further confirmation of the 
authenticity and integrity of the reporter plasmid and shows that it is complete.
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Figure 3.7. PCR analysis of the CYP3A4 promoter in the p3A4-cSPAP reporter 
plasmid.
The -951 to -33 bp region of the CYP3A4 promoter in p3A4-cSPAP was amplified 
by PCR and the product was run on a 1% agarose gel.
Lane A: Ikb DNA ladder
Lane B: positive control of the Promega PCR kit (280 bp)
Lane C: promoter region (617 base pairs from -951 to -33).
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Figure 3.8. Restriction digest analysis of the p3A4-cSPAP reporter vector.
1 pg sample of P3A4-cSPAP DNA was subjected to restriction enzyme digest and 
electrophoresed in a 1% agarose gel.
Lane A: DNA marker ladder
Lane B: p3A4-cSPAP digest with Xba I and Sal I (3324 and 3682 bps)
Lane C: uncut p3A4-cSPAP
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3.6. Modulation of CYP3A4 gene promoter activity in HepG2 cells: 
role of the glucocorticoid receptor
Transfection of the reporter plasmid p3A4-cSPAP into HepG2 cells had not resulted 
in reproducible responses to the in vivo CYP3A4 inducer dexamethasone. One reason 
considered was that the cells lacked sufficient levels of the nuclear glucocorticoid 
receptor hGR. In order to examine this probability, co-transfection experiments were 
performed using an expression plasmid pSG5-hGR containing the cDNA for the a  
form of the human glucocorticoid receptor (Ogg et al 1999). Transfection with this 
vector in HepG2 cells has been shown to result in substantially elevated intracellular 
levels of hGR.
3.6.1. Co-transfection of p3A4-cSPAP and pSG5-hGR in HepG2 cells
HepG2 cells were seeded in 96-well plates and incubated in medium for 24 hours at 
37°C. The plasmid DNAs of pCMV-cSPAP or p3A4-cSPAP were co-transfected 
with pSG5-hGR and incubation was continued in DCC-treated medium for a further 
24 hours. A 15 pi sample of the medium was taken from each well for baseline 
chemiluminescence alkaline phosphatase assay (day 3). The cells were dosed with 
DEX or RIF and incubated for a further 48 hours in DCC-treated medium. Another 
15 pi of the medium was taken for chemiluminescence alkaline phosphatase assay of 
day 5.
The results of these experiments were very similar to those in section 3.3. In some 
experiments, a significant induction was observed with DEX (Figure 3.9) in the 
presence of the hGR expression vector. hGR increased the fold induction caused by 
dexamethasone. These results are in agreement with others who showed that hGR 
increases the induction of CYP3A4 promoter constructs (Ogg et al 1999; El-Sankary 
et al 2000; Goodwin et al 1999). However, in most experiments no significant 
induction in CYP3A4 promoter activity was observed (Figures 3.10 and 3.11).
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Figure 3.9. Alkaline phosphatase expression in dexamethasone treated HepG2 
cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 50 pM
dexamethasone in DCC-treated MEM. Samples of medium were taken for alkaline 
phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Dex is 1.27, for Dex + GR is 3.11 and the fold change upon addition of 
GR was 2.45.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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Figure 3.10. Alkaline phosphatase expression in dexamethsone treated HepG2 
cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 50 pM
dexamethasone in DCC-treated MEM. Samples of medium were taken for alkaline 
phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Dex is 1.06, for Dex + GR is 1 and the fold change upon addition of GR 
was 0.094.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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Figure 3.11. Alkaline phosphatase expression in dexamethsone treated HepG2 
cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4). 24 hrs later the medium was removed and replaced by 20 pM
dexamethasone in DCC-treated MEM. Samples of medium were taken for alkaline 
phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Rif is 1.26, for Rif + GR is 0.98 and the fold change upon addition of 
GR was 0.77.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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3.6.2. Analysis of the integrity of the pSG5-hGR expression vector
Since co-transfection with the hGR cDNA containing expression vector had not led to 
reproducible, enhanced induction of the CYP3A4 promoter in p3A4-cSPAP, there 
was concern that the pSG5-hGR expression vector DNA used in the experiments had 
been damged during preparation, and even that the wrong plasmid might have been 
used. Using PGR, the plasmid DNA was examined to confirm the presence of the 
hGRa cDNA insert. At the same time the pSG5-hPXRAATG expression vector was 
also checked for integrity and authenticity (see section 3.8). PGR reactions were 
performed using primers designated to amplify diagnostic regions of the hGRa + 
P, hGRa, hGRP and hPXR cDNAs. As shown in Figure 3.12, successful 
amplifications were obtained with all the primer pairs except for the hGRP-specific 
set. The result confirms that the sample of pSG5-hGR DNA used in the transfection 
experiments did indeed contain the cDNA for hGRa cDNA. As expected it did not 
contain hGRP cDNA. The result indicate that the of effect of co-transfection with 
hGR was not due to a problem with the plasmid DNA used, but must be due to some 
other cause.
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Figure 3.12. PCR analysis of the hGR and hPXRAATG expression vectors.
Plasmid DNAs from pSG5-hGR and pSG5-hPXRAATG were amplified to confirm 
presence of the correct cDNA insert. PCR products were electrophoresed in a 1% 
agarose gel.
Lane A: DNA marker
Lane B: positive PCR control of the promega kit (280 bp)
Lane C: pSG5-hPXRAATG 
Lane D: pSG5-hGR (a  + p primers)
Lane E: pSG5-hGR (a  primers)
Lane F: pSG5-hGR (P primers).
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3.7. Modulation of CYP3A4 promoter activity in HepG2 ceils: role of 
hPXR
Since co-transfection with pSG5-hGR had no effect on the reproducibility of 
induction p3A4-cSPAP reporter vector experiments with dexamethasone or 
rifampicin, a further possible explanation considered was that the HepG2 cells lacked 
sufficient intracellular hPXR. To determine whether this was indeed the problem, co­
transfections with an expression vector pSG5-hPXRAATG (Lehmann et al 1998) 
were performed. This vector contains a modified codon 1 in the cDNA to provide a 
more efficient methionine (ATG), rather than the in vivo leucine (CTG), start for 
ribosomal translation of the hPXR mRNA following transfection.
3.7.1. Co-transfection experiments with pSG5-hPXR
HepG2 cells were seeded in 96-well plates and incubated in minimum essential 
medium for 24 hours at 37°C. The plasmid DNAs of pCMV-cSPAP or p3A4-cSPAP 
were co-transfected with pSG5-hPXRAATG and incubation was continued in DCC- 
treated medium for a further 24 hours. A 15 pi sample of the medium was taken from 
each well for baseline chemiluminescence alkaline phosphatase assay (day 3). The 
cells were dosed with DEX or RIF and incubated for a further 48 hours. Another 15 
pi of the medium was taken for chemiluminescence alkaline phosphatase assay of day 
5. Results followed a similar pattern as for hGR, i.e. some experiments showed 
significant fold increase of the CYP3A4 promoter activity by rifampicin in the 
presence of pSG5-hPXRAATG (Figure 3.13) but in most of them no effect was 
observed (Figure 3.14).
Co-transfection of HepG2 cells with p3A4-cSPAP reporter vector and pSG5- 
hPXRAATG expression vector had not led to reproducible responses to the in vivo 
CYP3A4 inducers DEX or RIF. Some possible reasons could be considered.
1. There might be something wrong with pSG5-hPXRAATG expression vector 
used in the experiments. Possible damage of the vector during growth of the 
bacteria or during isolation of the expression vector was a possibility.
116
2
<
DMSO RifSOuM
[IpCMV 
□  p3A4 
HpCMV+PXR  
®p3A4+PXR
Figure 3.13. Alkaline phosphatase expression in rifampicin treated HepG2 cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were co-transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3 A4) and pSG5-hPXRAATG. 24 hrs later the medium was removed and replaced 
by 20 pM rifampicin in DCC-treated MEM. Samples of medium were taken for 
alkaline phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of 
DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Rif is 1.72, for Rif + hPXR is 3.62 and fold change upon addition of 
hPXR was 2.1.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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Figure 3.14. Alkaline phosphatase expression in rifampicin treated HepG2 cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were co-transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4) and pSG5-hPXRAATG. 24 hrs later the medium was removed and replaced 
by 20 pM rifampicin in DCC-treated MEM. Samples of medium were taken for 
alkaline phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 after addition of 
DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Rif is 1.26, for Rif + hPXR is 0.98 and fold change upon addition of 
hPXR was 0.78.
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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2. HepG2 cells may not be a suitable host cell line for the study of CYP3A4 
gene regulation by xenobiotics. Selection of another cell line like HUH7 or 
Caco-2 may help to solve the problem.
3. During transfection experiments with RIF a significant reduction in the 
total amount of AP production of all wells was observed (Figure 3.14 and 
3.18). A similar effect was not observed with DEX (Figure 3.18). As this 
effect was observed in all wells exposed to RIF, the possibility of cell toxicity 
needs to be considered. The results of possible cytotoxicity of RIF is in 
agreement with others who observed this effect in human and animal in vitro 
and in vivo studies. Rifampicin was shown to have cellular toxicity in human 
and animal experiments. It produced toxic effects on human liver (Skakun et 
al 1991; Schreiber et al 1999). The drug also produced toxic actions on the 
hepatic and haematopoetic systems in mice (Rao et al 1998). Pre-incubation 
of HepG2 cells with RIF increased the cytotoxicity of isoniazid and 
acetaminophen on HepG2 cells (Nicod et al 1997). The mechanism of RIF 
cell toxicity is not clearly understood but this drug causes a direct inhibition 
of protein synthesis in rat thymic and hepatic microsomes and in human 
hepatic microsomes (Buss et al 1978).
3.8. Re-analysis of the pSG5-hPXRAATG expression vector
Since co-transfection of HepG2 cells with the hPXR cDNA containing expression 
vector had not led to reproducibly enhanced induction of the CYP3A4 promoter in 
p3A4-cSPAP, the possibility existed that the pSG5- hPXRAATG expression vector 
used in the experiments had been damaged during preparation or even the wrong 
plasmid had been used. To examine and confirm the presence of the hPXR insert and 
the integrity of the whole vector, the following analyses were performed.
3.8.1. PCR analysis of the pSG5-hPXR expression vector
PCR reactions were performed using primers designed to amplify diagnostic regions 
of hPXR. No band of appropriate size for hPXR in pSG5-hPXRAATG construct (422 
bp)was observed (Figure 3.12 band C). This result shows that the hPXR expression 
vector was defective.
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3.8.2. Restriction digest of the pSG5-hPXRAATG expression vector
In order to further confirm the results of the PCR reactions, restriction digest 
experiments for the expression vector were performed. pSG5-hPXRAATG had been 
constructed using Eco RI and Bam HE. These two restriction enzymes were used by 
Kliewer et al (1998) for preparation of the 1.3 kb of hPXR cDNA insert. They should 
normally cut the plasmid into two pieces of 1.3 kb (hPXRAATG insert) and 4 kb 
(pSG5 plasmid). The results (Figure 3.15) confirmed that the authentic hPXR 
expression vector had not been used in the experiments.
Further digests with the previous enzymes together with Sac I were also performed. 
Sac I cuts PXR cDNA at position 1199 bp. The results (Figure 3.16) confirmed the 
previous ones and showed that this expression vector is not authentic.
After receiving a new sample of pSG5-hPXRAATG expression vector from Dr 
Kliewer, a PCR reaction using specific primers for hPXR cDNA was performed. The 
result of the PCR reaction (Figure 3.17) shows that the new vector is authentic. For 
additional confirmation restriction enzyme digests were performed with Bam HI and 
Eco RI. As shown in Figure 3.17, restriction digestion produced two fragments of 
approximately 1.3 kb and 4 kb as expected. It is clear that care has to be taken to 
analyse plasmid DNA samples obtained from other workers.
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Figure 3.15. Restriction enzyme digest analysis of the original pSG5-hPXRAATG 
expression vector.
HPXRAATG expression vector used for co-transfection experiments was digested by
Eco RI and Bam HI and the DNA fragments were electrophoresed on 1% agarose gel.
Lane A: DNA marker ladder
Lane B: pSG5-hPXRAATG, BamHI digested
Lane C: pSG5-hPXRAATG, EcoRI digested
Lane D: pSG5-hPXRAATG, BamHI + EcoRI digested
Lane E: intact pSG5-hPXRAATG
* : The values are approximate sizes.
# : This is not the right size for the plasmid. The uncut plasmid position in the gel 
also depends on conformation. In the super-coiled conformation, it moves faster than 
the linear conformation.
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Figure 3.16. Restriction enzyme digest analysis of the original pSG5-hPXRAATG 
expression vector.
Lane A and H: DNA marker ladder 
Lane B: pSG5-hPXRAATG, BamHI digested 
Lane C: pSG5-hPXRAATG, EcoRI digested 
Lane D: pSG5-hPXRAATG, Sac I digested 
Lane E: pSG5-hPXRAATG, BamHI + EcoRI digested 
Lane F: pSG5-hPXRAATG, BamHI + Sac I digested 
Lane G: pSG5-hPXRAATG, Eco RI + Sac I digested
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Figure 3.17. PCR and restriction enzyme digest analysis of the new pSG5- 
hPXRAATG expression vector.
PCR product from amplification using primers specific for hPXR cDNA and DNA 
fragments from Bam HI and Eco RI digests of the pSG5-hPXRAATG DNA used for 
transfection were electrophoresed on 1% agarose gel.
Lane A: DNA marker ladder 
Lane B: positive PCR control (280 bp)
Lane C: PCR product from pSG5-hPXRAATG 
Lane D: pSG5-hPXRAATG, BamHI digest 
Lane E: pSG5-hPXRAATG, Eco RI digest 
Lane F; pSG5-hPXRAATG, BamHI + Eco RI digest
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3.8.3. Co-transfection experiments using the new pSG5-hPXRAATG expression 
vector
Co-transfection of HepG2 cells with p3A4-cSPAP and the old pSG5-hPXRAATG 
DNAs had not led to reproducible induction of CYP3A4 promoter. Subsequent PCR 
and restriction enzyme digest analysis of pSG5-hPXRAATG expression vector 
produced unexpected results and showed that the authentic hPXR expression vector 
had not been used. Thus, the possibility could be considered that the problem of 
reproducibility of induction of CYP3A4 promoter by DEX or RIF was caused by use 
of the wrong hPXR expression vector. To evaluate this hypothesis, a number of co­
transfection experiments were performed using the new and authentic pSG5- 
hPXRAATG expression vector.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs, the 
cells were co-transfected with pCMV-cSPAP or p3A4-cSPAP and the new pSG5- 
hPXRAATG expression vector. 24 hrs later, a 15-pl sample of the medium from each 
well was taken for chemiluminescence alkaline phosphatase assay of day 3. The 
medium was removed and replaced by 50 pM DEX or RIF in DCC-treated medium. 
Incubation continued for 48 hrs and then another 15-pl sample of the medium from 
each well was taken for chemiluminescence alkaline phosphatase assay of day 5.
As shown in Figure 3.18, there is no induction of CYP3A4 activity by DEX or RIF in 
co-transfection experiments with the new pSG5-hPXRAATG expression vector. Thus 
the problem of the reproducibility of induction of CYP3A4 promoter activity is not 
due to use of the wrong reagents. Other possibilities must therefore be considered. 
One possibility is that HepG2 cells are not the right host cells for the experiments of 
induction of CYP3A4 gene regulation because these cells do not express this enzyme 
in vitro. Selection of another CYP3A4-expressing cell line for this purpose would 
thus be suggested. The other possibility is that the CYP3A4 promoter region in this 
vector is not sufficient to reliably reproduce the in vivo induction of this gene by 
xenobiotics and additional DNA motifs are required.
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Figure 3.18. Alkaline phosphatase expression in rifampicin or dexamethasone 
treated HepG2 cells.
HepG2 cells were seeded in 96-well plates and incubated at 37°C. After 24 hrs the 
cells were co-transfected with DNAs from pCMV-cSPAP (pCMV) or p3A4-cSPAP 
(p3A4) and pSG5-hPXRAATG. 24 hrs later the medium was removed and replaced 
by 20 pM rifampicin or dexamethasone in DCC-treated medium. Samples of medium 
were taken for alkaline phosphatase assay 48 hrs and 96 hrs later (day 3 and day 5 
after addition of DNA).
Each data point was derived from 8 replicates in a representative experiment. Fold 
induction for Dex 50uM is 0.88, for Rif 50uM is 1.29, for Dex 50uM+ PXR is 0.87, 
for Rif 50uM + PXR is 0.95, fold change for Dex 50uM upon addition of hPXR was 1 
and for Rif 50uM upon addition of hPXR was 0.74.
* : significant difference from DMSO or dexamethasone counterpart (p<0.05)
AP ratio =
Normalised alkaline phosphatase level at day 5 
Normalised alkaline phosphatase level at day 3
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3.9. Discussion
Human HepG2 hepatoma cells are one of the most commonly used cell lines in 
molecular biology for the study of hepatic gene expression including cytochrome 
P450s gene regulation. In order to evaluate the ability of this cell line to modulate the 
expression of reporter constructs containing the CYP3A4 proximal promoter region 
and to examine the effect of co-transfection with cDNAs for hPXR and hGR on 
modulation of the CYP3A promoter constructs in these cells a number of co­
transfection experiments were performed.
The results of the transfection experiments generally failed to demonstrate 
reproducible induction of the transfected CYP3A4 promoter by DEX or RIF, the 
classic inducers of this gene in vivo. Also, hGR and hPXR co-transfection did not 
rectify the situation. When a positive result was obtained it was in agreement with 
others who observed induction of p3A4-cSPAP construct by these two drugs with or 
without hGR or hPXR expression vector co-transfections (Ogg et al 1999; El-Sankary 
et al 2000). Reproducible induction of the CYP3A4 promoter in HepG2 cells has 
however been obtained using different constructs (Goodwin et al 1999). They 
showed that the reproducible induction of a CYP3A4 construct needs the potent 
XREM enhancer module situated approximately 8 kb distal to the transcription start 
point in the CYP3A4 gene. It is thus possible that the promoter region in the reporter 
construct used in our studies was not long enough or did not have all the necessary 
DNA motifs required to produce effective induction of the reporter gene.
It should also be noted that HepG2 cells do not express CYP3A4 enzyme in culture 
(Schuetz et al 1993b) but are able to express the cDNA for this isoenzyme (Salmela et 
al 2001). Relling et al (1995) also observed that the cDNA for human CYP3A4 could 
be functionally expressed in HepG2 cells using a vaccinia viral vector. Of more 
relevance, Ourlin et al (1997) demonstrated that the expression of a CYP3A4 
promoter construct was increased by cotransfection with liver-enriched transcription 
factor C/EBP alpha cDNA. It is thus possible that deficiency of other transcription 
factors (or indeed the activation of some inhibitory factors) also leads to the lack of 
reproducible CYP3A4 promoter induction and gene expression in this cell line. 
CYP3A4 has been identified as being differentially expressed between human
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hepatocellular carcinoma (HCC) cells and matched non-tumorous liver tissues 
(Kondoh et al 1999). Also Sumida et al (2000) detected 1.6 kb of a CYP3A4 mRNA 
containing the protein coding region in HepG2 cells. These results collectively 
suggest that CYP3A4 is not normally expressed in HepG2 cell if at all. Selection of a 
CYP3A4-expressing cell line, e.g. colon carcinoma cell line (Caco-2) or colon 
adenocarcinoma (LSI80) for these studies may have some advantage over HepG2 
cells because the expression of this enzyme in these cells ensures that all necessary 
factors for CYP3A4 expression is available in the cells.
Two other factors that may affect the inducibility of CYP3A4 promoter reporter gene 
assays are cell density and passage number. Greuet et al (1997) demonstrated that 
maintaining primary human adult hepatocytes under conditions that favoured cell 
proliferation (i.e. plating at low cell density plus addition of EGF to the culture 
medium) reduced their ability to respond to prototypical inducers such as RIF. It has 
also been shown that the inducibility of the CYP3A4 promoter reporter gene assay in 
HepG2 cells reduces at passages more than 16 (Ogg et al 1999). The results of 
endogenous CYP3A induction in this study by RT-PCR also suggest a variation of 
induction in different passages of this cell line. Complete clarification of the effects 
of these factors requires further experimentation.
Thus it would appear that transfection of the minimal CYP3A4 vector p3A4-cSPAP 
into HepG2 cells is not a reliable approach to the study of CYP3A regulation in this 
cell line and alternative approaches should be considered. Reverse transcription 
polymerase chain reaction (RT-PCR) is a highly specific, reproducible, rapid, and 
sensitive method that is able to detect even very low levels of mRNA that may not be 
detected by other techniques. It can also be used for quantitative or semi-quantitative 
studies of gene expression. This technique has recently been used successfully for the 
study of induction of CYPs by xenobiotics in organs and cell culture (e.g. Rodriguez- 
Antona et al 2000; Sumida et al 2000). However RT-PCR technique can only be used 
in transcriptional induction studies and cannot detect factors responsible for the other 
steps of gene expression e.g. translation. There are several factors that may affect 
mRNA half-life through different splicing or stabilisation and the others that may 
affect mRNA translation. The resultant protein may also be subject to stabilisation or 
inactivation in specific cell types and these steps can not be detected by RT-PCR
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technique. Thus the technique is again only an indirect approach to the analysis of 
gene regulation. However, it can be used to answer questions relating to the 
transcriptional activation of specific genes.
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Chapter 4. ANALYSIS OF XENOBIOTIC MODULATED 
GENE EXPRESSION IN HepG2 CELLS USING RT-PCR
RT-PCR is one of the most specific techniques in molecular biology. It is of great 
value in detecting and quantitating low level gene expression not detectable by other 
techniques. It is also a robust alternative to other techniques like Northern Blotting, 
Western Blotting and transfection for the investigation of the regulation of gene 
expression by endobiotics or xenobiotics. It has been used successfully for the study 
of cytochrome P450 gene expression in various animal species (Kullman et al 2000) 
and in human tissues (Anttila et al 1997) including liver (Rodriguez-Antona et al 
2000). It has also been used for the study of gene induction in cell culture including 
primary human hepatocytes (Bowen et al 2000) and HepG2 cells (Sumida et al 2000). 
As the transfection experiments (Chapter 3) using the reporter construct p3A4-cSPAP 
in HepG2 cells failed to show reproducible activation of the CYP3A4 gene promoter 
by classical inducers of this isoenzyme, RT-PCR was used to assess directly the 
endogenous production of mRNA for the CYP3A isoenzymes and nuclear receptors in 
this cell line.
4.1. Standardisation of RT-PCR analysis
A series of preliminary experiments were performed to confirm the specificity of the 
RT-PCR primers under standard reaction conditions using a commercially supplied 
control human liver mRNA. The CYP3A primers used in these preliminary 
experiments did not distinguish between the CYP3A isoenzyme mRNAs. However, 
once the sequences of the different CYP3A genes had been confirmed, isoenzyme- 
specific primers were used to distinguish between CYP3A4, CYP3A5 and CYP3A7 
mRNAs.
RT-PCR experiments for the identification of hGRa, hPXR, CYP3A, glyceraldehyde 
phosphate dehydrogenase (GAPDH), retinoid X receptor (RXR), hepatocyte nuclear 
factor 4 (HNF-4) and steroid receptor co-activator 1 (SRC-1) mRNAs in human liver 
mRNA were performed using 40-cycle reactions and specific primers. For each 
reaction, a number of experiments were performed to standardise the RT-PCR 
conditions especially the annealing temperature. For hGRa, hPXR, CYP3A,
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GAPDH, RXR and SRC-1 good amplification was obtained at an annealing 
temperature of 58°C. In the case of CYP3A4-specific primers the best annealing 
temperature was again 58°C, but for specific CYP3A5 and CYP3A7 amplifications 
the best result was obtained at 55°C. HNF-4 was also amplified best at 55°C. The 
other important factor in RT-PCR experiments, the optimal concentration of MgS0 4 , 
was also tested. It found that the recommended concentration of 1 mM was the best 
for these amplifications.
40-cycles of amplification were used in section 4.1 and although this does not allow 
quantitation, due to possible rate-limitation of RT-PCR components at high cycle 
number, some initial conclusions may be drown. Figures 4.1 and 4.2 suggest that 
there was high expression of CYP3A and hPXR mRNA as expected from the 
literature. The expression of hGRa and GAPDH mRNA was lower, with hGRa 
having the lowest expression in human liver mRNA. Figure 4.3 confirms the 
expression of RXR and SRC-1 mRNAs in human liver and in HepG2 cells. Finally 
Figure 4.4 demonstrates the expression of HNF-4 in human liver and HepG2 cells.
These results demonstrate the efficacy of the primers used and confirms the 
expression of all these genes in human liver cells. The expression of the CYP3A 
subfamily of enzymes (mainly CYP3A4) is high in human liver and constitutes 30% 
of the cytochrome P450 content of the liver (Guengerich 1999; Westlind et al 1999). 
It also constitutes 70% of the small intestinal cytochrome P450 content (Schuetz et al 
1996). Thus the CYP3A band from human liver mRNA in Figure 4.1 mainly reflects 
the expression of CYP3A4 even though the ‘nonspecific’ primers may also have 
amplified CYP3A5 and CYP3A7 mRNAs. In fact the expression of CYP3A5 
(Jounaidi et al 1996) and CYP3A7 (Harvey et al 2000; Greuet et al (1996) is lower 
than CYP3A4 in human liver but they could contribute to this band. Subsequent RT- 
PCR reactions using isoenzyme-specific primers confirmed the presence of CYP3A5 
and CYP3A7 mRNAs as well as CYP3A4 mRNA in the control human liver mRNA 
sample (Figure 4.18).
GAPDH is a gene used as an internal standard in semi-quantitative RT-PCR 
experiments of cytochrome P450 and nuclear receptors (hGRa and hPXR) gene
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Figure 4.1. RT-PCR amplification of hGRa, hPXR, CYP3A and GAPDH mRNA 
sequences in human liver mRNA.
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A: DNA marker ladder 
Lane B: hGRa (493 bp)
Lane C: hPXR (442 bp)
Lane D: CYP3A (293 bp)
Lane E; GAPDH (427 bp)
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Figure 4.2. Preliminary analysis of the transcription of hGRa, hPXR, CYP3A 
and GAPDH mRNA sequences in human liver mRNA.
RT-PCR product bands from Figure 4.1 for hGRa, hPXR, CYP3A and GAPDH 
mRNAs were quantitated by scanning to compare the amount of transcription of each 
gene in human liver. The levels of gene expression were then normalised to that of 
GAPDH.
132
500 bp 
250 bp
A B C D F G H
Figure 4.3. RT-PCR amplification of RXRa and SRC-1 mRNA sequences in 
human liver and HepG2 cell mRNA.
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A and H: DNA marker ladder
Lane B: RXRa in human liver mRNA (370 bp)
Lane C: RXRa in HepG2 cells (passage 5) mRNA 
Lane D: RXRa in HepG2 cells (passage 10) mRNA 
Lane E: SRC-1 (395 bp) in human liver mRNA 
Lane F: SRC-1 in HepG2 cells (passage 5) mRNA 
Lane G: SRC-1 in HepG2 cells (passage 10) mRNA
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Figure 4.4. RT-PCR ampliOcation of HNF-4 mRNA sequences in human liver 
and HepG2 cell mRNA.
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A: DNA marker ladder
Lane B: HNF-4 in human liver mRNA (340 bp)
Lane C: HNF-4 in HepG2 cell (passage 5) mRNA
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induction because it is not modulated by classical inducers of CYP3A gene 
expression. In these experiments, GAPDH mRNA was found in both human liver and 
HepG2 mRNAs at easily detectable levels.
4.2. Confirmation of RT-PCR product authenticity by DNA 
sequencing
RT-PCR reactions with human liver mRNA using specific primers resulted in 
successful amplification of hGRa, hPXR, CYP3A, GAPDH, RXRa, HNF-4 and 
SRC-1 mRNAs. In order to confirm these results, the resulting RT-PCR products 
were sequenced. This removes the possibility of any primer mismatched with 
nonspecific mRNAs in the sample.
The RT-PCR products were electrophoresed in 1% agarose gel and the resultant band 
for each DNA product was cut out carefully using a sharp clean knife. In some cases 
(e.g. CYP3A) where there could be more than one band precautions were taken to 
avoid mixing one band with the next. The DNA samples extracted from the 
electrophoresis gels were sequenced using the RT-PCR primers to prime the forward 
and reverse sequencing reactions.
The quality of the results of DNA sequencing depends on several factors. These are 
the purity of the DNA extracted from gel, the quality of sequencing instrument and 
the quality of work and expertise of the operators. The in-house sequencing facilities 
used for this purpose were good enough to check the DNAs for authenticity. The data 
is presented as a printout of the sequencing peaks and shows variable clarity. The 
clearest part in each printout was used for confirmation of the specificity of the RT- 
PCR reactions. In situations where the instrument could not clearly define the 
nucleotide, an ‘N’ was called instead. Careful re-examination of the peak in these 
cases usually helped identify the nucleotide base.
The hGRa primers amplify 493 bases (from +2168 to +2661) of the corresponding 
mRNA. As Figure 4.5 shows, sequencing results in the forward reaction from +2189 
to +2335 are in agreement with the corresponding cDNA sequence apart from the two 
nucleotides designated N. The first one at position 2249 has a stronger peak for A
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Figure 4.5. DNA sequencing of the hGRa RT-PCR product.
Following RT-PCR of hGRa sequences in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 493 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis using an AB1 373A 
sequencer and dye termination reactions. The results are presented as direct machine 
readout to demonstrate the authenticity of the RT-PCR product as deriving from the 
hGRa mRNA. In cases the machine could not ‘call’ a base with certainty it was 
designated N.
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(adenine) that matches with hGRa cDNA but the second one at position 2325 cannot 
be assigned. This shows that specific amplification of hGRa mRNA was achieved.
A second band in the hGRa lane was occasionally observed in the RT-PCR reactions 
with HepG2 cell mRNA (Figure 4.16 and 4.17, the lower band in lane B). This band 
was also isolated and sequenced. Using a BLAST search, it was identified (data not 
shown) as a protein, KIAA0179, of unknown function on chromosome 21 (Gene 
Bank accession number of D80001).
The CYP3A primers amplify 293 bases (from +1312 to +1604) of CYP3A mRNA. 
Two bands were formed in some RT-PCR reactions especially with HepG2 mRNA. 
The lower one is from CYP3A mRNA as was confirmed by DNA sizing and 
sequencing. Figure 4.6 shows the sequencing results. There is good agreement in the 
region from 1358 to 1541 (184 base pairs) in the forward reaction with the 
corresponding CYP3A mRNA sequence (Figure 4.6). Eight nucleotides were not 
identified by the instrument and designated N. Two of them (positions 105 and 107 in 
Figure 4.6) give stronger peaks for A and T respectively, but the others are not 
resolvable by eye. These results show that the designated primers are able to amplify 
CYP3A mRNA with good specificity.
Using a BLAST search the second (larger) band produced in some RT-PCR reactions 
with the CYP3A primers was found to have a sequence highly homologous to the 
mRNA for human ribosomal protein S I8. The sequencing results (Figure 4.7) are in 
good agreement with S18 cDNA for 179 base pairs but 3 nucleotides not identified by 
the instrument. Again using the BLAST search, two regions that were likely to bind 
to RT-PCR primers were identified. As shown in Figure 4.8, both primers matched in 
at least 50% of the bases with S18 cDNA. However, perhaps more importantly, the 
pairings occurred in groups of 4 to 7 bases in length at 3' ends of the primers, are rich 
in G or C and thus could play crucial role in attachment to the S18 mRNA.
The hPXR primers amplify 442 bases (from +678 to +1119) of the corresponding 
mRNA. As Figure 4.9 shows, sequencing results are in agreement in the range from 
+687 to +998 (310 base pairs) in the forward reaction. An extra T at position 240 of
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Figure 4.6. DNA sequencing of the CYP3A RT-PCR product.
Following RT-PCR of CYP3A sequence in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 293 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis in house using a 373A 
sequencer and dye termination reaction. The results are presented as direct machine 
readout to demonstrate the authenticity of the RT-PCR product as deriving from the 
CYP3A mRNAs. In cases the machine did not detect a base with certainty it was 
designated N.
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Figure 4.7. DNA sequencing of the S18 RT-PCR product.
Following RT-PCR of CYP3A sequence in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The extra band in the CYP3A 
lane (440 bp) amplified by CYP3A primers in some reactions was cut from the gel 
and extracted prior to DNA sequence analysis in house using a 373A sequencer and 
dye termination reaction. Using BLAST search it was identified as a sequence highly 
homologous to S18 ribosomal protein. The results are presented as direct machine 
readout and in cases where the machine did not detect a base with certainty it was 
designated N.
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s 18 sense strand (from 58 bp) GAT CCCTGA AAAGTTCCA OCA TAT
* * * * * * zM * ** * *
CYP3A4 sense primer TOG ACA GAG CCTGAG AAGTTCC
S18 antisense strand (from 498 bp) TTC TTGGAC ACA CCC ACG GTG C
* * * * * * * * * * * *  »
CYP3A antisense primer ATT CAGGCT CCA CTT ACG GTG C
Figure 4.8. Matching sites between CYP3A primers and S18 cDNA.
Following the amplification of SIS mRNA by CYP3A primers, the possible matching 
sites were identified. This is in agreement with the size of the SIS band in gel 
electrophoresis (441 bp).
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the figure was identified and a C was missing at position 288. In both situations the 
peaks are in agreement with the corresponding cDNA (3 peaks of T at position 240 
and a clear peak at position 288) but an extra T or G was called by the instrument for 
same reason. The nucleotide at position 291 of the Figure 4.9 was not identified by the 
machine and designated N. The sequencing results are also in good agreement in the 
range from +1062 to +814 (249 base pairs) in the reverse reaction (data not shown) 
hPXR cDNA. These results reconfirm the specificity of hPXR primers and identity of 
the product band.
A second band was occasionally observed in the hPXR lane (Figure 4.16 and 4.17, the 
top band lane C) in RT-PCR reactions with HepG2 cell mRNA. As two hPXR 
isoforms had previously been identified (Lehmann et al 1998), it was suggested that 
the second band might derive from the mRNA for the other hPXR isoform. In order 
to confirm this, the band was also cut out and sequenced (data not shown). However, 
the sequencing results were not in agreement with the hPXR mRNA sequence. Using 
a BLAST search, it was identified as a human acidic protein rich in leucine (accession 
number of BC000476).
The GAPDH primers amplify 427 bases (from +67 to +493) of the corresponding 
mRNA. The sequencing result shown in Figure 4.10 is in good agreement in the 
region from +109 to +368 (260 bps) in the forward reaction with GAPDH cDNA but 
two extra Ts at positions 269 and 291 and an extra G at position 283 were called 
erroneously. These results demonstrate specificity of the GAPDH RT-PCR primers 
and confirm the product identity.
The CYP3A4 primers amplify 324 bases (from +1279 to +1602) of the corresponding 
mRNA. The sequencing results are in good agreement with the corresponding cDNA 
sequence in the range from +1303 to +1456 (163 base pairs) in the forward reaction 
(Figure 4.11) and in the range from +1577 to +1444 (144 base pairs) in the reverse 
reaction (data not shown). These results confirm specificity of the primers for 
CYP3A4 detection and confirm the product band identity.
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Figure 4.9. DNA sequencing of the hPXR RT-PCR product.
Following RT-PCR of hPXR sequence in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 442 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis in house using a 373A 
sequencer and dye termination reactions.
The results are presented as direct machine readout to demonstrate the authenticity of 
the RT-PCR product as deriving from the hPXR mRNA. In cases the machine did not 
detect a base with certainty it was designated N. In the region between 239 to 242 
there are three peaks for T but they have been called incorrectly as four Ts. Also, a 
similar error occurred between 314 to 317 for Gs. The actual peaks are in agreement 
with the corresponding cDNA sequences.
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Figure 4.10. DNA sequencing of the GAPDH RT-PCR product.
Following RT-PCR of GAPDH sequence in human liver mRNA with specific 
primers, the product was electrophoresed in a 1% agarose gel. The 427 bp DNA 
fragment was cut from the gel and extracted prior to DNA sequence analysis in house 
using a 373A sequencer and dye termination reactions.
The results are presented as direct machine readout to demonstrate the authenticity of 
the RT-PCR product as deriving from the GAPDH mRNA. Where the machine did 
not detect a base with certainty it was designated N. There are two peaks for G at 
position 281 to 283 but it has been erroneously called as 3 Gs. A similar error was 
happened at positions 268 and 290 where one peak for T was called as two Ts. The 
actual peaks are in agreement with the corresponding cDNA sequence.
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Figure 4.11. DNA sequencing of the CYP3A4 RT-PCR product.
Following RT-PCR of CYP3A4 sequence in human liver mRNA with specific 
primers, the product was electrophoresed in a 1% agarose gel. The 324 bp DNA 
fragment was cut from the gel and extracted prior to DNA sequence analysis in house 
using a 373A sequencer and dye termination reaction. The results are presented as 
direct machine readout to demonstrate the authenticity of the RT-PCR product as 
deriving from the CYP3A4 mRNA.
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The CYP3A5 primers amplify 472 base pairs (from +1065 to +1536) of the 
corresponding mRNA. Sequencing results shown in Figure 4.12 are in good 
agreement in the range from +1099 to +1207 (108 base pairs) in the forward reaction 
with one nucleotide at position 133 of the figure not identified and designated N. The 
results show that the primers were specific for CYP3A5 mRNA detection and confirm 
the identity of RT-PCR product.
The CYP3A7 primers amplify 475 bases (from +1041 to +1515) of the corresponding 
mRNA. As Figure 4.13 shows, sequencing results are in good agreement with 
CYP3A7 cDNA in the range from +1489 to +1227 (259 base pairs) in the reverse 
reaction with three bases not identified and designated N. There is also a base 
substitution (G to C) at position 274 of the figure. The forward sequencing reaction is 
also in agreement with CYP3A7 cDNA in the range from +1067 to +1257 (191 base 
pairs) (data not shown). These results demonstrate the specificity of the primers for 
detection of CYP3A7 mRNA and confirm the identity of RT-PCR product.
The RXRa primers amplify 370 bases (from +1255 to +1624) of the corresponding 
mRNA. Figure 4.14 shows that the sequencing results are in complete agreement 
with the RXRa cDNA in the range from +1255 to +1591 (336 base pairs) in the 
forward reaction. This again implies a successful primer design and confirms the 
identity of the RT-PCR product.
The SRC-1 primers amplify 395 bases (from +585 to +979) of the corresponding 
mRNA. Sequencing results are in agreement in the range from +953 to +841 (112 
base pairs) in the reverse reaction with three bases not identified by the instrument 
(Figure 4.15). This result shows specific primer design and confirms the identity of 
the RT-PCR product.
In the case of HNF-4, a RT-PCR experiment was carried out, using a pair of primers 
kindly provided by a colleague to determine whether that this transcription factor is 
expressed in HepG2 cells. Sequencing results confirmed the specificity of the primers 
and the identity of the product (Swales K, personal communication).
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Figure 4.12. DNA sequencing of the CYP3A5 RT-PCR product.
Following RT-PCR of CYP3A5 sequence in human liver mRNA with specific 
primers, the product was electrophoresed in a 1% agarose gel. The 472 bp DNA 
fragment was cut from the gel and extracted prior to DNA sequence analysis in house 
using a 373A sequencer and dye termination reaction.
The results are presented as direct machine readout to demonstrate the authenticity of 
the RT-PCR product as deriving from the CYP3A5 mRNA. In cases the machine did 
not detect a base with certainty it was designated N.
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Figure 4.13. DNA sequencing of the CYP3A7 RT-PCR product.
Following RT-PCR of CYP3A7 sequence in human liver mRNA with specific 
primers, the product was electrophoresed in a 1% agarose gel. The 475 bp DNA 
fragment was cut from the gel and extracted prior to DNA sequence analysis in house 
using a 373A sequencer and dye termination reaction. The results are presented as 
direct machine readout to demonstrate the authenticity of the RT-PCR product as 
deriving from the CYP3A7 mRNA. In cases where the machine did not detect a base 
with certainty it was designated N. There is also a substitution of G to C at position of 
274 compared to the CYP3A7 cDNA sequence.
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Figure 4.14. DNA sequencing of the RXRa RT-PCR product.
Following RT-PCR of RXRa sequence in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 370 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis in house using a 373A 
sequencer and dye termination reaction.The results are presented as direct machine 
readout to demonstrate the authenticity of the RT-PCR product as deriving from the 
RXRa mRNA.
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Figure 4.15. DNA sequencing of the SRC-1 RT-PCR product.
Following RT-PCR of SRC-1 sequence in human liver mRNA with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 395 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis in house using a 373A  
sequencer and dye termination reaction. The results are presented as direct machine 
readout to demonstrate the authenticity of the RT-PCR product as deriving from the 
SRC-1 mRNA. In cases where the machine did not detect a base with certainty it was 
designated N.
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The results above show that the specific primers were able to reproducibly amplify 
their corresponding mRNAs and the identity of any additional product bands was 
determined. However due to time constricts, not all of these primers were used in the 
subsequent quantitative measurement of gene expression and modulation in HepG2 
cells. In the following experiments, the modulation of CYP3A4, CYP3A5, CYP3A7, 
hGRa and hPXR mRNA expression by xenobiotics is analysed. Using the data and 
protocols defined here, expression and modulation of RXRa, SRC-1 and HNF-4 in 
HepG2 cells could be easily studied in the future.
4.3. Expression of CYP3A and nuclear receptor genes in HepG2 cells
Quantitative measurements of gene expression by RT-PCR techniques are not 
straightforward due to the fact that minor variations in reaction rate are greatly 
magnified during the amplification. For this reason, RT-PCR reactions must be 
optimised prior to analysis of changes due to xenobiotic modulation of gene 
expression.
The simplest way to quantify induced changes in mRNA levels is to express the data 
as a ratio between the specifically amplified cDNA and the expression of another gene 
(e.g. GAPDH) which shows no change in expression during treatment of the tissue or 
cells with specific agents (the ‘internal standard’ method). In this way it is possible to 
provide semi-quantitative information on relative changes in mRNA levels, but not on 
the absolute mRNA content (Rodriguez-Antona et al 2000). This type of experiment 
is very useful for the study of the effects of drugs or xenobiotics on the transcription 
of genes.
A technique used for absolute quantitation of mRNA copy number is ‘competitive’ 
RT-PCR (Rodriguez-Antona et al 2000). Competitive RT-PCR is based on the co­
amplification of a specific target sequence together with known amounts of a 
synthetic competing internal standard mRNA in the same reaction tube. The internal 
standard is designated to share primer recognition sites with the specific template but 
can be distinguished by product size or restriction enzyme digestion. This procedure 
relies on the assumption that the two sequences are co-amplified with the same 
efficiency.
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In the experiments reported here, the semi-quantitative procedure was used with the 
expression of GAPDH mRNA as the internal control.
4.3.1. Measurement of basal expression levels
In order to have an estimate of the basal level of transcription of CYP3A and nuclear 
receptor (hGRa and hPXR) mRNA in HepG2 cells, RT-PCR experiments were 
performed with mRNAs extracted from cells at passages 4, 8 and 15 post recovery 
from frozen stock. The objective was to determine if passage number affected the 
expression of these genes.
The RT-PCR experiments were performed using the same format as for human liver 
mRNA (40-cycle reactions and the same annealing temperatures). The results shown 
in Figures 4.16, 4.17 and 4.18 and 4.19 show that while hGRa and hPXR mRNAs are 
expressed in HepG2 cells, their levels are substantially lower than in human liver 
mRNA (one half to one third). There does not be any change with passage number. 
In the case of CYP3A mRNA, however, it is clear that this primer set detects very 
little mRNA in HepG2 cells compared to human liver mRNA (perhaps only 1-2%, at 
the level of detection). However, since the CYP3A primers were designed using the 
sequence of CYP3A4, it was possible that they detected primarily CYP3A4 mRNA 
and that it was only this CYP3A mRNA which was absent from HepG2 cells.
To investigate the expression of individual CYP3A mRNA in HepG2 cells, the 
specific primers of Anttila et al (1997) were used in specific RT-PCR (40-cycle) 
reactions. As figure 4.20 shows, there is high expression of CYP3A7 mRNA in 
HepG2 cells, relatively lower expression of CYP3A5 mRNA and indeed no 
expression of CYP3A4 mRNA. Subsequent RT-PCR experiments did not detect any 
sign of CYP3A4 transcription in this cell line even after treatment of cells with the 
standard in vivo inducers of this isoenzyme, DEX and RIF (data not shown).
The presence of CYP3A7 as the major CYP3A isoenzyme in HepG2 cells is in 
agreement with others (Schuetz et al 1993b). There is also agreement on the absence 
of CYP3A4 expression in HepG2 cells. Results of RT-PCR reactions using
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Figure 4.16. RT-PCR amplification of hGRa, hPXR, CYP3A and GAPDH 
mRNA from HepG2 cells (passage 4).
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A and F: DNA marker ladder 
Lane B; hGRa (upper band, 493 bp)
Lane C: hPXR (lower band, 442 bp)
Lane D: S18 (440 bp)
Lane E: GAPDH (427 bp)
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Figure 4.17. RT-PCR amplification of hGRa, hPXR, CYP3A and GAPDH 
mRNA from HepG2 cells (passage 8).
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A and F: DNA marker ladder 
Lane B: hGRa (upper band, 493 bp)
Lane C: hPXR (lower band, 442 bp)
Lane D: CYP3A (lower pale band, 293 bp) and S18 (upper band, 440 bp)
Lane E: GAPDH (427 bp)
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Figure 4.18. RT-PCR amplification of hGRa, hPXR, CYP3A and GAPDH 
mRNA from HepG2 cells (passage 15).
RT-PCR products from the amplification reactions were electrophoresed in a 1% 
agarose gel.
Lane A and F: DNA marker ladder 
Lane B: hGRa (upper band, 493 bp)
Lane C: hPXR (lower band, 442 bp)
Lane D: S18 (440 bp)
Lane E; GAPDH (427 bp)
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Figure 4.19. Comparative analysis of gene expression in mRNA from different 
passages of HepG2 cells and in human liver mRNA.
The amount of RT-PCR products for the amplification of hGR, hPXR and CYP3A in 
HepG2 (Figures 4.16, 4.17 and 4.18) and human liver (Figure 4.1) mRNAs were 
quantified and plotted compared to GAPDH in each experiment.
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Figure 4.20. Specific RT-PCR amplification of CYP3A isoenzymes in human 
liver and HepG2 mRNAs.
RT-PCR reactions using isoenzyme specific primers for the detection of human 
members of CYP3A subfamily in human liver and HepG2 mRNAs were performed 
and the products were electrophoresed in 1% agarose gel.
Lane A: DNA marker ladder
Lane B; human liver mRNA CYP3A4 (324 bp)
Lane C: HepG2 mRNA CYP3A4 (no product)
Lane D: human liver mRNA CYP3A5 (427 bp)
Lane E: HepG2 mRNA CYP3A5 (427 bp)
Lane F: human liver mRNA CYP3A7 (475 bp)
Lane G: HepG2 mRNA CYP3A7 (475 bp)
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specific primers with the expression of high amounts of CYP3A7 and no expression 
of CYP3A4 strengthen the hypothesis that the ‘nonspecific’ CYP3A primers mainly 
amplified CYP3A4 and did not substantially amplify other members of the CYP3A 
subfamily, especially CYP3A7. CYP3A5 transcription also was detected in these RT- 
PCR reactions and is the first time that the transcription of this mRNA has been 
reported in HepG2 cells. This is important because the pattern of the expression of 
CYP3A isoenzymes in this cell line is very similar to human foetal liver in which high 
expression of CYP3A7, very low or no expression of CYP3A4 and low expression of 
CYP3A5 was detected (Oesterheld 1998). Considering this similarity, HepG2 cells or 
their microsomes may thus be an alternative for the study of the metabolism of 
xenobiotics by human foetal liver.
4.3.2. Modulation of gene expression in HepG2 cells by xenobiotics
In order to investigate the inducibility of CYP3A, hGRa and hPXR gene expression 
by classical inducers of CYP3A expression (dexamethasone and rifampicin), RT-PCR 
experiments were performed with mRNAs isolated from HepG2 cells at passages 5, 
10 and 20. The effect of passage number on the inducibility of the genes and 
reproducibility of the results were also a focus of these experiments.
HepG2 cells were grown in medium at 37°C for 24 hours. The cells were dosed with 
10 or 50 pM DEX or RIF and incubated in DCC-treated medium at 37°C for a further 
48 hours. mRNAs were extracted from the cells using the PolyATract system 1000 
{Promega) kit and 40-cycle RT-PCR reactions were performed using the conditions 
described in 4.1 to study the effects of these drugs on the transcription of hGRa, 
hPXR and CYP3A. In these experiments, the nonspecific CYP3A primers were used 
and as indicated in section 4.3.1 were probably detecting only a small proportion of 
the total CYP3A5 and CYP3A7 mRNA. Each experiment was performed twice for 
passages 5 and 10 and once for passage 20. The results were normalised to the 
expression of GAPDH and then expressed relative to the expression with DMSO 
alone.
As Figures 4.21, 4.22, and 4.23 show, both DEX and RIF increased the expression of 
hGRa, hPXR and CYP3A mRNA in passages 5 and 10 HepG2 cells. There is no
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Figure 4.21. Results of RT-PCR amplification (40-cycle reactions) of hGR in 
different passages of HepG2 cells.
RT-PCR amplification of hGR in HepG2 cells were performed and the bands were 
quantified. The amount of hGRa expression was normalised to the expression of 
GAPDH and was then expressed as a ratio compared to that with DMSO alone (n =2).
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Figure 4.22. Results of RT-PCR amplification (40-cycIe reactions) of hPXR in 
different passages of HepG2 cells.
RT-PCR amplification of hPXR in HepG2 cells were performed and the bands were 
quantified. The amount of hPXR expression was normalised to the expression of 
GAPDH and was then expressed as a ratio compared to that with DMSO alone (n =2).
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Figure 4.23. RT-PCR amplification (40-cycIe reactions) of CYP3A in different 
passages of HepG2 cells.
RT-PCR amplification of CYP3A in HepG2 cells were performed and the bands were 
quantified. The amount of CYP3A expression was normalised to the expression of 
GAPDH and was then expressed as a ratio compared to that with DMSO alone (n =2).
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induction of these genes at passage 20. As can be seen the pattern of induction is 
similar in passages 5 and 10, however induction of CYP3A by REF decreased in 
passage 10 compared to passage 5. This might be a reflection of decreased response 
of the CYP3A promoters to hPXR. Also, induction of hGRa by DEX in passage 10 
decreased significantly. These changes might be the preliminary signs of a loss of 
capability of HepG2 cells with respect to drug responses. However, as the CYP3A 
primers in these experiments only detected a small proportions of the CYP3A mRNA 
in these cells it is difficult to reveal a definite conclusion about the role of hGRa or 
hPXR in the regulation of each CYP3A mRNA in HepG2 cells from this experiment. 
However, it is clear that there is a relationship between the modulation of the two 
receptor genes and CYP3A induction as a whole.
The results presented here develop the possibility that the hGRa and hPXR genes are 
regulated in parallel with the CYP3A genes. The results of hPXR transcription 
induction are in agreement with Pascussi et al (1999) who showed that DEX is able to 
increase the transcription of hPXR in cultured primary human hepatocytes even at low 
concentration where it presumably acts only as a glucocorticoid. Also, RIF has been 
demonstrated to be a ligand for hGRa (Zhang et al 1999). The lack of reproducibility 
of CYP3A and nuclear receptor gene induction by CYP3A inducers at passage 20 is 
in agreement with Ogg et al (1999).
4.3.3. Analysis of CYP3A gene promoter sequences in HepG2 cell genomic DNA
Following the discovery of the lack of CYP3A4 expression (and the high expression 
of CYP3A7) in HepG2 cells, the possibility arose that some alteration in the promoter 
region of CYP3A genes had occurred in HepG2 cells and caused these significant 
differences from adult liver cells. As the conversion of normal cells to cancer cells is 
associated with mutations in key regulatory proteins (e.g. p53), similar mutations in 
the CYP3A gene promoter regions in HepG2 cells might have occurred as part of the 
process leading to the formation of this cell line. It should be noted, however, that 
mutations in the promoter region of CYP3A genes do not always lead to decreased 
activity of the gene compared to the wild type. In fact, Paulussen et al (2000) 
identified two linked mutations in transcriptional regulatory element of CYP3A5 that 
were associated with increased expression of the gene. Thus the possibility that
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mutation in CYP3A7 promoter may be associated with increased expression cannot be 
ruled out. To examine this hypothesis, PCR amplifications were performed to 
examine the promoter region of CYP3A genes in HepG2 cell genomic DNA.
4.3.3.1. CYP3A4
HepG2 cell genomic DNA was isolated using the genomic DNA extraction kit 
{Promega). PCR reactions with an annealing temperature of 59°C and using specific 
primers were performed. The products of the reactions were isolated from a 1% 
agarose gel using the DNA gel extraction kit {ChamBio Ltd) and sequenced by MWG- 
Biotech (Ebessberg, Germany).
Results of sequencing the promoter region of CYP3A4 in HepG2 cells, as 
demonstrated in Figure 4.24, showed no mutation or deletion in the fragment 
containing the PXR motif (-390 to +43) and demonstrated that this critical region of 
CYP3A4 promoter in HepG2 cells is intact. Therefore, other factors must be 
responsible for the lack of CYP3A4 expression in this cell line. It has been proposed 
previously that replicating cells like HepG2 are frequently deficient in the amount of 
trans-acting factors, such as hGR (Schuetz et al 1996b). The results presented here 
(Figure 4.19) also confirm that HepG2 cells express lower levels of nuclear receptors, 
especially hPXR compared to human liver and this could be the cause of a dramatic 
reduction in CYP3A4 expression in this cell line. It is also possible that an inhibitor 
or a repressor is responsible for the lack of endogenous expression of CYP3A4 in this 
cell line because HepG2 cells can reproduce the xenobiotic induction of CYP3A4 
gene in transfection experiments using reporter genes containing the CYP3A4 
promoter region (plus the upstream enhancer region) without hGRa or hPXR co­
transfection (Goodwin et al 2000; Bertilsson et al 2001). This could be due to the 
swamping of the endogenous inhibitor by the excess transfected DNA.
4.3.3.2. CYP3A5
PCR reactions using HepG2 cell genomic DNA and specific primers for the 
amplification of CYP3A5 promoter region was performed at annealing temperature of 
55°C. The resultant product was isolated and sequenced as before.
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The results of the CYP3A5 promoter region (-721 to +15) in the reverse direction 
(Figure 4.25) showed two heterozygous mutations at positions -44 (G to A) and -554 
(C to T) compared to the wild type which are different from the mutation previously 
reported in CYP3A5 promoter in humans (Kuehl et al 2001). The mutation at 
position -554 was also confirmed by forward reaction but the -44 mutation was not 
confirmed due to poor sequencing results in the last 200 base pairs. No data is 
available on the biological significance of these mutations. However, the level of 
expression of CYP3A5 in HepG2 cells is very similar to that in human liver cells 
(Figure 4.20) and so these mutations cannot have a significant effect on the expression 
of this isoenzyme.
4.3.3.3. CYP3A7
Two experiments to sequence the CYP3A7 promoter in HepG2 cell DNA were 
unsuccessful but could not be repeated due to lack of time.
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Figure 4.24. DNA sequencing of the CYP3A4 promoter region in HepG2 cell 
genomic DNA.
Following PCR of the CYP3A4 promoter region (-390 to +43) with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 434 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis.
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Figure 4.25. DNA sequencing of the CYP3A5 promoter region (reverse reaction) 
in HepG2 cells genomic DNA.
Following PCR of the CYP3A5 promoter region (-721 to +15) with specific primers, 
the product was electrophoresed in a 1% agarose gel. The 735 bp DNA fragment was 
cut from the gel and extracted prior to DNA sequence analysis.
^  shows the mutation sites and the numbers indicate the position of mutation from the 
transcription start point.
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4.4. Semi-quantitative analysis of CYP3A and hPXR mRNA 
expression in HepG2 cells
4.4.1. Optimisation of the RT-PCR reactions
In order to provide a more accurate semi-quantitative analysis, RT-PCR reactions 
were optimised in terms of the number of reaction cycles required. Amplification 
reactions were performed using different numbers of cycles with mRNAs extracted 
from control and RIF treated HepG2 cells.
HepG2 cells were grown in medium at 37°C for 24 hours. The cells were then dosed 
with 10 or 50 pM dexamethasone or rifampicin and incubated in DCC-treated 
medium at 37°C for a further 48 hours. mRNAs were extracted using the PolyATract 
system 1000 kit and RT-PCR reactions were performed using the CYP3A primers at 
an annealing temperature of 58°C with different number of cycles (20, 24, 28, 32, 36 
and 40). The resultant products were electrophoresed in 1% agarose gel and the bands 
were quantitated in the Image Master (Amersham Pharmacia Biotech).
The results in Figure 4.28 show that in the 20 and 24-cycle reactions there is no 
detectable amplification of the CYP3A mRNAs in HepG2 cells. Discrimination 
between the amount of CYP3A RT-PCR product from the mRNA in control and RIF- 
treated cells starts at 32-cycles of reaction. However, at 40-cycles the amount of RT- 
PCR product in both samples plateaus and the discrimination is abolished. From this 
point an increase in the number of cycles will not change the amount of RT-PCR 
product in neither of the two samples. The distinction is highest at between 32 and 
36-cycles and this is the best region of the plot to use for the quantitation of CYP3A 
mRNA induction by xenobiotics.
Using RT-PCR it is possible to demonstrate a linear relationship in a log-log plot 
between the amount of mRNA and the intensity of light detected from the product of 
the RT-PCR reaction. Using this relationship, it is possible to conclude a 
mathematical relationship between these two parameters and thus (if required) 
quantify gene expression on an mRNA concentration basis.
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Figure 4.26. Relationship between the number of RT-PCR cycles and the amount 
of CYP3A RT-PCR product from HepG2 cell mRNA.
HepG2 cells were grown in medium at 37°C for 24 hours and then incubated in DCC- 
treated medium containing DMSO or rifampicin in DMSO for a further 48 hours. The 
mRNAs were extracted and RT-PCR reactions with primers for the amplification of 
CYP3A mRNA were performed for different number of cycles. The products were 
electrophoresed in a 1% agarose gel and quantified using the Image Master 
{Amersham Biotech Pharmacia).
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35-cycle RT-PCR reactions were performed with different amounts of human liver or 
HepG2 mRNAs (0.01, 0.1, 1 and 10 ng mRNA per 50-pl reaction tube) using specific 
primers for hGRa, CYP3A, CYP3A4, CYP3A5, CYP3A7, hPXR and GAPDH, the 
products electrophoresed and scanned and the appropriate mathematical relationships 
derived from log-log plots (Figure 4.27, 4.28 and 4.29). Using this approach it is 
possible to compare experiments where there are substantial differences in the amount 
of mRNA extracted from the cells. In such experiments (Figures 4.30-4.32), the 
logarithms of the light intensity values were used for the calculation of the gene 
expression ratios.
4.4.2. Modulation of human CYP3A5,CYP3A7 and hPXR mRNA expression hy 
xenobiotics
As figure 4.26 shows it is clear that 32 to 36-cycle RT-PCR reactions have the best 
discrimination for the study of CYP3A gene induction. Therefore, a 35-cycle 
protocol was used routinely as the method of choice for the semi-quantitative analysis 
of mRNA expression for CYP3A4, CYP3A5, CYP3A7 and hPXR in HepG2 cells.
HepG2 cells were grown at 37°C for 24 hours. The medium was changed to DCC- 
treated or serum-free medium (as indicated) containing the desired concentration of 
the drug and incubated for a further 48 hours at 37°C. The mRNAs were extracted 
using PolyATract 1000 kit and stored in -80°C.
The yields of total mRNA extracted from HepG2 cells incubated in DCC-treated and 
serum-free medium showed significant differences, the means being 2233 ng and 398 
ng per 2x 10  ^cells respectively. The reason for this substantial difference is not clear 
but could be due to:
1. The protein-free growth environment created by serum-free medium made 
the HepG2 cells behave abnormally as could be seen in their loose 
attachment to the cell culture flask. They were also very sensitive to the 
effect of trypsin compared to the cells grown in normal medium.
2. Foetal calf serum contains a number of steroid and peptide hormones, some 
of which (e.g. glucocorticoids) play important roles in gene transcription and
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Figure 4.27. Relationship between the amount of mRNA and the intensity of light 
emitted from the hGRa and CYP3A5 RT-PCR products.
35-cycle RT-PCR experiments using specific primers for hGRa and CYP3A5 with 
different amounts of HepG2 mRNA were performed and the intensity of light emitted 
from each band plotted against the corresponding amount of mRNA on a log-log 
scale.
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Figure 4.28. Relationship between the amount of mRNA and the intensity of light 
emitted from the hPXR and CYP3A7 RT-PCR products.
35-cycle RT-PCR experiments using specific primers for hPXR and CYP3A7 with 
different amounts of HepG2 mRNA were performed and the intensity of light emitted 
from each band plotted against the corresponding amount of mRNA on a log-log 
scale.
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Figure 4.29. Relationship between the amount of mRNA and the intensity of light 
emitted from the CYP3A, CYP3A4 and GAPDH RT-PCR products.
35-cycle RT-PCR experiments using specific primers for CYP3A and CYP3A4 with 
different amounts of human liver mRNA and for GAPDH with different amounts of 
HepG2 mRNA were performed and the intensity of light emitted from each band 
plotted against the corresponding amount of mRNA on a log-log scale.
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mRNA production. It is true that there were reduced amounts of hormones 
in DCC-treated medium but not all hormones bind to charcoal.
As Figures 4.30, 4.31 and 4.32 show, at passage 5 DEX and RIF induce the 
transcription of CYP3A5, CYP3A7 and hPXR mRNA. The induction of hPXR 
follows the same pattern as CYP3A5 and CYP3A7 and provides further insight as to 
how hPXR modulates the induction of both these genes in HepG2 cells. Induction of 
CYP3A5, CYP3A7 and hPXR is significantly higher at passage 10 and there is 
agreement between the pattern of induction of CYP3A5, CYP3A7 and hPXR 
compared to passage 5. There is no induction of CYP3A5 by clotrimazol (CLT) at 
passage 10 but there is still a two-fold induction of CYP3A7 and hPXR by this drug. 
There was no significant induction at passages 15 and 20 in DCC-treated medium 
(data not shown). CYP3A5, CYP3A7 and hPXR transcription was however induced 
in passage 15 cells grown in SFM. The fold induction for hPXR is comparable to 
passage 5 but there is greater induction for CYP3A5 and CYP3A7.
The greater induction of CYP3A5, CYP3A7 and hPXR gene transcription at passage 
10 implies that HepG2 cells did not respond fully to inducers at low passage numbers 
after recovery from liquid nitrogen storage but did regain their ability to respond fully 
by passage 10. It is also interesting that although serum-free medium decreased the 
amount of total mRNA produced by the cells it did not decrease their response to the 
CYP3A inducers, while cells at passage 15 grown in DCC-treated medium did not 
show significant induction of CYP3A5, CYP3A7 and hPXR by xenobiotics, dosing of 
the cells in SFM did maintain the induction pattern.
The results of CYP3A7 induction by DEX and RIF are in agreement with Schuetz et 
al (1993b) who showed that these drugs induce CYP3A7 expression in HepG2 cells. 
Using a reporter construct, Schuetz et al (1996b) demonstrated that the CYP3A5 
promoter is inducible in HepG2 cells and immortalised primary human hepatocytes. 
The CYP3A5 mRNA induction demonstrated here is in agreement with this. The 
results of RT-PCR experiments with mRNA isolated from passages 15 and 20 cells 
are in agreement with Ogg et al (1999) who observed the loss of CYP3A4 induction 
using a reporter construct after passage 16. Thus the ability to demonstrate xenobiotic 
modulation of gene expression in HepG2 cells is very closely associated with the
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conditions under which the cells are grown and treated with drugs. Clearly there is a 
narrow window following recovery of stored cells during which the phenotype of 
drug responsiveness is apparent. This is clearly lost with extended passage/growth of 
the cells, perhaps due to the genotypic instability of hepatocarcinoma cells. Certainly, 
morphological changes in the cells are observed around passage 15 post storage. It is 
also interesting that the responsive phenotype can be maintained if the drug treatment 
is performed in SFM. This may relate to incompatibility between cell division and 
xenobiotic induction in the later passage cells.
4.5. Discussion
RT-PCR is an alternative to techniques such as Northern Blotting, Western Blotting 
and transfection for the investigation of the regulation of gene expression by 
endobiotics or xenobiotics, especially when the expression of a gene is very low. As 
the transfection experiments using the reporter construct p3A4-cSPAP failed to show 
reproducible induction in HepG2 cells of the proximal CYP3A4 gene promoter by 
classical inducers of this isoenzyme, RT-PCR was used to investigate the induction of 
CYP3 A isoenzymes and nuclear receptors in this cell line.
4.5.1. Specificity of the RT-PCR reactions and authenticity of products
The results of RT-PCR reactions with human liver mRNA using primers for the 
amplification of hGRa, hPXR, CYP3A (nonspecific primers), CYP3A4, CYP3A5, 
CYP3A7, RXRa, SRC-1 and HNF-4 showed that the primers were able to 
specifically amplify their corresponding mRNAs. Subsequent sequencing of the RT- 
PCR products confirmed that the products were authentic. Where on occasion 
additional product bands were obtained with some primer sets, these were identified 
by DNA sequencing.
4.5.2. Constitutive expression of CYP3A and nuclear receptor mRNAs in HepG2 
cells
Preliminary RT-PCR experiments with HepG2 cell mRNA from cells at passages 4, 8 
and 15 demonstrated that the transcription of hGRa, hPXR and GAPDH mRNAs in 
this cell line followed a pattern similar to human liver. CYP3A transcription was 
weak at passages 4 and 8 and apparently absent at passage 15. Subsequent RT-PCR
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experiments using isoenzyme mRNA specific primers demonstrated that the non­
specific CYP3A primers mainly amplified CYP3A4 mRNA which is not expressed in 
HepG2 cells. However, there was significant expression of CYP3A5 and CYP3A7 
mRNAs in this cell line. This is the first time that constitutive and inducible 
expression of CYP3A5 mRNA has been identified in HepG2 cells.
4.5.3. Induction of CYP3A and hPXR gene expression in HepG2 cells
40-cycle RT-PCR reactions were performed to have a general idea about the ability of 
CYP3A inducers in induction of the constitutive expression of these enzymes in 
HepG2 cells. These reactions are not able to give quantitative results in RT-PCR 
experiments because, as can be seen in figure 4.26, they are very close to plateau.
Semi-quantitative RT-PCR experiments were performed using specific primers for 
CYP3A4, CYP3A5, CYP3A7 and hPXR to investigate the induction of these genes 
by xenobiotics. Quantitation of mRNA expression in samples was performed using a 
logarithmic correlation to compare the amount of RT-PCR product obtained for each 
mRNA from HepG2 cells at different passages. 35-cycle reactions were performed 
for maximal discrimination during the log phase of amplification.
The results confirmed that CYP3A4 mRNA was not expressed in HepG2 cells even 
after induction by DEX or RIF. This is in agreement with ‘other author’ who did not 
detect constitutive CYP3A4 expression in this cell line (Schuetz et al 1993b). The 
results of RT-PCR experiments for CYP3A5, CYP3A7 and hPXR show that DEX and 
RIF induce the transcription of these genes at passage 5 and 10 of the HepG2 cells. 
The magnitude of induction is higher in passage 10 cells. There is no significant 
induction of these genes in passage 15 or 20 except in the case where the HepG2 cells 
were dosed in serum-free medium. In this case, a similar induction to passage 10 
occurred for passage 15 cells. These results show that HepG2 cells are at their highest 
responsiveness to inducers of gene induction between passages 5 and 15. Also, the 
results indicate that RT-PCR can provide reproducible results for CYP3A gene 
induction in HepG2 cells.
Although the HepG2 cells did not express CYP3A4 endogenously in these 
experiments, they have been shown to be able to reproduce the in vivo CYP3A4
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induction by xenobiotics in experiments where XREM-containing reporter constructs 
were introduced by transfection (e.g. Goodwin et al 2000; Bertilsson et al 2001). The 
failure of the cells to express CYP3A4 endogenously shows that an inhibitory factor 
might act in the cell to prevent expression of this gene from genomic DNA but that it 
cannot prevent CYP3A4 promoter activation in certain reporter constructs. Whether, 
this inhibitor can act on parts of the promoter other than the 1 kb proximal promoter 
or 350 bp XREM enhancer (Goodwin et al 2000; Bertilsson et al 2001) or whether it 
only functions to de-activate genomic DNA (e.g. via histone acetylase/deacetylase) 
remains to be investigated.
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Chapter 5: DISCUSSION AND FINAL CONCLUSION
Human HepG2 hepatoma cells are used widely as a replicating cell system that 
express numerous liver specific functions, including those associated with 
biotransformation of foreign chemicals. HepG2 cells or extracts of these cells 
catalyse the metabolism of xenobiotics to polar products and mutagenic derivatives 
(Schuetz, et al 1993). HepG2 cells also show induction of cytochrome P450 enzyme 
activities by xenobiotics (Dawson et al 1985; Schuetz et al 1993). The resemblance 
of these cells to human hepatic cells for several liver specific functions is claimed to 
make it a useful in vitro substitute for the study of cytochrome P450 gene induction in 
human liver.
CYP3A is the most important cytochrome P450 subfamily in man providing about 
30% of cytochrome P450 content of the liver (Shimada et al 1994) and plays a 
significant role in the metabolism of more than half of the drugs in clinical use. In the 
experiments presented here, the use of HepG2 cells as an in vitro system for the 
analysis of the induction of gene expression of members of the human CYP3A 
subfamily and the nuclear receptors hGRa and hPXR was examined.
5.1. DNA transfection using a CYP3A4 promoter-containing reporter 
gene construct
To evaluate the reproducibility of CYP3A4 gene induction by the classic CYP3A 
xenobiotic inducers, a number of transfection experiments were performed. In these 
experiments an alkaline phosphatase reporter plasmid containing a cytomegalovirus 
(CMV) promoter preceded by 1 kb of the CYP3A4 promoter region (-1087 to -57) 
(p3A4-cSPAP) was used for this investigation.
The transfection experiments did not reproducibly demonstrate a significant activation 
of the CYP3A4 promoter by DEX or RIF. When a positive result was obtained was 
in agreement with others who showed that these drugs are able to activate a 
transfected CYP3A4 promoter in HepG2 cells (Ogg et al 1999; El-Sankary et al 2000; 
Goodwin et al 1999). Since replicating cells such as HepG2 are frequently deficient 
in the amount of trans-acting factors such as hGRa (Schuetz et al 1996b) or hPXR, a
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number of co-transfection experiments were performed using hGRa and hPXR 
expression vectors to enhance the intracellular levels of these receptors. The results 
again did not show reproducible induction of the transfected CYP3A4 promoter in 
most experiments, implying that using a minimal CYP3A4 promoter this system is 
not able to reliably reproduce the in vivo hepatic induction of CYP3A4 by DEX or 
RIF. The authenticity of the reporter construct or the possibility of damage to it 
during plasmid DNA isolation was ruled out as the cause of failure to obtain 
reproducible induction.
Subsequent examination of the hGRa and hPXR expression vectors revealed that the 
pSG5-hPXRAATG expression vector was not authentic. This demonstrated that 
reagents in such experiments must be properly validated before use. Transfection 
experiments with the authentic pSG5-hPXRAATG expression vector did not however 
produce induction of the CYP3A4 promoter in p3A4-cSPAP by DEX or RIF.
The discrepancy in the results obtained in my transfection experiments might be due 
to passage number, as stated previously by Ogg et al (1999) and was shown in RT- 
PCR experiments in this study for induction of endogenous CYP3A. An alternative 
explanation is or cell density as was shown by Greuet et al (1997) who demonstrated 
that at low density cells do not respond well to the inductive effects of RIF on 
CYP3A4 expression. More experiments are needed to clarify the effects of these 
factors.
It is also likely that the reporter construct used in these experiments did not contain all 
the necessary DNA motifs for CYP3A4 promoter activation. Goodwin et al (1999) 
demonstrated that RIF can give hPXR activation and CYP3A4 gene induction in a 
reporter construct containing the XREM enhancer motif at -8  kb of the CYP3A4 
promoter region in HepG2 cells. Significantly, when a similar reporter construct to 
the one used here containing -1.2 kb to +53 bp of CYP3A4 promoter was tested, they 
did not observe any induction of the reporter gene by RIF. After the inclusion of a 
DNA fragment containing 350 bp of the XREM enhancer motif (-7493 to -7836) a 3- 
fold induction was restored. In a similar study Bertilsson et al (2001) demonstrated 
that the XREM enhancer motif is present in both CYP3A4 and CYP3A7 promoters at
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approximately -8  kb and is a necessary motif for the induction of these genes through 
PXR or CAR by xenobiotics. They concluded that the 1 kb promoter proximal 
element on its own only confers a weak PXR response if any.
Finally, it is possible that the dose of the drugs used in these experiments were too 
high to cause a reproducible induction of the transfected CYP3A4 promoter. 
Goodwin et al (1999) observed that maximal induction of CYP3A4 promoter activity 
was at 5 to 10 pM of RIF after which the response tended to decrease. The E C 5 0  of 
rifampicin in their experiments was 1 to 2 pM. During the transfection experiments 
here, a significant reduction in alkaline phosphatase expression in all wells exposed to 
RIF was observed. This implies that the drug may have a cytotoxic effect on HepG2 
cells. This observation is in agreement with others. The mechanism of RIF cell 
toxicity is not clearly understood but this drug causes a direct inhibition of protein 
synthesis in rat thymic and hepatic microsomes, and in human hepatic microsomes 
(Buss et al 1978). There is also evidence for oxidative injury by RIF in the liver (Attri 
et al 2000). Thus the concentration of RIF in experiments on gene regulation in 
biological systems should be restricted to 5 to 10 pM since at higher concentrations 
cytotoxicity or inhibition of protein synthesis may exert unpredictable effects on the 
process of gene regulation.
5.2. Direct analysis of endogenous gene expression in HepG2 cells 
using RT-PCR
RT-PCR is a specific technique for the detection and quantitation of gene expression 
used successfully in several studies. Preliminary RT-PCR experiments with 
commercially supplied human liver mRNA using primers designed for the 
identification of hGRa, hPXR, CYP3A, CYP3A4, CYP3A5, CYP3A7, GAPDH, 
RXRa, SRC-1 and HNF-4 mRNAs resulted in amplification. These results 
demonstrated the efficiency of primers and the constitutive expression of these genes 
in human liver. In order to confirm the results of RT-PCR reaction and authenticity, 
the resultant RT-PCR products were subjected to sequencing. Results of the 
sequencing reactions confirmed the identity of the products. The results also 
demonstrated the reproducibility of gene amplification in these reactions.
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Comparative analysis of total CYP3A and nuclear receptors mRNA in human liver 
cells and HepG2 cells suggested that CYP3A mRNA was not expressed sufficiently in 
HepG2 cells. However, in subsequent RT-PCR experiments the expression of 
CYP3A5 and CYP3A7 was demonstrated. It was also shown that CYP3A4 was not 
expressed. Thus it is clear that the ‘nonspecific’ CYP3A primers in fact mainly 
amplified CYP3A4 mRNA, particularly in the human liver mRNA, but had little 
efficacy towards CYP3A5 or CYP3A7 mRNAs. The expression of hGRa and hPXR 
mRNAs is significantly higher in human liver compared to HepG2 cells. It is possible 
that low expression of the nuclear receptors especially hPXR caused the loss of 
detectable expression of CYP3A4, alternatively inhibitory factors may be present or 
the gene may be completely shut down. This absence of expression of CYP3A4 in 
HepG2 cells is in agreement with Schuetz et al (1993b) who observed CYP3A7 but 
not CYP3A4 in HepG2 cells.
There can be several possible reasons for this abnormal or absent expression of 
CYP3A4 mRNA in the HepG2 cells. First, it is possible that mutation or deletion in 
the endogenous promoter region had occurred in HepG2 cells. Sequencing of the 
region of the endogenous CYP3A4 promoter from -390 to +43 showed that there is 
no mutation or deletion in the PXR-binding region. Sequencing of more fragments in 
CYP3A4 promoter in HepG2 cell DNA may help clarifying this.
The other possible reason is a lack of the necessary transcription factors. Replicating 
cells like HepG2 are frequently deficient in the amount of trans-acting factors, such as 
hGRa (Schuetz et al 1996b). However, the results of RT-PCR reactions with HepG2 
mRNA showed that this receptor is expressed in reasonable but lower amounts 
compared to human liver. Ourlin et al (2000) observed that plasmid constructs 
containing the CYP3A4 or CYP3A7 promoter show increased expression of the 
reporter gene in the presence of the liver specific transcription factor C/EBP alpha in 
HepG2 and WRL68 cells. Deficiency or lack of these factors or the inhibition of their 
expression by some HepG2 specific factor may lead to the absence or different 
expression of CYP3A4 in HepG2 cells compared to normal liver cells. The presence 
of specific co-repressors of CYP3A4 transcription must also be considered. The 
promoter regions of CYP3A4 and CYP3A7 are very similar, even in the XREM
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enhancer region at -8kb (Bertilsson et al 2001). The two promoters differ mainly in 
two proximal promoter regions the HFLa-SE and the so-called ‘nifedipine specific’ 
element (Hashimoto et al 1993). HFLa-SE is present in CYP3A7 but is absent from 
the CYP3A4 promoter region. The ‘nifedipine specific’ element is found in the 
CYP3A4 promoter but not in CYP3A7. It is possible that a specific CYP3A4 co­
repressor in HepG2 cells binds to this ‘nifedipine specific’ motif but this hypothesis 
needs more investigation.
CYP3A7 is the only human CYP3A isoenzyme whose expression in HepG2 cells has 
been known for some time (Schuetz et al 1993b). The high expression of this 
isoenzyme allowed its identification by various techniques. CYP3A7 is also found in 
other proliferating cells including tumours. It is expressed in human hepatocellular 
carcinoma (HCC) cells (Kondoh et al 1999), human hepatoma (HepG2) cells, human 
foetal liver (Oesterheld 1998), human uterus (Schuetz et al 1993b) and some other 
cancer cells (Murray et al 1999; Hukkanen et al 2000). However, The relationship 
between CYP3A7 expression and cell proliferation has not been fully investigated, 
although its role in human foetal liver is clearer. CYP3A7 is abundantly expressed in 
human foetal liver constituting up to 50% of its cytochrome P450 content (Ring et al 
1999) and is proposed as being responsible for the protection of foetus from the 
effects of maternal steroids, DHEA-S (Schuetz et al 1993a) and retinoid acid (Chen et 
al 2000) which are known to be toxic to the foetus in high concentrations. CYP3A7 is 
indeed more potent than CYP3A4 and other cytochrome P450s in the detoxification 
of these agents. RT-PCR experiments have also shown that both CYP3A5 mRNA 
and CYP3A7 mRNA were consistently present in tumour and normal human renal 
cells, while CYP3A4 mRNA was present in only 65% of tumours as opposed to 90% 
of normal samples (Murray et al 1999). CYP3A7 was also identified in the human 
lung adenocarcinoma cell line A549 and CYP3A4 was not detected in this cell line 
(Hukkanen et al 2000). The reverse pattern of expression for these cytochrome P450s 
was identified in normal human lung tissue (Anttila et al 1997). Huang et al (1996) 
also showed that CYP3A4 mRNA was present in (8/11) normal breast tissues and 
(2/13) tumour tissues. These data together suggest a possible relationship between the 
increased expression of CYP3A7 and the reduction or absence of CYP3A4 expression 
in proliferating cells including cancer cells. However, CYP3A7 mRNA was also
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higher in the nontumourous hepatic tissue in HCC patients (Kondoh et al 1999) a 
finding that has yet to be fully explained.
High expression of CYP3A7 and low or no expression of CYP3A4 in HepG2 and 
other proliferating cells including normal and cancerous proliferating cells suggests 
that there might be a factor responsible for this phenomenon. Most probably, this 
factor should affect the different motifs on the promoter regions of these two CYP3A 
isoenzymes, HFLa-SE and ‘nifedipine specific’ element on CYP3A7 and CYP3A4 
promoters respectively. It is also possible that this factor affect some other processes 
in the cell that might relate to the production or inhibition of proliferation and cancer. 
Identification of this factor and elucidation of the mechanism of its regulation might 
open up an interesting field in the study of proliferation and cancer.
Expression of CYP3A5 mRNA in HepG2 cells was identified for the first time in this 
study. This is important because the pattern of CYP3A expression in HepG2 cells is 
thus very similar to human foetal liver, in which a high expression of CYP3A7, a low 
expression of CYP3A5 and virtually no expression of CYP3A4 is typical. Therefore, 
HepG2 cells or their microsomes could be a good m vitro model for human foetal 
liver and the study of xenobiotic metabolism by CYP3A enzymes in this organ.
The results of sequencing of the endogenous CYP3A5 promoter region in HepG2 
cells showed two heterozygous mutations at positions -44 (G to A) and -554 (C to T). 
These mutations have not been identified in the human CYP3A5 gene in vivo and are 
different from the mutation previously reported (Paulussen et al 2000; Kuehl et al 
2001). The mutations do not appear to have significant effects on the expression of 
this mRNA since the level of CYP3A5 mRNA in HepG2 cells is very similar to that 
in human liver cells.
5.3. Regulation of CYP3A and nuclear receptor gene expression in 
HepG2 cells
Two set of RT-PCR experiments with mRNAs extracted from different passages of 
HepG2 cells using primers for the amplification of CYP3A, CYP3A4, CYP3A5, 
CYP3A7, hGRa and hPXR were performed. In the first, the inducibility of hGRa,
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CYP3A and hPXR by the classical inducers of CYP3A in passages 5, 10 and 20 of 
HepG2 cells were examined by 40-cycle RT-PCR reactions. These reactions were 
performed to have a general idea about the ability of CYP3A inducers on constitutive 
expression of these enzymes in HepG2 cells. These reactions are not able to give 
quantitative results in RT-PCR experiments because, as can be seen in figure 4.26, 
they are very close to plateau and hence some components may be rate-limiting. The 
results showed that these genes are inducible by DEX and RIF in passages 5 and 10 
cells but not at passage 20. The lack of inducibility of passage 20 in these cells is in 
agreement with Ogg et al (1999).
The second set of experiments was performed for the semi-quantitative analysis of 
CYP3A5, CYP3A7 and hPXR gene induction by the classical CYP3A inducers. It 
was shown that 32 to 36-cycle RT-PCR reactions provide the best discrimination for 
quantitative analysis. Therefore, 35-cycle reactions were performed in this set of 
experiments. The results showed that DEX, RIF and CLT induce the expression of 
CYP3A5, CYP3A7 and hPXR in passage 5 and 10 cells post resuscitation from 
storage. Induction of CYP3A5, CYP3A7 and hPXR is significantly higher in passage 
10 than passage 5. The greater induction of CYP3A5, CYP3A7 and hPXR gene 
transcriptions at passage 10 by classical inducers of CYP3A genes implies that 
HepG2 cells do not respond fully to inducers at the low passage numbers after 
resuscitation from liquid nitrogen. However, they do regain their inducibility after 
further growth (e.g. at passage 10). There was no induction observed in passages 15 
or 20 of the HepG2 cells. However, dosing in serum-free medium at passage 15 
produced significant induction by DEX and CLT.
The induction of CYP3A5 mRNA by classical inducers of CYP3A in HepG2 cells is 
in agreement with Schuetz et al (1996b) who demonstrated that CYP3A5 isoenzyme 
can be induced in HepG2 cells and primary and continuous cultures of human 
hepatocytes. Induction of CYP3A5 was also shown by DEX in other experiments in 
human lung adenocarcinoma cell line (Hukkanen et al 2000) and by CLT in human 
colon carcinoma cells (Schuetz et al 1996a). Induction of CYP3A7 in HepG2 cells by 
CYP3A inducers is also in agreement with the results of others (Schuetz et al 1993b; 
Bertilsson et al 2001) and with work in human primary cultures of adult hepatocytes 
(Greuet et al 1996).
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HepG2 cells expressed hPXR in all passages and the results also showed that classical 
activators of this nuclear receptor are able to upregulate its expression in HepG2 cells. 
These results are in agreement with Pascussi et al (1999) who showed that DEX 
increases the expression of hPXR mRNA in cultured human hepatocytes. A similar 
effect has also been observed in the rat (Huss & Kasper 2000) where DEX induced 
hPXR gene expression in the presence of hGRa.
In fact, the RT-PCR experiments showed that HepG2 cells contain all the known 
nuclear factors required for the expression of CYP3A isoenzymes. They express 
notably hGRa and hPXR but also RXR, HNF-4 and SRC-1. The expression of all 
these transcription factors make this cell line a suitable substitute to human liver for 
the study of CYP3A gene expression. The CYP3A expression pattern in this cell line 
is comparable to human foetal liver and this makes it an excellent in vitro system for 
the study of xenobiotic metabolism in this tissue.
5.4. Future work
In order to optimise the use of HepG2 cells for the study of CYP3A gene expression 
further studies should be performed.
1. The necessary motifs for the expression of CYP3A4 reporter genes should be 
determined and if there is any inhibitor of CYP3A4 expression in these cells it 
should be characterised.
2. Considering the transcription of an incomplete, aberrant CYP3A4 mRNA 
identified in HepG2 cells by Sumida et al (2000), its translatibility and the activity 
of any resultant enzyme should be determined.
3. The necessary transcription factors for the expression of CYP3A4 in this cell line 
should also be studied. The expression of hPXR, hGRa, RXR, SRC-1 and HNF-4 
and the lack of CYP3A4 expression implies that there must be some other factors 
(inhibitory or stimulatory) affecting transcription of this gene in HepG2 cells.
4. Comparison should be made between HepG2 cells and other cell lines in their 
abilities to reproduce the in vivo induction of CYP3A gene regulation by 
xenobiotics. It is possible that a non-hepatic line such as Caco-2 may reproduce 
the pattern seen in adult liver cells.
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APPENDIX 1 
SOLUTIONS, MEDIA AND BUFFERS
Advantage -HF 2 PCR kit (Clontech)
lOX HF 2 PCR buffer
lOX Advantage 2 PCR buffer
10XHF2dNTPmix
PCR-grade H2O
Control DNA template, X DNA (0.2 ng/pl)
Control primer mix (10 pM each)
Ampicillin stock solution:
100 mg/ml in distilled water, sterilise by filtration. Store at -20°C, use at 100 pg/ml
in growth media for selection of ampicillin resistant bacteria.
P-galactosidase staining kit
X-gal solution in DMSO
Iron buffer (potassium ferrocyanide and potassium ferricyanide in PBS, stabilised)
Calcium chloride stock solution (2.5M):
67.5g CaC12. 6 H2O
Make up to 100 ml with distilled water. Sterilise by filtering through a 0.22-micron
filter. For use in transfection store in 5-ml aliquots at -20°C.
Chemiluminescence kit (Aurora™ AP assay) for alkaline phosphatase assay 
Starlight™ chemiluminescent substrate
Aurora™ AP assay buffer contains a mixture of differential alkaline phosphatase 
inhibitors.
Aurora™ AP reaction buffer diluent contains luminescence enhancer.
5x dilution buffer 
Control enzyme
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Clontech advantage HF 2 PCR kit
lOx HF 2 PCR buffer 
lOx Advantage 2 PCR buffer 
lOx HF 2 dNTP mix 
PCR-grade H2O
Control DNA template (X DNA 0.2 ng/pl)
Control primer mix (10 pM each)
DNA purifîcation kit from agarose gel
Ultra sait (sodium iodide solution)
Ultra bind (unifom size silica matrix)
Ultra wash (NaCl/Tris/EDTA solution)
EDTA solution (0.5M)
186.1 g EDTA 
20 g of NaOH pellets
Add 800 ml distilled water, adjust to pH 8.0, make up to 1 litre with distilled water.
Ethidium bromide:
Stock solution of 10 mg/ml in TAE
Use at 0.2 pg/ml in agarose gel solution for DNA staining.
Genomic DNA purification kit
Cell lysis solution (details not revealed)
Nuclei lysis solution (details not revealed)
Protein precipitation solution (details not revealed)
DNA rehydration solution (10 mM tris.HCl, pH 7.4 and 1 mM EDTA, pH 8.0) 
RNAse solution (details not revealed)
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HBS (2x)
1.6gNaCl 
0.074 g KCl
0.027gNa2H P04. 2 H2O 
0.2 g glucose 
IgHEPES
make up to 90 ml with distilled water. Adjust to pH 7.05 and make up to 100 ml. 
Sterilise by filtering through a 0.22-micron filter. Store in 5-ml aliquots at -20°C.
LB agar
15 g agar/1 of LB medium, autoclaved, cooled to 58 °C and poured into 16-ml petri 
dishes.
LB (Luria-Bertaini) medium:
10 g trypton 
10 g NaCl 
5 g yeast extract
Add distilled water to 1 litre, sterilise by autoclaving.
PBS:
(Dulbecco ‘A’ tablets, Oxoid)
1 tablet dissolved in 100 ml of distilled water 
sterilise by autoclaving.
PCR Core System II (promega)
Taq DNA polymerase
Thermophilic DNA polymerase lOX reaction buffer, MgCL-free 
MgCL, 25 mM solution
Taq DNA polymerase buffer lOX buffer w/15 mM MgCL
PCR nucleotide mix, 10 mM each nucleotide
Positive control plasmid DNA
Upstream control primer, 15 pM
Downstream control primer, 15 pM
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Qiagen Endo-Free Maxi prep kit components:
Buffer PI (resuspension buffer, 50mM tris.Cl pH 8.0, lOmM EDTA and lOOmg/ml 
Rnase)
Buffer P2 (lysis buffer, 200mM NaOH and 1% SDS)
Buffer P3 (netralisation buffer, 3M potassium acetate pH 5.5)
Buffer ER (endotoxin neutralisation buffer)
Buffer QBT (column equilibrium buffer, 750mM NaCl, 50mM MOPS pH 7, 15% 
isopropanol and 0.15% triton X-100)
Buffer QC (wash buffer, 1.6mM NaCl, 50mM tris.HCl pH 8.5 and 15% isopropanol) 
Buffer QN (elution buffer, 1.6mM NaCl, 50mM MOPS pH 7 and 15% isopropanol 
Buffer TE (lOmM tris pH 8.0 and 1 mM EDTA)
Access RT-PCR system {Promega)
AMV reverse transcriptase; 5 u/pl 
Tfl DNA polymerase, 5 u/pl 
AMV/Tfl 5X reaction buffer 
MgS0 4 , 25 mM
dNTP mixture, 10 mM each of dATP, dCTP, dGTP and dTTP 
Positive control RNA with carrier (1.25 attomole/pl)
Upstream control primer, 15 pM 
Downstream control primer, 15 pM 
Nuclease-free water
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